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ABSTRACT 
Amanda Mathis: Accumulation and Intracellular Distribution of Aromatic Diamidines in 
African Trypanosomes (under the direction of James E. Hall) 
 
 Human African Trypanosomiasis (HAT), also known as sleeping sickness, is a 
devastating disease that affects millions of people in the poor nations of sub-Saharan Africa.  
There is a great need for new treatments of this disease, as only four drugs are currently 
available, and all are associated with toxicity and other problems.  The diamidine, 
pentamidine, has long been used for the treatment of trypanosomiasis, despite its toxicity and  
lack of knowledge of its mechanism of action.  Drug development efforts have recently 
focused on creating less toxic, more potent diamidine derivatives of pentamidine with an 
orally bioavailable formulation.  DB289, the prodrug of DB75, is in Phase III clinical trials as 
an oral treatment of HAT.  Almost 2000 diamidines and related compounds have been 
synthesized, many with potent anti-trypanosomal activity.  Although DB75 and other 
diamidines are potent DNA binders, the overall mechanism of action of this series of 
compounds is unknown.   
The focus of this research is to investigate diamidine accumulation and distribution in 
trypanosomes in vitro and in vivo.  Diamidines such as DB75 accumulate to high 
concentrations in vitro and in vivo in trypanosomes, and localize to the kinetoplast and 
nucleus, which contain DNA, as well as the acidocalcisomes.  The increase in treatment 
failures of anti-trypanosomal compounds has been a major concern in recent years, especially 
with melarsoprol.  Several trypanosome lines have been developed which are resistant to 
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DB75 in the laboratory, and methods developed to investigate intracellular accumulation and 
distribution were extended to these lines.  These lines lack the P2 transporter, thought to be 
the main uptake transporter for DB75.  DB75 accumulation was lower in the resistant lines, 
with intracellular distribution also altered. Total accumulation, however, was substantial in 
these lines, despite lack of the major uptake transporter described for this compound.   
 Benzofuran and benzimidazole diamidines were also investigated.  The benzofuran 
series was found to accumulate in non-DNA containing organelles, which may represent a 
new mechanism of action for these diamidines.  Together, the studies in this dissertation have 
proven that diamidines selectively accumulate in trypanosomes and that there is likely more 
than one mechanism of action for diamidines.   
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A.  INTRODUCTION 
Human African trypanosomiasis, caused by Trypanosoma brucei gambiense and T. b. 
rhodesiense, is a devastating disease that has the potential to affect millions in sub-Saharan 
Africa (82).  Treatment options for the disease are limited, as there are only four drugs 
available.  All four compounds are associated with many problems, including cost, route of 
administration, increasing incidence of treatment failure, and reports of drug resistance (43, 
51).  Drug development efforts recently have focused on creating novel less toxic and more 
potent diamidine derivatives of pentamidine and on developing an orally active drug (80).  A 
prodrug approach has been utilized to create orally available, lipophilic compounds which 
are transformed metabolically by cytochrome P450 (CYP450s) and cytochrome b5 enzymes 
to form active diamidines (65, 78).  Pafuramidine, or DB289, the prodrug of DB75 
(furamidine) is currently in Phase III clinical trials as an oral treatment of early stage 
trypanosomiasis.   
To date, numerous diamidines and related compounds have been synthesized, many 
with potent anti-trypanosomal activity.  Although several of these diamidines, such as DB75 
and the closely related analog, DB820 are potent DNA binders, the overall mechanism of 
action of this series of compounds is unknown.  Previous studies (3, 4, 50, 52, 60, 61) have 
established that the shape of the diamidine may affect the ability of the compounds to bind 
DNA, but it is not known whether this correlates with increased or decreased anti-
trypanosomal activity.  The compounds DB75 and DB820 are known to accumulate in 
several organelles, primarily in the DNA–containing nucleus and kinetoplast, but also in 
other organelles, such as the acidocalcisomes, which lack DNA.   
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Although the mechanism of action of diamidines is thought to be related to DNA 
binding, it is not known if diamidines like DB75 have targets in other organelles.  The 
combined effects of modifying aromatic diamidine structures on intracellular localization and 
anti-trypanosomal activity has not been extensively investigated.  The overall hypotheses for 
this research are that 1) diamidines are actively transported into trypanosomes where they 
exert their mechanism of action by interacting with DNA, and 2) that structural alterations 
lead to increased or decreased activity by altering both uptake and intracellular distribution in 
the trypanosomes.  These hypotheses are based on three lines of evidence:  1) diamidine 
compounds bind DNA in AT rich regions of the minor groove (12), 2) structural 
modifications of diamidines have been shown to alter DNA binding and distribution in 
cancer cells (48), and 3) the recognition moiety for at least one known uptake transporter on 
the trypanosome surface includes a diamidine recognition site (24). 
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B.  TRYPANOSOMIASIS: HISTORY AND CURRENT SITUATION        
Human African trypanosomiasis, also known as African sleeping sickness, is a 
parasitic disease caused by Trypanosoma brucei subspecies rhodesiense and gambiense.  
Trypanosomiasis has affected sub-Saharan Africa for hundreds of years, with Atkins in 1721 
and Winterbottom (in 1803) first describing the disease (22).  However, it wasn’t until the 
late 1800s–early 1900s that the causative agents of both the human infection and related 
animal infection were described.  In 1894, David Bruce investigated an outbreak of the cattle 
wasting disease, nagana, in sub-Saharan Africa.  Bruce identified trypanosomes in the blood 
of infected cows.  He also experimentally determined that the trypanosomes isolated from 
infected cattle were able to cause nagana in other animals.  Additionally, Bruce recognized 
that the tsetse fly (Glossina sp) could spread the disease, and noted nagana’s similarity to the 
human disease known to cause lethargy.  For his work, trypanosomes were later named after 
him (Trypanosoma brucei).  In 1909, Freidrich Kleine demonstrated the essential role of the 
tsetse fly in the transmission of trypanosomiasis.  Everett Dutton in 1902 identified the 
trypanosome that caused Gambian, or chronic trypanosomiasis (Trypanosoma brucei 
gambiense).  Finally, in 1910, J. W. W. Stephens and Harold Fantham described T. b. 
rhodesiense, the causative agent of the acute form of human trypanosomiasis (22, 38).    
There have been several epidemics of human African trypanosomiasis (HAT) in 
Africa during the last century (82).  Through surveillance, control and treatment efforts of the 
colonial powers, the disease was brought under control by the 1960s.  However, once the 
colonies gained their freedom, control efforts lapsed and the disease began its resurgence in 
the 1970s (82).   
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In Angola for example, efforts to control and prevent trypanosomiasis began in 1901, 
and evolved into mobile teams in the 1940s to provide treatment and prophylactic services 
(71).  This culminated in the development of the ‘Brigade for Pentamidization’ and the 
development of 26 health sectors, in certain regions of the country, in endemic areas affected 
by trypanosomiasis.  By the time the country gained its independence in 1974, there were 
only 3 new cases detected in the country as a result of these control efforts (71).  
Unfortunately, the control infrastructure under the new government was never fully 
established and was impeded by lack of officers, equipment, vehicles and medical facilities.  
Outside support led to some work on trypansomiasis control.  In the early 1990s, the 
program’s capabilities were again destroyed by civil war, only to resume with the aid of 
outside agencies such as Médicins sans Frontières (MSF).  Conflict in the late 1990s again 
impeded efforts to control trypanosomiasis, and the numbers of infected patients began to 
rapidly rise again (71).  This pattern of control and resurgence of the disease has been 
repeated in many other newly independent African nations.   
In the current epidemic, HAT has the potential to affect 60 million people in Sub-
Saharan Africa.  The disease is at epidemic levels in Angola, southern Sudan, and the 
Democratic Republic of Congo, and is highly endemic in countries such as Uganda. In some 
villages in these countries, the prevalence of trypanosomiasis is between 20 and 50%, with 
mortality higher than that of HIV/AIDS (46, 82).  Through recent control efforts, surveillance 
has increased and the number of new cases reported between 1998 and 2004 for the disease 
decreased by 20,000 patients (82).   
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B.1.  Trypanosomiasis Manifestations and Symptoms 
Trypanosomiasis is a vector borne disease, with transmission occurring after the bite 
of an infected tsetse fly (Glossina sp.)  The parasites T. b. gambiense and T. b. rhodesiense 
are morphologically identical parasites, although the disease manifests itself differently 
depending on the subspecies (79).  The parasites also differ in terms of geographical location 
and reservoirs.  It has long been thought that only T. b. rhodesiense had an animal reservoir, 
but T. b. gambiense has recently been shown to exist in 8 wild animal species (15).  It is still 
unknown what role these species may play as a reservoir of the Gambian infection.   
Gambian sleeping sickness is a chronic disease found primarily in central and western 
Africa, while the Rhodesian form of trypanosomiasis is an acute disease found in eastern and 
southern Africa (79).  Both chronic and acute trypanosomiases are characterized by two 
stages of infection, although the overall length of the infection differs.  Symptoms develop 
rapidly in T. b. rhodesiense infections, with symptoms of the second stage becoming 
apparent within weeks, whereas Gambian infections can persist for years in a subacute first 
stage before progressing to the second stage and death.   
Symptoms of the early stage (also known as the hemolymphatic stage) of both forms 
of the disease are general, and include malaise, fever, and lymphadenopathy.  The early stage 
of Gambian sleeping sickness is often asymptomatic for several months before proceeding to 
a subacute febrile period, which is then eventually succeeded by the late stage central 
nervous system (CNS) infection (51, 79)  After the initial bite of the tsetse fly, trypanosomes 
disseminate from the lymphatic system into the bloodstream and extravascular spaces.  In the 
early stage, trypanosomes are confined there and proliferate with waves of parasitemia, and 
manage to evade the host immune system by switching the variant surface glycoprotein 
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(VSG) antigen covering the surface of the parasite (45, 75).  The VSG antigen is the main 
surface protein found on the bloodstream trypanosome, and there are approximately 1000 
genes that encode VSGs (76).  As the disease progresses, the parasites are able to penetrate 
the blood brain barrier and invade the CNS.  Symptoms of the late CNS infection include 
meningoencephalitis, sensory disturbances and hallucinations, dementia, and reversal of the 
sleep cycle. If untreated, the patient lapses into a coma and dies (33, 79).   
B.2.  Diagnosis and Staging of Trypanosomiasis 
 Diagnosis of sleeping sickness is made primarily through several screening processes.  
The clinical presentations of early stage trypanosomiasis are often vague and variable, and 
the disease may be misdiagnosed.  The presence of a chancre or enlarged cervical lymph 
nodes (Winterbottom’s sign) are clinical signs that are indicative of trypanosomiasis.  
Suspected trypanosomiasis can be confirmed using serological and parasitological 
techniques.  The Card Agglutination Trypanosomiasis Test (CATT) is often used on whole 
blood as a preliminary screen to diagnose trypanosomiasis.  If the CATT is positive, the 
diagnosis is confirmed by visualizing trypanosomes in blood, lymph, or CSF (cerebrospinal 
fluid).  With the Gambian form of the infection, parasitemia is often very low, and blood 
must be concentrated to determine if trypanosomes are present.  The mini anion-exchange 
centrifugation test (mAECT) and capillary tube centrifugation test (CTC) are both used to 
concentrate trypanosomes in blood (1, 6, 43).  In the future, polymerase chain reaction, or 
PCR-based tests may be useful for the detection of trypanosomiasis in patients.  One of these 
techniques is a PCR-oligochromatography dipstick test, HAT-PCR-OC (29).  This test 
combines PCR and membrane chromatography to detect DNA, and is a very rapid test (<5 
min).  The HAT-PCR-OC test was consistently able to detect one parasite in 180 µl of blood, 
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or 5 fg of trypanosome DNA (29).  Additionally, the test does not cross react with other 
Kinetoplastid species and is specific for Trypanozoon species (29).  However, the feasibility 
of using this test in the clinic has not been investigated.   
 As treatments for trypanosomiasis are stage specific, it is important to determine what 
stage of infection patients have.  This is done by determining the presence of trypanosomes 
and white blood cells in the CSF.  The presence of trypanosomes in the CSF is indicative of 
late stage, or CNS infection.  However, if trypanosomes are not found in the CSF, the 
presence of greater than 5 leukocytes/mm3 has historically been used to indicate second stage 
trypanosomiasis (43).  Recently, the MSF programs operating in sub-Saharan Africa 
increased the threshold for determining late stage infection to 10 leukocytes/mm3.  This was 
done for several reasons, including evidence that pentamidine could be effective against 
patients with “intermediate” CSF white blood cell counts (6-10 cells/mm3).  This was also 
done to reserve the use of the very toxic drug, melarsoprol, the first line treatment for late 
stage HAT, in cases that could be cured with pentamidine (6).  However, preliminary results 
do show that treating patients with intermediate CSF white cell counts between 6-10 
cells/mm3 with pentamidine, does lead to three times the treatment failure than those with 
CSF white cell counts between 0-5 cells/mm3 (6).  In this investigation, the relapse rate was 
still only 5% overall, which is an acceptable level of treatment failure (6). 
 A dot – ELISA test has been developed for staging of trypanosomiasis (21).  This test 
detects anti-neurofilament and anti-galactocerebroside proteins and cross-reacts with 
invariant membrane antigens of T. brucei.  Detection of these antibodies in CSF is 
characteristic of second stage infection (21).  The dot – ELISA test showed 80% sensitivity 
and 100% specificity in field testing (21).  This high level of sensitivity and specificity make 
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this test an excellent potential staging test, especially when patients have intermediate white 
blood cell counts in the CSF (21).  The test must be further investigated on a larger scale to 
verify its specificity and accuracy.   
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C.  TRYPANOSOMA BRUCEI 
T. brucei is a eukaryotic parasite belonging to the order Kinetoplastidia (56).  
Trypanosomes are digenetic organisms that progress through a life cycle as they are 
transmitted between vector and host (Fig 1.1)  Trypanosomes are transmitted between hosts 
by the tsetse fly (Glossina sp) (55).  The trypomastigote ingested by the tsetse fly blood meal, 
transforms into a procyclic trypomastigote.  The major protein that makes up the surface coat 
of the trypanosome is changed from the VSG into procyclin.  Additionally, the mechanism 
for energy generation is switched from primarily glycolysis to a mitochondrion based 
respiratory system, along with the necessary changes to the mitochondrion structure and 
metabolic activation.  The procyclic trypanosome proliferates in the tsetse fly midgut before 
moving to the salivary gland.  There the trypanosome undergoes further differentiation into a 
non-proliferating, VSG expressing, metacyclic bloodstream form (55).  The metacyclic 
trypanosome is injected into a host organism when the tsetse fly takes its blood meal.  The 
injected trypanosome differentiates into a slender bloodstream trypomastigote that relies on 
glycolysis for energy generation.  As trypanosomes proliferate in the bloodstream, they are 
transformed into non-proliferative short, stumpy forms.  The short stumpy forms limit 
trypanosome number and prolong host survival, which therefore increases the chance for 
transmission of the infection (55).   
All cellular organelles are present in both the procyclic (the vector, or fly form) and 
the bloodstream (infected host) form, although location of organelles within the cell may 
differ.  In addition to the characteristic organelles of eukaryotes, including the nucleus, 
mitochondria, lysosomes, Golgi apparatus and endoplasmic reticulum (ER) (37), 
trypanosomes have specialized organelles and structures, such as the acidocalcisomes (31) 
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and kinetoplast (35), as seen in Figure 1.2, and glycosomes (57).  Unique organelles found in 
trypanosomes could be potential drug targets since humans lack equivalent structures, for the 
most part.   
The acidocalcisomes, as the name suggests, are acidic calcium storage organelles 
found in many microorganisms, including eukaryotic parasites such as T. brucei and T. cruzi, 
Plasmodium spp., and Toxoplasma spp.  Acidocalcisomes sequester ions such as Ca2+, Mg2+, 
Zn2+, and Na+, and phosphorous in the form of polyphosphates and pyrophosphates (32).  
Polyphosphates accumulate in acidocalcisomes at millimolar to molar levels with an average 
phosphate chain length of 3.2 phosphates (31).   
On the surface of acidocalcisomes are several pumps and exchangers which 
concentrate ions in the organelle, including a vacuolar - H+-ATPase, a vacuolar - H+-
pyrophosphatase (PPase), a Ca2+-H+ - ATPase, a Ca2+/H+ - exchanger and a Na+/H+ - 
exchanger.  Many of these pumps and exchangers can be inhibited, resulting in the release of 
acidocalcisome contents into the cytosol (31).  The physiological role of acidocalcisomes is 
not known, but hypotheses include serving as an energy or calcium store for the parasite, and 
involvement in osmoregulation and pH homeostasis (32).  All three of these functions could 
explain why long and short chain polyphosphates accumulate in high levels in 
acidocalcisomes (32).  Recently in T. cruzi and other parasites, the acidocalcisomes have 
been implicated in an efflux pathway linked to the flagellar pocket.  This efflux pathway is 
involved with regulatory volume decreases and the release of molecules from the parasites 
(64).  Recent evidence also suggests that acidocalcisomes are conserved from prokaryotes to 
eukaryotes – including humans.  Dense granules that are similar to acidocalcisomes have 
recently been characterized in human platelets.  These granules are morphologically and 
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structurally similar to acidocalcisomes, and contain high levels of polyphosphates released 
after thrombin stimulation (31).  Acidocalcisome-like organelles have not been found in 
other human cells yet. 
The kinetoplast is a unique DNA structure found in the single mitochondrion of the 
trypanosome (68).  Kinetoplast DNA (kDNA) is comprised of circles of DNA – about 50 
maxicircles and about 10000 minicircles – that are interlocked into a disc – like network of 
about 107 kDa (68).  Maxicircles encode for many of the necessary enzymes and proteins for 
the mitochondrion, while the minicircles encode guide RNAs (gRNA), which are involved in 
RNA editing processes that occur within the trypanosome mitochondrion (68).  Guide RNAs 
correct mRNA gene transcripts by inserting or deleting uridine molecules in the transcript to 
create a functional mRNA.  The kinetoplast is connected to the flagellar basal body of 
trypanosomes (68), and the mitochondrion extends throughout the organism.  The function of 
the mitochondrion changes as the trypanosome proceeds through its life cycle (57, 68), 
especially in terms of energy metabolism.  Unlike the procyclic form found in the tsetse fly, 
the mitochondrion of the bloodstream form trypanosome has poorly developed cristae (68), 
and contains neither enzymes involved in the tricarboxylic acid cycle , or TCA cycle nor a 
cytochrome - containing respiratory chain (57).  Differences in the respiration and metabolic 
processes between human and trypanosome cells could likely be future targets for the 
development of antitrypanosomal drugs. 
 Glycosomes are peroxisome-related organelles in which carbohydrate metabolism is 
compartmentalized.  In the bloodstream form of the trypanosome, the first seven steps of 
glycolysis occur in the glycosome, with the remaining conversions occurring in the cytosol 
(67).  Bloodstream trypanosomes depend entirely on glycolysis for the production of ATP.  
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This form of the trypanosome is able to produce both pyruvate and glycerol from glucose 
(57).  Although the majority of the enzymes found in the glycosomes of bloodstream 
trypanosomes are related to glycolysis, the organelle is also involved in other metabolic 
processes throughout the trypanosome life cycle (57).  Inhibition of any of these metabolic 
processes could be potential drug targets.   
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D. TREATMENT OPTIONS 
Current therapy for trypanosomiasis is limited to four drugs (Figure 1.3), all of which 
are problematic.  Among the problems are toxicity, lack of an oral dosage form, lack of drug 
availability, high cost, and increased incidence of treatment failures and reports of drug 
resistance (51).  Drug therapy is especially problematic in rural Africa where 
trypanosomiasis occurs, due to the realities of field medicine in nations where the annual per 
capita health budget is less than $10 (82).  Treatment is dependent upon the parasite 
subspecies, and the clinical stage of infection.  Two drugs, pentamidine and suramin (Fig 1.3) 
are unable to cross the blood brain barrier, and are therefore inactive against secondary 
trypanosomiasis (43, 82).  The other two drugs used to treat trypanosomiasis, melarsoprol 
and eflornithine, are able to cross the blood brain barrier.  
D.1.  Early Stage Treatment – T. b. gambiense 
Pentamidine, an aromatic diamidine first used in 1940, is the first line treatment for 
early stage T. b. gambiense infections (51).  It has also been used as a treatment for early 
stage Rhodesian trypanosomiasis, but produces variable results (1).  As a hydrophilic 
dication, it is unable to pass the blood brain barrier, and is therefore ineffective against the 
CNS stage of infection (34).  Adverse effects of pentamidine include hypotension, 
hepatotoxicity, renal failure and hypoglycemia that can lead to diabetes (51).  Pentamidine is 
administered through a series of intramuscular (IM) injections at a dose of 4 mg/kg/day for a 
total of 7-10 injections.  Due to the compound’s long elimination half-life, pentamidine has 
in the past been used as a chemoprophylaxis for trypanosomiasis (1).  The elimination half-
life of pentamidine administered to trypanosomiasis patients has been calculated to be 
between 22 and 47 h (13). 
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The exact mechanism of action of pentamidine remains unknown, but several 
hypotheses exist.  These include binding to DNA, and the linearization and destruction of the 
circular DNA in the kinetoplast (69, 70).  Other authors theorize that the generation of 
dyskinetoplastic trypanosomes in the infected host would not be enough to kill the 
organisms, and that another mechanism must exist (77).  Additionally, pentamidine has been 
shown to reversibly inhibit S-adenosylmethionine decarboxylase (SAMDC) and may play a 
role in inhibiting polyamine metabolism in the trypanosomes (10, 11).   
Pentamidine accumulates in trypanosomes via uptake by three transporters on the 
surface of the cell: a High Affinity Pentamidine Transporter (HAPT1), a Low Affinity 
Pentamidine Transporter (LAPT1), and the P2 transporter (24).  Trypanosomes are 
scavengers in the bloodstream of infected hosts.  They require uptake of many biosynthetic 
precursors, such as purine bases and nucleosides, including adenine and adenosine.  Several 
transporters have been discovered that actively transport adenine, adenosine and other 
purines into trypanosomes.  These include the P2 and P1 transporters.  The P1 transporter 
exists in the procyclic and bloodstream forms, while the P2 transporter is found only in 
bloodstream form trypanosomes.  The recognition site for the P2 transporter appears to 
interact with the nitrogen at position 1 and the amine group at position 6 of adenosine, as 
seen in Figure 1.4.  This H2N-C(R1)-NR2 motif is found in diamidine compounds and 
melaminophenyl arsenicals such as melarsoprol (Figure 1.3).  Pentamidine however, is also 
taken up by additional transporters, the HAPT1 and LAPT1.  Uptake of pentamidine through 
HAPT1 is inhibited only by propamidine, while LAPT1 uptake is not inhibited by any other 
known diamidine compound, suggesting selectivity for pentamidine uptake (23).  No 
endogenous substrates for LAPT1 and HAPT1 have been discovered.  The presence of three 
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pentamidine transporters also suggests that transport-related resistance to pentamidine would 
be slow to develop, whereas compounds that are only substrates for one transporter, such as 
melarsoprol, might develop resistance much faster.  This has been seen in the field, where 
despite extensive use as a prophylactic and treatment for 60 years, trypanosomes have not 
developed resistance to pentamidine (23).  Other compounds such as melarsoprol for human 
trypanosomiasis and diminazene for treatment of animal trypanosomiasis, which are taken up 
by only one or two transporters, have generated resistant trypanosomes with extensive use 
(23). 
D.2. Early Stage Treatment – T. b. rhodesiense 
For early stage T. b. rhodesiense infections, the polysulfated napthylamine 
compound, suramin (Figure 1.3), is the drug of choice.  Suramin is a high molecular weight 
anion.  Like pentamidine, it is unable to cross the blood brain barrier (34, 51). Suramin, 
which has been used as a treatment since the 1920s, has also been associated with severe side 
effects including renal failure and anaphylactic shock (51).  Suramin is administered by 
intravenous (IV) injection at a typical dose of 20 mg/kg, with no more than 1 g administered 
per injection.  However, due to the risk of shock, a test dose (0.1 g) must be administered 
before treatment begins.  The treatment is 5-6 injections administered at intervals of 5-7 days 
(1, 11).  Suramin is transported into trypanosomes by pinocytosis, or receptor mediated 
endocytosis when bound to serum proteins (77).  Suramin is believed to inhibit several 
glycolytic enzymes in trypanosomes.  The drug exerts a slow trypanocidal effect, most likely 
because it cannot enter the glycosome compartment that contains the glycolytic enzymes, but 
instead, can only inhibit the enzymes when they are found in the cytoplasm while they are 
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transported between organelles after synthesis and modification (77).  Some reports do 
indicate that suramin acts synergistically with CNS treatments, such as melarsoprol (11).    
D.3. Late Stage Treatment  
D.3.a. Melarsoprol – T. b. gambiense and T. b. rhodesiense 
Melarsoprol is a melamine-based organic arsenical compound that has been used for 
treating both T. b. gambiense and T. b. rhodesiense CNS infections since the 1940s (51).  
Melarsoprol is very toxic, and causes a fatal reactive encephalopathy in 5-10% of patients.  
Additionally, melarsoprol has also been associated with increasing incidence of treatment 
failure (51).  Historically, melarsoprol has been administered using a 26 day treatment 
schedule (3-4 series of 3-4 injections are administered in increasing doses, interspaced with 
resting periods of 7-10 days).  A 10-day melarsoprol regimen recently has been proven to be 
equally efficacious against T. b. gambiense CNS infections (15, 66).  The shorter treatment 
regimen has several advantages including less drug used, shorter hospitalization 
requirements, and increased treatment compliance (15, 66). 
Melarsoprol is believed to kill trypanosomes by inhibiting glycolytic enzymes.  
Melarsoprol has been shown to inhibit pyruvate kinase, phosphofructokinase, and fructose-
2,6-bisphosphatase (77).  The inhibition of glycolysis leads to lysis of the cells, also seen 
with suramin (77).  Melarsoprol has also been shown to form a stable adduct with 
trypanothione, a cofactor similar to glutathione that is involved in the redox balance of 
trypanosomes.  Whether this plays a role in its mechanism of action still remains to be 
determined (77). 
There are several potential routes of entry into trypanosomes for melarsoprol.  The 
lipophilic compound may be able to passively diffuse across the trypanosome membrane 
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(23).  Melarsoprol is also accumulated in trypanosomes through the P2 transporter.  
Prevention of uptake could play an important role in the increased rates of melarsoprol 
resistance seen in the clinic.  Point mutations of the P2 transporter gene, or TbAT1 gene, have 
been associated clinically with melarsoprol resistance (23).  When a knockout of the P2 
transporter in trypanosomes was developed, however, melarsoprol resistance was only about 
2-3 fold over the wild type strain.  This indicates the potential for other mechanisms of 
uptake into trypanosomes (54), which may include passive diffusion as well as transport 
mechanisms that may be upregulated in the absence of the P2 transporter.  The P1 transporter 
has been shown to be upregulated in the TbAT1-/- line (36), and the same phenomena may be 
seen with other transporters.   
D.3.b. Eflornithine – T. b. gambiense 
The only new drug to be introduced for the treatment of trypanosomiasis in almost 50 
years is eflornithine (DL-α-difluoromethylornithine), or DFMO, which was first used for 
trypanosomiasis treatment in the 1980s (51).  Eflornithine was initially developed as an 
anticancer therapy.  Eflornithine is used for late stage Gambian infections; it is inactive 
against the Rhodesian form of the disease.  Adverse effects associated with eflornithine 
include panocytopenia, diarrhea, convulsions and hallucinations (16).  Although eflornithine 
has sufficient lipophilicity for use as an oral treatment, oral administration has been 
associated with higher rates of relapse and increased reports of adverse effects (51).  Like the 
other drugs, eflornithine is currently administered parenterally.  It is administered in a series 
of 56 intravenous infusions.  Recently, MSF has recommended that due to high relapse rates 
with melarsoprol, eflornithine be used as the first line treatment for all late stage cases of 
trypanosomiasis in the Republic of Congo (5).  
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Eflornithine is a suicide inhibitor of ornithine decarboxylase (ODC), an essential 
enzyme in the polyamine biosynthetic pathway (11, 77).  ODC is an essential enzyme which 
leads to the formation of essential polyamines such as putrescine, spermidine, and spermine 
(77).  Polyamines are vital for replication of trypanosomes (17).  DFMO is only effective 
against T. b. gambiense due to the slow turnover rate of the ODC enzyme in this parasite 
compared to the human form of the enzyme (23).  Eflornithine is inactive against T. b. 
rhodesiense because in this subspecies, the enzyme has a half – life of only 4.3 h compared 
to >18 hr for Gambian subspecies (23).  Inactivation of the ODC enzyme leads to the 
transformation of bloodstream trypanosomes to a short metacyclic form that is unable to 
divide and alter the surface antigen VSG.  These changes allow the host immune system to 
more effectively attack the invading parasite and clear parasitemia (11, 30).   
D.3.c. Combination Therapy for Late Stage Treatment 
A recent clinical trial investigated the potential for using combination therapy to treat 
late stage trypanosomiasis, due to the toxicity of melarsoprol and the long, costly 
administration of eflornithine (63).  This study investigated combinations of melarsoprol + 
eflornithine, melarsoprol + nifurtimox, and eflornithine + nifurtimox.  Nifurtimox (Figure 
1.3) is an oral treatment used for Chagas’ disease, caused by Trypanosoma cruzi.  Nifurtimox 
toxicity includes neurological and gastrointestinal disorders that increase with the length of 
therapy.  Nifurtimox is not registered for treatment of HAT, but has been used for 
compassionate treatment (63).  In the trial, the dosing regimens of all three drugs were 
shortened.  The authors found that the combination of melarsoprol and nifurtimox resulted in 
higher than expected fatalities, with 4/18 patients dying of reactive encephalopathy during 
treatment, and a less than 50% cure rate over 24 months.  The eflornithine + nifurtimox 
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group, on the other hand, was very effective, with a greater than 94% cure rate over the 24 
month observation period.  The combination of eflornithine, a trypanostatic drug and the 
trypanocidal nifurtimox would thus appear to be efficacious.  Additionally, nifurtimox is 
relatively cheap, and the combination therapy requires only half of the normal dose of 
eflornithine to be administered, which reduced side effects as well as cost (63).  However, the 
combination still needs to be evaluated in more patients.   
D.4.  Need for New Therapies 
There is still a great need for the development of new therapies for African 
trypanosomiasis.  The four drugs currently used are old, expensive and difficult to 
administer, in addition to toxicity and drug resistance issues.  The drug supplies are currently 
ensured, due to a five-year agreement was made between the World Health Organization, or 
WHO, and Aventis in 2001. In this agreement, Aventis donated $25 million dollars to 
support distribution of pentamidine, melarsoprol and eflornithine (81).  Bayer also provides 
suramin to the WHO free of charge.  Recently, due to the success of the program in 
controlling trypanosomiasis, the pharmaceutical companies have agreed to extend their 
support of WHO efforts to treat and prevent trypanosomiasis (82).  Only one drug for 
trypanosomiasis, eflornithine, has made it to market in the past 30 years, primarily because it 
was initially developed as a cancer therapy (58).  Few drugs since then have entered clinical 
trials.  Megazol, a nitroheterocyclic compound, a potent antitrypanosomal compound in vitro 
and in vivo, was being developed in recent years.  However, due to genotoxicity studies, 
development of the drug was not pursued (11).  Currently, DB289, or pafuramidine, which is 
being developed as an oral treatment for trypanosomiasis, is enrolled in Phase III clinical 
trials in Africa.  DB289 is the prodrug of DB75 (furamidine), an active diamidine analog of 
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pentamidine (Fig 1.4).  The compound is only active against the early stage of the disease, 
and has little effect against chronic trypanosomiasis in animal models (43). Therefore, it is 
essential that drug development continue until effective, cheap treatments are available for 
both early and late stage trypanosomiasis.   
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E.  Development of Novel Diamidine Compounds and Prodrugs 
Pentamidine is a diamidine compound that has been shown to be effective in vitro and 
in vivo (in vitro IC50 = 1.1 nM and in vivo ED50 = 3.2 µmol/kg against S427 T. b. brucei) for 
animal models of trypanosomiasis.  However, the drug is associated with many toxic effects, 
including hypoglycemia, liver toxicity, pruritis, rash, vomiting, and renal failure (11).  Some 
of these toxicities are believed to be related to metabolism of the compound.  Pentamidine 
has been shown to form at least seven phase I metabolites and several phase II metabolites.  
Metabolism appears to decrease the efficacy of the compound against microbes and several 
of the metabolites appear to be more toxic than pentamidine (7, 8, 14, 19, 20, 44).  A series 
of novel diamidines have been synthesized, many of which have good activity against 
trypanosomes in vitro (12, 39-41).  However, like pentamidine, other aromatic diamidines are 
unable to efficiently cross membrane barriers, and thus have poor oral bioavailability.  Oral 
administration would be of great advantage for the treatment of trypanosomiasis, given the 
many problems with parenteral administration in Africa.  Trypanosomiasis is primarily a 
rural disease and is found in many of the poorest nations in Africa.  Rural areas are not 
always adequately equipped to perform multiple sterile injections or long term infusions (43).   
Two lead compounds (Figure 1.5) have been identified from this series of 
pentamidine analogues, DB75 (2,5-bis(4-amidinophenyl)-furan) and DB820 (6-[5-(4-
carbamimidoyl-phenyl)-furan-2-yl]-nicotinamidine).  In animal models of acute 
trypanosomiasis, both of these compounds show efficacy against trypanosomes.  DB75 and 
DB820, while potent anti-trypanosomal agents (53), are unable to effectively cross 
membrane barriers such as the gut or blood brain barrier (83); therefore, a prodrug approach 
was utilized to develop prodrugs with sufficient lipophilicity to penetrate barriers (DB289 is 
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the prodrug for DB75, and DB844 for DB820).  DB289 and DB844 are methoxime prodrugs 
of DB75 and DB820 – i.e. hydrogen molecules on the terminal amidines have been replaced 
with a methoxy group (-OCH3) (Figure 1.5).  Prodrugs exhibit poor activity in vitro, 
reinforcing the requirement of an in vivo transformation to target parasites.  A more 
lipophilic prodrug will be able to be administered orally and be absorbed from the intestinal 
lumen.  The compound can then disseminate through the body, where it will be metabolized 
to the active diamidine compound necessary for killing trypanosomes.   
The drug development efforts of the UNC consortium have concentrated on aromatic 
diamidine compounds.  These compounds are synthesized at UNC and Georgia State 
University.  A library of more than 2000 compounds exists and contains active diamidines 
and their prodrugs.  Diamidines and prodrugs are tested in vitro and in vivo in models for 
trypanosomiasis as well as other parasitic diseases (40, 42, 72).   
E.1. DNA Binding and the Mechanism of Action of Diamidine Compounds 
 Diamidine compounds such as pentamidine have a long history of use as 
antimicrobial agents, especially for the treatment of various human parasitic diseases, 
including Pneumocystis pneumonia and trypanosomiasis (80).  Pentamidine and analogs such 
as DB75 and DB820, also bind to AT rich regions of the minor groove of DNA (12, 18, 50, 
59).  Analogs that have a single amidine moiety (monoamidines) are unable to bind to the 
minor groove, and exhibit poor anti-trypanosomal activity (12).  Although it is known that 
diamidine compounds bind to the minor groove of DNA with varying affinities, the exact 
mechanism of action of killing remains unknown.  For example, compounds could interfere 
with transcription, or could inhibit DNA dependent enzymes (12).  Additionally, a compound 
could selectively target DNA in either the kinetoplast or nucleus, with little effect on other 
 24
organelles.  The possibility also exists that there are multiple mechanisms of action of 
diamidine compounds, including some that may not involve DNA binding at all (62).   
 The effect of diamidine substitution could also affect the mechanism of action of 
compounds.  For example, a phenyl substituted analog of DB75, DB569, has similar DNA 
binding properties to DB75.  Both compounds bind to the minor groove of AT rich regions 
with similar affinity (K >107) (48).  Studies in tumor cell lines have shown markedly 
different intracellular localization, however, with DB75 localizing in the nucleus, and DB569 
localizing in cytoplasmic granules.  This study concluded that substitution of diamidine with 
a phenyl ring, regardless of core structure of the compound, was the only substitution that 
shifted intracellular distribution from the nucleus to the cytoplasm (48).  This shift did not 
greatly affect the cytotoxicity of DB569 when compared to DB75 (48).  The in vitro IC50 
values for DB569 against STIB 900 (T. b. rhodesiense) and S427 (T. b. brucei) parasites is 
much higher than DB75 – but it is unknown whether this is related to differences in 
intracellular distribution of the compounds in trypanosomes.  DB569 has been shown to have 
increased activity compared to DB75 against T. cruzi and Leishmania parasites (26), but both 
compounds appear to have similar intracellular distribution in these parasites.  The 
hypothesis of differential distribution for DB569 in T. brucei parasites cannot be ruled out as 
of yet, since both of the organisms are quite different than T. brucei, despite belonging to the 
same order.  The possibility exists of more than one mechanism of action for diamidines, 
which could be manifested in different distribution within trypanosomes. 
E.2.  Selective Uptake into Trypanosomes 
Selective uptake of diamidines into trypanosomes is likely important to their 
mechanism of action.  As mentioned previously, diamidines have been shown to accumulate 
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in trypanosomes by three transporters so far, the HAPT1, LAPT1, and P2 transporter (24).  
Diamidines have also been shown to potently inhibit uptake of adenosine by the P2 
transporter (25, 49).  Selective uptake into trypanosomes would not only enhance efficacy, 
but also reduce toxicity, due to less being taken up by host cells.  To this end, there are 
several efforts underway to develop anti-trypanosomal drugs that are selectively accumulated 
in trypanosomes.  One effort has focused on the development of compounds that have 
benzamidine or melamine moieties, but this approach has not yet yielded very potent anti-
trypanosomal compounds (73, 74).  Aromatic diamidines, having a benzamidine moiety on 
either end, also appear to accumulate in trypanosomes by one or more transporters.  The ideal 
diamidine would be transported, like pentamidine, into the trypanosome by multiple 
transporters, in order to prevent transporter related drug resistance.   
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F.  Rationale for Proposed Studies 
 There is a great need for new treatments of human African trypanosomiasis and other 
parasitic diseases worldwide.  Major pharmaceutical companies often neglect drug 
development for diseases of the developing world, such as sleeping sickness.  Although the 
consortium’s approach to the development of novel therapies has generated many dicationic 
compounds with anti-parasitic activity, there is little known about the exact mechanisms of 
action.  Currently, a library of greater than 2000 compounds exists, with compounds 
synthesized at both UNC and GSU.  Many researchers have proposed mechanisms of action 
for diamidine compounds through the years, with the primary theories being DNA binding, 
linearization of the kinetoplast DNA structure, and interfering with RNA editing (11, 69).  
Knowledge of the intracellular distribution of compounds could provide insight into possible 
mechanisms of action.  Fluorescent compounds like the ones available in the aromatic 
diamidine libraries can be especially helpful for identifying unknown potential mechanisms 
of action or loss in the trypanosomes.  Some of the compounds investigated in this 
dissertation have been examined in cancer cells with fluorescence microscopy to visualize 
distribution (47, 48), to determine mechanism of action or loss.  Although these studies with 
select compounds have investigated multiple compounds in a series (47, 48), to our 
knowledge these studies have not been performed with T. brucei strains.   
As seen with cancer cells, the structure of potential anti-trypanosomal compounds 
could also affect uptake and accumulation into trypanosomes, in addition to the distribution 
of the compounds within the organism.  Aromatic diamidines may be taken up by any one of 
three transporters in the bloodstream form trypanosome, and substrate recognition may be 
affected by structure modifications.  This could lead to alternative uptake mechanisms, and 
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therefore, increased or decreased efficacy.  The number of transporters utilized for compound 
uptake could also affect the potential for drug resistance, as seen with pentamidine and other 
diamidines (54).  An overall goal for development of diamidine compounds is to develop a 
compound that displays the uptake properties of pentamidine, but is less toxic.  Knowledge 
of the effects of structure on the mechanism of action, uptake and distribution, and anti-
trypanosomal activity could lead to the development of more potent molecules in the future.  
The effect that structures have on intracellular distribution could explain why some 
compounds are not efficacious against trypanosomes.  Many compounds that have been 
synthesized by the Boykin and Tidwell laboratories also have a lack of correlation between in 
vitro and in vivo activity, which could be related to uptake or distribution.  The studies 
outlined here could determine the cause of activity or the lack thereof.  Many studies in the 
past have investigated the interaction between structure and anti-trypanosomal activity of 
investigational compounds (2, 9, 26-28, 39-41), but few studies have investigated the 
intracellular distribution of the compounds, which may be essential to activity.  If a 
compound does not reach the target of interest in the cell, anti-trypanosomal activity will be 
poor.  The investigations outlined in this proposal will incorporate studies of multiple aspects 
of the anti-trypanosomal activity – uptake, distribution, and accumulation, and the 
relationship these have to compound structure. 
 
The major hypothesis governing the experiments in this dissertation is that diamidine 
compounds rapidly accumulate in trypanosomes via uptake transporters such as the P2 
transporter and distribute to the DNA containing kinetoplast and nucleus.  In order to 
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investigate this hypothesis, accumulation and distribution of diamidines in trypanosomes was 
evaluated through the following specific objectives: 
1. Determine the accumulation and intracellular distribution patterns of DB75 and 
DB820, two lead compounds for the treatment of HAT in African trypanosomes.  
Hypothesis:  DB75 and DB820 are selectively accumulated in trypanosomes, and 
are localized to the nucleus and kinetoplast, the DNA containing organelles 
(Chapter 2).   
a).  Determine in vitro activity and in vitro accumulation of DB75 and DB820 in 
African trypanosomes. 
b). Determine in vivo accumulation and distribution of DB75 and DB820 in 
trypanosomes isolated from infected rodents.   
2.  Investigate accumulation and distribution of DB75 in wild type and resistant 
strains of S427 T. b. brucei.  Hypothesis:  Accumulation of DB75 in the 
‘resistant’ strains is less than in the wild type strain.  Distribution will be the 
same, but will take longer to equilibrate into compartments (Chapter 3). 
a). Determine in vitro activity of DB75 in wild type (S427), TbAT1-/-  (P2 
transporter knockout), DB75R-CL1 strain (DB75 resistant strain), and B428 
(pentamidine resistant TbAT1-/-). 
b).  Determine in vitro accumulation and distribution of DB75 in all four strains 
over time. 
   c).  Determine in vivo accumulation and distribution of DB75 in all four strains 
of trypanosomes over 8 hours.   
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3.  Identify differences in in vitro accumulation and distribution of diamidine 
analogues of DB75 and DB820.  Hypothesis:  Compounds with a higher IC50 
value accumulate in trypanosomes less than more potent compounds.  Less potent 
compounds do not distribute to the proposed target organelles (i.e. the DNA 
containing nucleus and kinetoplast) (Chapter 4). 
a). Determine in vitro activity of analogues of DB75 and DB820 in African 
trypanosomes.  
b).  Determine DNA binding affinity of analogues of DB75 and DB820. 
c).  Determine in vitro accumulation and distribution of analogues of DB75 and 
DB820 in African trypanosomes (Chapter 4).   
d).  Investigate in vitro activity and intracellular distribution of other diamidine 
analogues – the benzofurans and benzimidazoles (Chapter 5). 
 In addition to the above studies, experiments investigating the effects of temperature 
on distribution and accumulation of DB75 and DB249 in trypanosomes are presented in 
Appendix I.  Appendix II presents preliminary data for the isolation of trypanosome 
organelles.  Potential implications, future studies, and the conclusions drawn from this 
research are presented in Chapter 6.   
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 Figure 1.1:  Life cycle of Trypanosoma brucei, the African trypanosome (Image obtained 
with permission from CDC Public Health Image Library).   
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Figure 1.2:  Diagram of trypanosome and organelles, modified from Grünfelder et al. 2003 
(37). 
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Figure 1.3:  Structure of currently used treatments for human African trypanosomiasis. 
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Figure 1.4:  Recognition site for the P2 transporter.  
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Figure 1.5:  Structure of DB75 and DB820, and their prodrugs, DB289 and DB844.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
NH2
O
N
NH2
OCH3
OCH3
NH
NH2
N
O
NH
NH2
NH
NH2
O
NH
NH2
N
NH2
N
O
N
NH2
OCH3
OCH3
   DB289, or
Pafuramidine
DB75
DB844
DB820  
    DB289 
(pafuramidine) 
 35
G.  References 
 
1. Apted, F. I. 1980. Present status of chemotherapy and chemopropylaxis of human 
trypanosomiasis in the eastern hemisphere. Pharmacol Ther 11:391-413. 
2. Azema, L., S. Claustre, I. Alric, C. Blonski, M. Willson, J. Perie, T. Baltz, E. Tetaud, 
F. Bringaud, D. Cottem, F. R. Opperdoes, and M. P. Barrett. 2004. Interaction of 
substituted hexose analogues with the trypanosoma brucei hexose transporter. 
Biochem Pharmacol 67:459-67. 
3. Bailly, C., R. K. Arafa, F. A. Tanious, W. Laine, C. Tardy, A. Lansiaux, P. Colson, 
D. W. Boykin, and W. D. Wilson. 2005. Molecular determinants for DNA minor 
groove recognition: Design of a bis-guanidinium derivative of ethidium that is highly 
selective for at-rich DNA sequences. Biochemistry 44:1941-52. 
4. Bailly, C., C. Tardy, L. Wang, B. Armitage, K. Hopkins, A. Kumar, G. B. Schuster, 
D. W. Boykin, and W. D. Wilson. 2001. Recognition of atga sequences by the 
unfused aromatic dication db293 forming stacked dimers in the DNA minor groove. 
Biochemistry 40:9770-9. 
5. Balasegaram, M., S. Harris, F. Checchi, S. Ghorashian, C. Hamel, and U. 
Karunakara. 2006. Melarsoprol versus eflornithine for treating late-stage gambian 
trypanosomiasis in the republic of the congo. Bull World Health Organ 84:783-91. 
6. Balasegaram, M., S. Harris, F. Checchi, C. Hamel, and U. Karunakara. 2006. 
Treatment outcomes and risk factors for relapse in patients with early-stage human 
african trypanosomiasis (hat) in the republic of the congo. Bull World Health Organ 
84:777-82. 
7. Berger, B. J., N. A. Naiman, J. E. Hall, J. Peggins, T. G. Brewer, and R. R. Tidwell. 
1992. Primary and secondary metabolism of pentamidine by rats. Antimicrob Agents 
Chemother 36:1825-31. 
8. Berger, B. J., V. V. Reddy, S. T. Le, R. J. Lombardy, J. E. Hall, and R. R. Tidwell. 
1991. Hydroxylation of pentamidine by rat liver microsomes. J Pharmacol Exp Ther 
256:883-9. 
9. Bhattacharya, G., J. Herman, D. Delfin, M. M. Salem, T. Barszcz, M. Mollet, G. 
Riccio, R. Brun, and K. A. Werbovetz. 2004. Synthesis and antitubulin activity of n1- 
and n4-substituted 3,5-dinitro sulfanilamides against african trypanosomes and 
leishmania. J Med Chem 47:1823-32. 
 36
10. Bitonti, A. J., J. A. Dumont, and P. P. McCann. 1986. Characterization of 
trypanosoma brucei brucei s-adenosyl-l-methionine decarboxylase and its inhibition 
by berenil, pentamidine and methylglyoxal bis(guanylhydrazone). Biochem J 
237:685-9. 
11. Bouteille, B., O. Oukem, S. Bisser, and M. Dumas. 2003. Treatment perspectives for 
human african trypanosomiasis. Fundam Clin Pharmacol 17:171-81. 
12. Boykin, D. 2002. Antimicrobial activity of the DNA minor groove binders furamidine 
and analogs. J Braz. Chem. Soc. 13:763-71. 
13. Bronner, U., F. Doua, O. Ericsson, L. L. Gustafsson, T. W. Miezan, M. Rais, and L. 
Rombo. 1991. Pentamidine concentrations in plasma, whole blood and cerebrospinal 
fluid during treatment of trypanosoma gambiense infection in cote d'ivoire. Trans R 
Soc Trop Med Hyg 85:608-11. 
14. Bronner, U., O. Ericsson, J. Nordin, I. Wikstrom, Y. A. Abdi, J. E. Hall, R. R. 
Tidwell, and L. L. Gustafsson. 1995. Metabolism is an important route of 
pentamidine elimination in the rat: Disposition of 14c-pentamidine and identification 
of metabolites in urine using liquid chromatography-tandem mass spectrometry. 
Pharmacol Toxicol 77:114-20. 
15. Brun, R., and O. Balmer. 2006. New developments in human african trypanosomiasis. 
Curr Opin Infect Dis 19:415-20. 
16. Burri, C., and R. Brun. 2003. Eflornithine for the treatment of human african 
trypanosomiasis. Parasitol Res 90 Supp 1:S49-52. 
17. Byers, T. L., T. L. Bush, P. P. McCann, and A. J. Bitonti. 1991. Antitrypanosomal 
effects of polyamine biosynthesis inhibitors correlate with increases in trypanosoma 
brucei brucei s-adenosyl-l-methionine. Biochem J 274 (Pt 2):527-33. 
18. Chaires, J. B., J. Ren, D. Hamelberg, A. Kumar, V. Pandya, D. W. Boykin, and W. D. 
Wilson. 2004. Structural selectivity of aromatic diamidines. J Med Chem 47:5729-42. 
19. Clement, B., M. Immel, R. Terlinden, and F. J. Wingen. 1992. Reduction of 
amidoxime derivatives to pentamidine in vivo. Arch Pharm (Weinheim) 325:61-2. 
 37
20. Clement, B., and F. Jung. 1994. N-hydroxylation of the antiprotozoal drug 
pentamidine catalyzed by rabbit liver cytochrome p-450 2c3 or human liver 
microsomes, microsomal retroreduction, and further oxidative transformation of the 
formed amidoximes. Possible relationship to the biological oxidation of arginine to 
ng-hydroxyarginine, citrulline, and nitric oxide. Drug Metab Dispos 22:486-97. 
21. Courtioux, B., S. Bisser, P. M'Belesso, E. Ngoungou, M. Girard, A. Nangouma, T. 
Josenando, M. O. Jauberteau-Marchan, and B. Bouteille. 2005. Dot enzyme-linked 
immunosorbent assay for more reliable staging of patients with human african 
trypanosomiasis. J Clin Microbiol 43:4789-95. 
22. Cox, F. E. 2002. History of human parasitology. Clin Microbiol Rev 15:595-612. 
23. de Koning, H. P. 2001. Transporters in african trypanosomes: Role in drug action and 
resistance. Int J Parasitol 31:512-22. 
24. de Koning, H. P. 2001. Uptake of pentamidine in trypanosoma brucei brucei is 
mediated by three distinct transporters: Implications for cross-resistance with 
arsenicals. Mol Pharmacol 59:586-92. 
25. de Koning, H. P., and S. M. Jarvis. 1999. Adenosine transporters in bloodstream 
forms of trypanosoma brucei brucei: Substrate recognition motifs and affinity for 
trypanocidal drugs. Mol Pharmacol 56:1162-70. 
26. De Souza, E. M., A. Lansiaux, C. Bailly, W. D. Wilson, Q. Hu, D. W. Boykin, M. M. 
Batista, T. C. Araujo-Jorge, and M. N. Soeiro. 2004. Phenyl substitution of 
furamidine markedly potentiates its anti-parasitic activity against trypanosoma cruzi 
and leishmania amazonensis. Biochem Pharmacol 68:593-600. 
27. De Souza, E. M., R. Menna-Barreto, T. C. Araujo-Jorge, A. Kumar, Q. Hu, D. W. 
Boykin, and M. N. Soeiro. 2006. Antiparasitic activity of aromatic diamidines is 
related to apoptosis-like death in trypanosoma cruzi. Parasitology 133:75-9. 
28. de Souza, E. M., G. M. Oliveira, D. W. Boykin, A. Kumar, Q. Hu, and N. Soeiro 
Mde. 2006. Trypanocidal activity of the phenyl-substituted analogue of furamidine 
db569 against trypanosoma cruzi infection in vivo. J Antimicrob Chemother 58:610-
4. 
 38
29. Deborggraeve, S., F. Claes, T. Laurent, P. Mertens, T. Leclipteux, J. C. Dujardin, P. 
Herdewijn, and P. Buscher. 2006. Molecular dipstick test for diagnosis of sleeping 
sickness. J Clin Microbiol 44:2884-9. 
30. Denise, H., and M. P. Barrett. 2001. Uptake and mode of action of drugs used against 
sleeping sickness. Biochem Pharmacol 61:1-5. 
31. Docampo, R., W. de Souza, K. Miranda, P. Rohloff, and S. N. Moreno. 2005. 
Acidocalcisomes - conserved from bacteria to man. Nat Rev Microbiol 3:251-61. 
32. Docampo, R., and S. N. Moreno. 1999. Acidocalcisome: A novel ca2+ storage 
compartment in trypanosomatids and apicomplexan parasites. Parasitol Today 
15:443-8. 
33. Enanga, B., R. J. Burchmore, M. L. Stewart, and M. P. Barrett. 2002. Sleeping 
sickness and the brain. Cell Mol Life Sci 59:845-58. 
34. Fairlamb, A. H. 2003. Chemotherapy of human african trypanosomiasis: Current and 
future prospects. Trends Parasitol 19:488-94. 
35. Fairlamb, A. H., P. O. Weislogel, J. H. Hoeijmakers, and P. Borst. 1978. Isolation and 
characterization of kinetoplast DNA from bloodstream form of trypanosoma brucei. J 
Cell Biol 76:293-309. 
36. Geiser, F., A. Luscher, H. P. de Koning, T. Seebeck, and P. Maser. 2005. Molecular 
pharmacology of adenosine transport in trypanosoma brucei: P1/p2 revisited. Mol 
Pharmacol 68:589-95. 
37. Grunfelder, C. G., M. Engstler, F. Weise, H. Schwarz, Y. D. Stierhof, G. W. Morgan, 
M. C. Field, and P. Overath. 2003. Endocytosis of a glycosylphosphatidylinositol-
anchored protein via clathrin-coated vesicles, sorting by default in endosomes, and 
exocytosis via rab11-positive carriers. Mol Biol Cell 14:2029-40. 
38. Hide, G. 1999. History of sleeping sickness in east africa. Clin Microbiol Rev 12:112-
25. 
39. Ismail, M. A., R. K. Arafa, R. Brun, T. Wenzler, Y. Miao, W. D. Wilson, C. 
Generaux, A. Bridges, J. E. Hall, and D. W. Boykin. 2006. Synthesis, DNA affinity, 
 39
and antiprotozoal activity of linear dications: Terphenyl diamidines and analogues. J 
Med Chem 49:5324-32. 
40. Ismail, M. A., A. Batista-Parra, Y. Miao, W. D. Wilson, T. Wenzler, R. Brun, and D. 
W. Boykin. 2005. Dicationic near-linear biphenyl benzimidazole derivatives as DNA-
targeted antiprotozoal agents. Bioorg Med Chem 13:6718-26. 
41. Ismail, M. A., R. Brun, J. D. Easterbrook, F. A. Tanious, W. D. Wilson, and D. W. 
Boykin. 2003. Synthesis and antiprotozoal activity of aza-analogues of furamidine. J 
Med Chem 46:4761-9. 
42. Ismail, M. A., R. Brun, T. Wenzler, F. A. Tanious, W. D. Wilson, and D. W. Boykin. 
2004. Dicationic biphenyl benzimidazole derivatives as antiprotozoal agents. Bioorg 
Med Chem 12:5405-13. 
43. Jannin, J., and P. Cattand. 2004. Treatment and control of human african 
trypanosomiasis. Curr Opin Infect Dis 17:565-71. 
44. Jones, H. E., G. K. Blundell, R. R. Tidwell, J. E. Hall, S. J. Farr, and R. J. Richards. 
1993. The accumulation of pentamidine and the toxic effects of the drug, its selected 
analogues and metabolites on isolated alveolar cells. Toxicology 80:1-12. 
45. Keiser, J., A. Stich, and C. Burri. 2001. New drugs for the treatment of human african 
trypanosomiasis: Research and development. Trends Parasitol 17:42-9. 
46. Kioy, D., J. Jannin, and N. Mattock. 2004. Human african trypanosomiasis. Nat Rev 
Microbiol 2:186-7. 
47. Lansiaux, A., L. Dassonneville, M. Facompre, A. Kumar, C. E. Stephens, M. Bajic, F. 
Tanious, W. D. Wilson, D. W. Boykin, and C. Bailly. 2002. Distribution of 
furamidine analogues in tumor cells: Influence of the number of positive charges. J 
Med Chem 45:1994-2002. 
48. Lansiaux, A., F. Tanious, Z. Mishal, L. Dassonneville, A. Kumar, C. E. Stephens, Q. 
Hu, W. D. Wilson, D. W. Boykin, and C. Bailly. 2002. Distribution of furamidine 
analogues in tumor cells: Targeting of the nucleus or mitochondria depending on the 
amidine substitution. Cancer Res 62:7219-29. 
 40
49. Lanteri, C. A., M. L. Stewart, J. M. Brock, V. P. Alibu, S. R. Meshnick, R. R. 
Tidwell, and M. P. Barrett. 2006. Roles for the trypanosoma brucei p2 transporter in 
db75 uptake and resistance. Mol Pharmacol 70:1585-92. 
50. Laughton, C. A., F. Tanious, C. M. Nunn, D. W. Boykin, W. D. Wilson, and S. 
Neidle. 1996. A crystallographic and spectroscopic study of the complex between 
d(cgcgaattcgcg)2 and 2,5-bis(4-guanylphenyl)furan, an analogue of berenil. Structural 
origins of enhanced DNA-binding affinity. Biochemistry 35:5655-61. 
51. Legros, D., G. Ollivier, M. Gastellu-Etchegorry, C. Paquet, C. Burri, J. Jannin, and P. 
Buscher. 2002. Treatment of human african trypanosomiasis--present situation and 
needs for research and development. Lancet Infect Dis 2:437-40. 
52. Mallena, S., M. P. Lee, C. Bailly, S. Neidle, A. Kumar, D. W. Boykin, and W. D. 
Wilson. 2004. Thiophene-based diamidine forms a "super" at binding minor groove 
agent. J Am Chem Soc 126:13659-69. 
53. Mathis, A. M., J. L. Holman, L. M. Sturk, M. A. Ismail, D. W. Boykin, R. R. Tidwell, 
and J. E. Hall. 2006. Accumulation and intracellular distribution of antitrypanosomal 
diamidine compounds db75 and db820 in african trypanosomes. Antimicrob Agents 
Chemother 50:2185-91. 
54. Matovu, E., M. L. Stewart, F. Geiser, R. Brun, P. Maser, L. J. Wallace, R. J. 
Burchmore, J. C. Enyaru, M. P. Barrett, R. Kaminsky, T. Seebeck, and H. P. de 
Koning. 2003. Mechanisms of arsenical and diamidine uptake and resistance in 
trypanosoma brucei. Eukaryot Cell 2:1003-8. 
55. Matthews, K. R. 2005. The developmental cell biology of trypanosoma brucei. J Cell 
Sci 118:283-90. 
56. Molyneux, D., and Ashford, RW. 1983. The biology of trypanosoma and leishmania, 
parasites of man and domestic animals. New York: International Publications Service, 
Taylor & Francis Inc., 1983. 
57. Moyersoen, J., J. Choe, E. Fan, W. G. Hol, and P. A. Michels. 2004. Biogenesis of 
peroxisomes and glycosomes: Trypanosomatid glycosome assembly is a promising 
new drug target. FEMS Microbiol Rev 28:603-43. 
58. Na-Bangchang, K., F. Doua, J. Konsil, W. Hanpitakpong, B. Kamanikom, and F. 
Kuzoe. 2004. The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) 
 41
in patients with late-stage t.B. Gambiense sleeping sickness. Eur J Clin Pharmacol 
60:269-78. 
59. Neidle, S., and C. M. Nunn. 1998. Crystal structures of nucleic acids and their drug 
complexes. Nat Prod Rep 15:1-15. 
60. Nguyen, B., D. Hamelberg, C. Bailly, P. Colson, J. Stanek, R. Brun, S. Neidle, and 
W. D. Wilson. 2004. Characterization of a novel DNA minor-groove complex. 
Biophys J 86:1028-41. 
61. Nguyen, B., C. Tardy, C. Bailly, P. Colson, C. Houssier, A. Kumar, D. W. Boykin, 
and W. D. Wilson. 2002. Influence of compound structure on affinity, sequence 
selectivity, and mode of binding to DNA for unfused aromatic dications related to 
furamidine. Biopolymers 63:281-97. 
62. Nok, A. J. 2003. Arsenicals (melarsoprol), pentamidine and suramin in the treatment 
of human african trypanosomiasis. Parasitol Res 90:71-9. 
63. Priotto, G., C. Fogg, M. Balasegaram, O. Erphas, A. Louga, F. Checchi, S. Ghabri, 
and P. Piola. 2006. Three drug combinations for late-stage trypanosoma brucei 
gambiense sleeping sickness: A randomized clinical trial in uganda. PLoS Clin Trials 
1:e39. 
64. Rohloff, P., A. Montalvetti, and R. Docampo. 2004. Acidocalcisomes and the 
contractile vacuole complex are involved in osmoregulation in trypanosoma cruzi. J 
Biol Chem 279:52270-81. 
65. Saulter, J. Y., J. R. Kurian, L. A. Trepanier, R. R. Tidwell, A. S. Bridges, D. W. 
Boykin, C. E. Stephens, M. Anbazhagan, and J. E. Hall. 2005. Unusual 
dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and nadh 
cytochrome b5 reductase. Drug Metab Dispos 33:1886-93. 
66. Schmid, C., M. Richer, C. M. Bilenge, T. Josenando, F. Chappuis, C. R. Manthelot, 
A. Nangouma, F. Doua, P. N. Asumu, P. P. Simarro, and C. Burri. 2005. 
Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human 
african trypanosomiasis: Confirmation from a multinational study (impamel ii). J 
Infect Dis 191:1922-31. 
 42
67. Schnaufer, A., G. J. Domingo, and K. Stuart. 2002. Natural and induced 
dyskinetoplastic trypanosomatids: How to live without mitochondrial DNA. Int J 
Parasitol 32:1071-84. 
68. Schneider, A. 2001. Unique aspects of mitochondrial biogenesis in trypanosomatids. 
Int J Parasitol 31:1403-15. 
69. Shapiro, T. A., and P. T. Englund. 1990. Selective cleavage of kinetoplast DNA 
minicircles promoted by antitrypanosomal drugs. Proc Natl Acad Sci U S A 87:950-4. 
70. Shapiro, T. A., V. A. Klein, and P. T. Englund. 1989. Drug-promoted cleavage of 
kinetoplast DNA minicircles. Evidence for type ii topoisomerase activity in 
trypanosome mitochondria. J Biol Chem 264:4173-8. 
71. Stanghellini, A., and T. Josenando. 2001. The situation of sleeping sickness in angola: 
A calamity. Trop Med Int Health 6:330-4. 
72. Stephens, C. E., R. Brun, M. M. Salem, K. A. Werbovetz, F. Tanious, W. D. Wilson, 
and D. W. Boykin. 2003. The activity of diguanidino and 'reversed' diamidino 2,5-
diarylfurans versus trypanosoma cruzi and leishmania donovani. Bioorg Med Chem 
Lett 13:2065-9. 
73. Stewart, M. L., C. Boussard, R. Brun, I. H. Gilbert, and M. P. Barrett. 2005. 
Interaction of monobenzamidine-linked trypanocides with the trypanosoma brucei p2 
aminopurine transporter. Antimicrob Agents Chemother 49:5169-71. 
74. Stewart, M. L., G. J. Bueno, A. Baliani, B. Klenke, R. Brun, J. M. Brock, I. H. 
Gilbert, and M. P. Barrett. 2004. Trypanocidal activity of melamine-based 
nitroheterocycles. Antimicrob Agents Chemother 48:1733-8. 
75. Stich, A., M. P. Barrett, and S. Krishna. 2003. Waking up to sleeping sickness. 
Trends Parasitol 19:195-7. 
76. Vanhamme, L., E. Pays, R. McCulloch, and J. D. Barry. 2001. An update on 
antigenic variation in african trypanosomes. Trends Parasitol 17:338-43. 
77. Wang, C. C. 1995. Molecular mechanisms and therapeutic approaches to the 
treatment of african trypanosomiasis. Annu Rev Pharmacol Toxicol 35:93-127. 
 43
78. Wang, M. Z., J. Y. Saulter, E. Usuki, Y. L. Cheung, M. Hall, A. S. Bridges, G. 
Loewen, O. T. Parkinson, C. E. Stephens, J. L. Allen, D. C. Zeldin, D. W. Boykin, R. 
R. Tidwell, A. Parkinson, M. F. Paine, and J. E. Hall. 2006. Cyp4f enzymes are the 
major enzymes in human liver microsomes that catalyze the o-demethylation of the 
antiparasitic prodrug db289 [2,5-bis(4-amidinophenyl)furan-bis-o-
methylamidoxime]. Drug Metab Dispos 34:1985-94. 
79. Welburn, S. C., and M. Odiit. 2002. Recent developments in human african 
trypanosomiasis. Curr Opin Infect Dis 15:477-84. 
80. Werbovetz, K. 2006. Diamidines as antitrypanosomal, antileishmanial and 
antimalarial agents. Curr Opin Investig Drugs 7:147-57. 
81. WHO. 2001. Http://www.Who.Int/inf-pr-2001/en/pr2001-23.Html. 
82. WHO. 2006. Http://www.Who.Int/mediacentre/factsheets/fs259/en/. 
83. Zhou, L., K. Lee, D. R. Thakker, D. W. Boykin, R. R. Tiwell, and J. E. Hall. 2002. 
Enhanced permeability of the antimicrobial agent 2,5-bis(4-amidinophenyl)furan 
across caco-2 cell monolayers via its methylamidoxime prodrug. Pharm Res 19:1689-
95. 
 
 
 
CHAPTER 2 
 
 
ACCUMULATION AND INTRACELLULAR DISTRIBUTION OF THE ANTI-
TRYPANOSOMAL DIAMIDINE COMPOUNDS DB75 AND DB820 IN AFRICAN 
TRYPANOSOMES 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was published in Antimicrobial Agents and Chemotherapy 50(6): 2185-91, 
2006. 
 
  45
A. Abstract  
The aromatic diamidine pentamidine has long been used to treat early stage Human African 
trypanosomiasis (HAT).  Two analogs of pentamidine, DB75 and DB820, have been shown 
to be more potent and less toxic than pentamidine in murine models of trypanosomiasis.  The 
diphenyl furan diamidine, DB75, is the active metabolite of the prodrug DB289, which is 
currently in Phase III clinical trials as a new orally active candidate drug to treat first stage 
HAT.  The new aza analog, DB820, is the active diamidine of the prodrug DB844, currently 
undergoing preclinical evaluation as a new candidate to treat CNS HAT.  Exact mechanisms 
of anti-trypanosomal activity of aromatic dications remain poorly understood, with multiple 
mechanisms hypothesized.  Pentamidine is known to be actively transported into 
trypanosomes and binds to DNA within the nucleus and kinetoplast.  A long hypothesized 
mechanism of action has been that DNA binding leads ultimately to interference with DNA-
associated enzymes.  Both DB75 and DB820 are intensely fluorescent, which provides an 
important tool for determining the kinetics of accumulation and intracellular distribution in 
trypanosomes.  We show in the current study that DB75 and DB820 rapidly accumulate and 
highly concentrate within trypanosomes, with intracellular concentrations over 15,000 fold 
higher than mouse plasma concentrations.  Both compounds initially accumulate in the 
DNA-containing nucleus and kinetoplast, but at later time points concentrate in non-DNA-
containing cytoplasmic organelles.   Analysis of the kinetics of uptake and intracellular 
distribution are necessary to begin to define anti-trypanosomal mechanisms of action of 
DB75, DB820 and other aromatic diamidines. 
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B. Introduction 
Human African trypanosomiasis (HAT), a devastating disease caused by 
Trypanosoma brucei gambiense and T. b. rhodesiense, has the potential to affect 60 million 
people in sub-Saharan Africa (27).  HAT has two stages: an early stage, in which 
trypanosomes are confined to the bloodstream and other extracellular fluids; and a late stage 
in which trypanosomes are able to cross the blood brain barrier and invade the central 
nervous system.   Symptoms of early stage HAT are general and include intermittent fever, 
malaise, and lymphadenopathy.  Infections caused by T. b. gambiense and T. b. rhodesiense 
differ primarily in the manifestation of the disease.  The Gambian form of the disease is a 
chronic disease which takes years to progress, while Rhodesian trypanosomiasis is an acute 
infection in which the late stage develops only a few weeks or months following infection 
(26).   
Four drugs are currently available for treatment of HAT, all of which are associated 
with problems, including toxicity, increasing incidences of treatment failure and the route of 
administration (14, 15).  Pentamidine and suramin are used for the treatment of early stage 
trypanosomiasis.  Pentamidine is used as a first line treatment for infections caused by T. b. 
gambiense, and suramin is used to treat T. b. rhodesiense infections (11, 15).  Melarsoprol 
and eflornithine are used for CNS or second stage infections.  Melarsoprol is the drug most 
often used to treat second stage CNS infections caused by both parasites.  However, 
melarsoprol is associated with increasing reports of treatment failure (up to 30% in certain 
areas of central Africa), and it causes a reactive encephalopathy which can be fatal in up to 
10% of treated patients (15).  Eflornithine, also known as DFMO is only used against T. b. 
gambiense CNS infections (15).  Additionally, all of the treatments currently used must be 
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administered by parenteral injection, which is difficult in the rural areas affected by 
trypanosomiasis (14).  Thus, the need for new treatments is very pressing due to the problems 
associated with current therapy.   
DB75 (2,5-bis(4-amidinophenyl)furan), also known as furamidine (Figure 2.1) is the 
active metabolite of DB289 (2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime), a 
prodrug designed to orally treat HAT (T. b. gambiense is the parasite causing the current 
epidemic).  DB289 recently began Phase III clinical trials in the Democratic Republic of 
Congo and Angola, and the trial has started recruiting patients in southern Sudan.  DB75 is a 
diamidine analogue of pentamidine in which the alkoxy chain linking the phenyl rings has 
been replaced with a furan ring.  DB75 has shown excellent in vitro and in vivo activity in 
mouse and monkey models of first stage infection (4, 7, 11, 13).  DB820 (6-[5-(4-
phenylamidinophenyl)-furanyl-2-yl]-nicotinamide), is an aza analogue of DB75.  DB820 
(Figure 1) is more potent than DB75 in the T. b. rhodesiense STIB 900 model of first stage 
infection, despite having similar in vitro activity against that strain (13).  DB844, the O-
methylamidoxime prodrug of DB820, has excellent activity in mouse and monkey models of 
CNS trypanosomiasis.  DB844 is a leading candidate for the development of a new oral 
treatment for CNS trypanosomiasis.   
Previous studies have shown that pentamidine is actively transported into 
trypanosomes via the P2, HAPT1 and LAPT1 transporters, with very high concentrations 
accumulating within trypanosomes (6, 8).  Another diamidine, diaminazene, has been shown 
to be transported into trypanosomes primarily by the P2 transporter (9).  Little is known, 
however, about the intracellular distribution of pentamidine, particularly over the time 
periods required for this slowly acting compound to kill trypanosomes.  The lack of 
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fluorescence of pentamidine prevents microscopy studies which could determine localization.  
The structural modifications of DB75 and DB820 have increased the fluorescence emission 
of these compounds upon exposure to UV light.  Therefore, we are currently able to combine 
studies of accumulation with studies of distribution in trypanosomes.   
The mechanism of action of DB75 and DB820, as well as many other diamidines, is 
not known, and using fluorescence microscopy we can evaluate distribution to identify sites 
of action, or potential sites of loss, for the compounds in trypanosomes.  In this study, a T. b. 
brucei strain, S427, was used to investigate the intracellular accumulation and intracellular 
distribution of the UV-fluorescent DB75 and DB820 using HPLC analysis and fluorescence 
microscopy.   
This study determined that both DB75 and DB820 achieve millimolar concentrations 
in trypanosomes at each respective Tmax, or the time at which the maximum concentration is 
achieved.  DB75 and DB820 also demonstrate a progression in their intracellular distribution.  
These compounds first accumulate in the nucleus and kinetoplast, the DNA containing 
organelles of trypanosomes.  By later time points, both are also found in organelles that are 
believed to be the acidocalcisomes as well as other non DNA-containing organelles.  
Accumulation at multiple sites in trypanosomes may be crucial to understanding the 
mechanism of action of DB75, DB820, and that of other diamidines. 
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C.  Materials and Methods 
Materials.  Complete Baltz’s Modified Essential Media (CBMEM) was prepared from 
Minimal Essential Media (MEM) supplemented with 100 mM hypoxanthine, 2 mM 
adenosine, 10 mM thymidine, 2 mM sodium pyruvate, 2 mM L-glutamine, 2-
mercaptoethanol, and 10% v/v heat inactivated fetal bovine serum (Atlanta Biologicals, 
Atlanta, GA).  HPLC grade water and acetonitrile were obtained from Fisher Scientific 
(Pittsburgh, PA).  All chemicals were obtained from Sigma – Aldrich Co (St. Louis, MO) 
unless otherwise specified.   
Parasites.  T. b. brucei strain S427 was cultivated in CBMEM media as described previously 
(2).  Trypanosomes were maintained in Corning 24-well plates (Fisher Scientific) and were 
subpassaged every 3-5 days when trypanosomes reached a density of 105 – 106 trypanosomes 
per ml.   
Anti-trypanosomal Agents.  DB75 dihydrochloride salt was synthesized by Medichem 
(Chicago, IL) using previously described methods (5, 7).  DB820 trihydrochloride salt was 
synthesized in the laboratory of Dr. David Boykin as previously described (13).  For in vitro 
testing, DB75 and DB820 were prepared as 1 mM stocks in sterile water, and for in vivo 
testing the compounds were prepared in sterile saline (0.9% weight/vol).   
In vitro Anti-trypanosomal Activity.  In order to determine IC50 values, S427 
trypanosomes (2 x 103 per ml) were cultured with serial dilutions of DB75 or DB820 for 70 h 
using a method described by Raz et al. (20).  Alamar blue™ (10% vol/vol) (Biogen Intl, 
Camarillo, CA) was then added, and trypanosomes were further incubated for 2 h.  The 
fluorescence of Alamar Blue was measured using a PolarStar fluorescence plate reader 
(BMG, Durham, NC) using an excitation wavelength of 544 nm and an emission wavelength 
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of 588 nm.  Fluorescence emission at this wavelength is an indication of cell viability (20).  
The fluorescence emission derived from each drug concentration was normalized to 
fluorescence of the untreated control trypanosomes.  The background fluorescence 
(determined in wells in which Alamar Blue (10% vol/vol) was added to CBMEM media) was 
subtracted from total fluorescence values.  Dose response curves were generated from the 
Alamar Blue fluorescence shift using Prism™ (Graphpad Software, San Diego, CA).  
Experiments were performed in triplicate.  IC50 values were determined using the Hill 
Equation.   
In vitro accumulation in trypanosomes.  To determine in vitro accumulation, 106 
trypanosomes were incubated with either 7.5 µM DB75 or 7.5 µM DB820 for time periods 
ranging from 1 h to 24 h.  At each time point, cells were washed twice in fresh drug-free 
media, lysed, and extracted in 4 volumes of 8:1 methanol: 0.1 N HCl (vol/vol).  Half of each 
sample was evaporated in a Zymark (Hopkinton, MA) Turbovap-LV under nitrogen gas (7 
psi) and reconstituted in 50 µl of HPLC solvent A (described in detail in HPLC Analysis of 
DB75 and DB820).  Concentrations were determined as described below.   
In vivo Anti-Trypanosomal Activity.  Dose escalation studies in infected mice were used to 
determine in vivo anti-trypanosomal activity.  All animal experiments adhered to guidelines 
outlined by the University of North Carolina-Chapel Hill Institutional Animal Care and Use 
Committee (IACUC).  Each test group consisted of 6 mice obtained from Charles Rivers 
(Wilmington, MA).  Male Swiss Webster (20-30 g) mice were inoculated with 105 S427 
trypanosomes intraperitoneally on Day 0.  On day three, mice were treated with a single 
intravenous dose (ranging from 0.63 to 10 µmol/kg) of either compound.  The compounds 
were administered in 0.9% (weight/vol) saline.  The dose volume administered to each 
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mouse was less than 0.2 ml.  Untreated mice were administered the same saline vehicle.  A 
drop of tail vein blood from each mouse was collected and examined for trypanosomes using 
a light microscope (40X magnification) daily for 2 weeks post-treatment.  After that, tail vein 
blood was examined twice a week for 60 days.  Mice were considered cured when no 
parasites were found in blood after the 60 day period.  Untreated mice typically died within 5 
to 6 days of infection.  The percentage of animals cured in each test group was used to 
determine the dose response curve.  ED50 values were calculated in Prism™ using the Hill 
Equation.   
Plasma Concentrations of DB75 and DB820 in infected mice.  Plasma concentrations of 
DB75 and DB820 were determined in infected animals.  In these experiments, mice were 
treated with intravenous (IV) 7.5 µmol/kg of DB75 or DB820 on the third day after infection.  
Parasitemia was typically about 107 – 108 trypanosomes per ml.  Animals with lower 
parasitemia were excluded from the experiments before treatment.   
Plasma samples were prepared as described previously (24), with the following 
modifications.  Mice were euthanized by CO2 asphyxiation, blood was collected by cardiac 
puncture, and the blood was separated into two lithium heparin-coated BD Microtainer tubes 
(Fisher Scientific), each with about 400-500 µl of blood.  One microtainer tube of the blood 
was used for determining DB75 and DB820 plasma concentrations after a 7.5 µmol/kg dose 
IV through the tail vein, and the second was used to determine concentrations of DB75 and 
DB820 in trypanosomes isolated from the infected mice in certain experiments.   
Blood was centrifuged at 3000 rpm (1500g) in a Marathon 8K centrifuge (Fisher 
Scientific) for 5 minutes to separate plasma from red blood cells.  Plasma was removed, 
ensuring that the buffy coat was undisturbed.  The buffy coat contains white blood cells and 
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trypanosomes in infected animals.  Approximately 5 – 10 µl of plasma was examined under a 
light microscope (40 X - 100 X magnification) to ensure that it was not contaminated with 
trypanosomes.  DB75 and DB820 were extracted from plasma in 4 volumes of methanol: 
0.1N HCl (8:1 vol/vol), vortexed briefly and centrifuged at 3000 rpm (1500g) for 5 minutes.  
100 µl of supernatant was removed and evaporated as described previously (24).  The residue 
was reconstituted in 50 µl of HPLC solvent A (for each respective compound) and 
transferred to 200 µl polypropylene inserts for use in 2.0-ml glass HPLC vials (Agilent 
Technologies, Palo Alto, CA).  Samples were analyzed by HPLC as described below.   
Area Under the Curve (AUC) and half life (t1/2) were determined from plasma 
concentrations using noncompartmental analysis in Winonlin 4.1 (Pharsight, Mountain View, 
CA).  The t1/2 was calculated from the terminal elimination rate constant (kel), calculated 
between 4 and 24 hours.  AUC was not extrapolated beyond 24 hours as concentrations in 
plasma were often below the limit of quantification after this time (21). 
In vivo Accumulation of DB75 and DB820 in trypanosomes.  Male Swiss Webster mice 
were infected with 105 trypanosomes per ml intraperitoneally.  On the third day post 
infection, mice were treated with DB75 or DB820 at a dose level of 7.5 µmol/kg by a single 
tail vein injection.  This dose level is curative for both compounds in this model of infection.  
At various time points after treatment, mice were euthanized by CO2 inhalation, and blood 
was collected by cardiac puncture.  The trypanosomes were collected by centrifuging the 
blood on a Percoll (Sigma) gradient as described by Grab and Bwayo (12), with minor 
modifications to the centrifugation conditions.  Briefly, blood was mixed with an equal 
volume of 100% Percoll supplemented with 0.25 M sucrose and 0.11 M glucose, in 2.0-ml 
centrifuge tubes.  The blood and Percoll mixture was centrifuged for 16100 g for 35 minutes 
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in an Eppendorf 5415R microcentrifuge (Fisher Scientific).  Trypanosomes were removed 
from the supernatant, and washed twice (1 ml buffer) and counted.  Compounds were 
extracted from the trypanosomes using 4 volumes of methanol: 0.1N HCl (8:1 vol/vol).  
Samples were evaporated under nitrogen gas (7psi) in a Zymark Turbovap and resuspended 
in 100µl of the HPLC solvent A for each respective compound.  The average concentration 
of DB75 and DB820 in trypanosomes was determined using an estimated cell volume of 58 
µm3 (or 58 fl) for the S427 trypanosome (17).  AUC0→24h and t1/2 were calculated from 
trypanosome concentrations using noncompartmental analysis in Winonlin 4.1.  As with 
plasma, t1/2 was calculated from the kel between 4 and 24 h.   
Intracellular Localization of DB75 and DB820 in Trypanosomes.  To determine the 
localization of DB75 and DB820 in trypanosomes, blood smears were made using a drop of 
tail blood at each time point after treatment with DB75 or DB820.  Blood smears prepared 
from untreated mice were also examined.  Blood smears were examined using Nikon 
Microphot FXA (Garden City, NJ) with a 60 DM x 1.4 NA objective lens, a mercury lamp, 
and an Optronics DEI 750 CCD camera (Goleta, CA).  The microscope was equipped with a 
Nikon UV2A cube that limits excitation wavelengths to 330-380 nm and emission 
wavelengths to ≥ 420 nm.   
HPLC Analysis of DB75 and DB820.  Analytical methods for DB75 were conducted as 
described previously (24).  Briefly the solvent system for DB75 analysis consisted of solvent 
A (15 mM ammonium formate/ 30 mM formic acid in 100% HPLC grade water) and solvent 
B had the same components in 4:1 acetonitrile: HPLC grade water.  A gradient elution was 
used to resolve DB75, with a starting concentration of 88% solvent A:12% solvent B.  This 
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gradient increased linearly to 80% solvent B over 40 min, followed by an 8 minute re-
equilibration time to initial solvent conditions.   
 Analytical methods for DB820 were slightly different.  For DB820, Solvent A 
contained 30 mM ammonium formate/60 mM formic acid in 100% HPLC grade water, and 
Solvent B was the same buffer in 4:1 acetonitrile: HPLC grade water.  A gradient elution was 
used to resolve the compound, with a starting concentration of 94% Solvent A:6% Solvent B.  
This gradient increased linearly to 80% Solvent B over 40 min, followed by re-equilibration 
back to starting concentrations by 48 min.   
An Agilent 1100 series HPLC equipped with a fluorescence detector (Agilent 
Technologies) was used for analytical procedures.  DB75 and DB820 were eluted on a 5.0 
µm Bonus – RP (Agilent Technologies) 2.1 x 150 mm column with a flow rate of 0.35 
ml/min.  The column was maintained at 40 ºC throughout the analytical method.  Injection 
volume for each sample was 25 µl.  The wavelengths used for fluorescence detection were 
λex = 365 nm and λem = 462 nm.  Compounds were quantified by comparing to standards 
injected during each analytical run.  This was used to determine the concentration of DB75 
and DB820 in plasma and in trypanosomes.  Concentrations for both compounds were 
expressed as µM and mM for plasma and trypanosomes, respectively.  Concentrations are 
reported as plus or minus the SE. 
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D. Results 
 
In vitro activity of DB75 and DB820.  Both DB75 and DB820 had potent activity against 
the T. b. brucei S427 strain.  The IC50 values were less than 10 nM (Table 2.1).  The related 
compound, pentamidine, was slightly more potent than DB75 and DB820 in vitro with an 
IC50 value of 1.1 nM.   
In vitro accumulation of DB75 and DB820.  Trypanosomes growing in vitro were exposed 
to DB75 or DB820 at concentrations of 7.5 µM, approximately 1000 times the IC50 values.  
This concentration is similar to that used in previous studies with pentamidine (5).  Uptake of 
both DB75 and DB820 increased over time, with millimolar concentrations in trypanosomes 
at 24 h (Figure 2.2).  There appears to be two rises in accumulation for both compounds – 
after an initial rise in concentrations, there is a slight plateau before concentrations rise again.  
Although DB75 and its aza analogue had similar in vitro activity, DB75 accumulated to a 
greater extent in trypanosomes than DB820 over the 24 h period.  At 24 h, trypanosomes 
accumulated DB75 to a concentration of 12.2 ± 0.8 mM (± SE), or 70.8 ± 4.7 nmol/108 
trypanosomes, almost five times the concentration of DB820 in trypanosomes at that time 
(2.6 ± 0.2 mM, or 15.0 ±1.4 nmol/108 trypanosomes).  Thus, DB820 and DB75 were 
concentrated inside trypanosomes approximately 400-2000 fold the extracellular incubation 
concentration at 24 h.   
In vivo activity of DB75 and DB820.  In vivo efficacy experiments showed that DB75 and 
DB820 were both very potent in vivo, with comparable dose response effects in terms of cure 
rates and survival times (Table 2.1).  A single IV dose of either DB75 or DB820 at 10 
µmol/kg cured all mice infected with T. b. brucei S427.  Cure was defined as survival with 
no parasitemia for 60 days after treatment.  ED50 values calculated from the cure rates were 
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comparable (1.3 µmol/kg for DB75 and 1.6 µmol/kg for DB820).  Pentamidine was less 
active in vivo, failing to completely cure all animals at 10 µmol/kg IV. The extrapolated 
ED50 value for pentamidine was 3.2 µmol/kg.  This ED50 value is higher than previously 
reported for pentamidine against the S427 strain, which was between 0.9 and 1.0 µmol/kg (or 
0.5-0.6 mg/kg) (3).  However in this experiment, mice were infected with trypanosomes, and 
treatment was begun 24 hours later.  In the experiments reported here, treatment was begun 3 
days post infection, which is a more stringent efficacy model.  The values reported here are 
still very similar to those determined previously.   
In vivo accumulation of DB75 and DB820 in trypanosomes and plasma.  Mice infected 
with T. b. brucei S427 were dosed with DB75 or DB820 at 7.5 µmol/kg IV.  Mouse plasma 
concentrations and trypanosome intracellular concentrations for both compounds were 
measured over a 24 hr period (Figure 2.3). 
Plasma concentrations of DB75 and DB820 in infected animals. The plasma time 
concentration profiles for DB75 and DB820 in infected mice were similar (Figure 2. 3).   The 
peak plasma concentration of DB75 in infected mice after IV administration was 295  ± 93 
nM at 15 min post treatment (Figure 3A), the earliest time point measured.  The Area Under 
the Curve between 0 and 24 hours (AUC0→24h) of DB75 in the plasma infected mice was 1.8 
µM*h.  The plasma half-life (t1/2) of DB75 was 4.5 h.  The peak concentration of DB820 in 
plasma was 442 ±145 nM at 15 min post treatment (Figure 2.3B).  The AUC for DB820 in 
infected plasma was 1.9 µM*h, with t1/2 of 12.4 h.  The half lives for DB75 and DB820 in 
plasma were calculated between 4 and 24 h.   
In vivo accumulation of DB75 and DB820 in trypanosomes.  To determine 
concentrations of DB75 and DB820 in trypanosomes, trypanosomes were isolated from 
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blood at multiple time points after the dosing.  Concentrations of DB75 and DB820 that 
accumulated in trypanosomes after a single 7.5 µmol/kg dose are plotted in Figure 2.3.  Both 
compounds were rapidly taken up and concentrated within trypanosomes, with 0.5 mM 
intracellular concentrations at 15 min post treatment, the earliest time point measured.  DB75 
peaked in trypanosomes at a concentration of 0.9 ± 0.2 mM (5.4 ± 1 nmol/108 trypanosomes) 
at 4 h after administration, approximately 6,000 times the corresponding plasma 
concentration.  The AUC0→24h for DB75 in trypanosomes was approximately 9,400 µM*h.  
The concentration of DB820 peaked in trypanosomes slightly later, at 4 h, with a maximum 
concentration of 1.8 ± 0.7 mM (9.6 ± 4.3 nmol/108 trypanosomes), which is about 17,000 
times the concentration in plasma at 4 h.  The AUC0→24h for DB820 in trypanosomes was 
approximately 17,000 µM*h.  Both DB75 and DB820 concentrations in trypanosomes 
declined over time with half-lives of 4.9 and 6.4 h respectively.   
Intracellular distribution of DB75 and DB820 in trypanosomes.  Fluorescence 
microscopy was used to determine the intracellular distribution of DB75 and DB820 within 
organelles of trypanosomes.  The fluorescence micrographs (Figure 2.4) show that DB75 and 
DB820 rapidly accumulated in trypanosomes, concentrating initially in the DNA-containing 
nucleus and kinetoplast.  At 15 min, when intracellular concentrations of DB75 and DB820 
were approximately 0.5 mM, cell nuclei showed a bright blue fluorescence.  The kinetoplast 
was also clearly visible at this early time point, with very intense white-yellow fluorescence 
observed (Figure 2.4A and 2.4F).  Nuclear and kinetoplast fluorescence is apparent at all 
time points examined to some degree, but the kinetoplast is not always yellow, as seen in 
Figure 2.4E.  Occasionally, some of the trypanosomes depicted at 24 h in the micrographs do 
not have fluorescent kinetoplasts (Figure 2.4J).  This appears to be a true phenomenon, with 
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approximately 1/4 of trypanosomes in multiple fields showing no kinetoplast fluorescence at 
24 h.   
Additionally, DB75 appears in unidentified punctate organelles in the perinuclear 
region and at the tip of the trypanosome where the flagellum emerges as a yellow 
fluorescence (Figure 2.4A).  This also occurs with DB820 (Figure 2.4F), but not as much as 
with DB75.  As early as 2 h post treatment, both compounds are found in organelles believed 
to be the acidocalcisomes based on a similar fluorescence pattern as acridine orange in 
trypanosomes (10).  DB75 appears as a yellowish color in these organelles, while DB820 is a 
yellowish-orange color.  The DB75 and DB820 accumulating organelles are usually 
concentrated at the posterior end of the trypanosome.  By 4 hours, the number of yellow 
fluorescent organelles increases (Figure 2.4E and 2.4J), and the numbers remain that way 
through 24 hours.  It is interesting to note that after 4 hours, concentrations of both 
compounds in trypanosomes begin declining.   
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E. Discussion 
DB75 and DB820 are potent analogues of pentamidine.  Although all three have very 
similar in vitro activity, in vivo, it is clear that both DB75 and DB820 have better anti-
trypanosomal activity than pentamidine.  Even at the highest dose tested, 20 µmol/kg IV of 
pentamidine, we were unable to cure the infection in all animals (unpublished results).  
Additionally, in the more stringent model of first stage trypanosomiasis, the STIB 900 T. b. 
rhodesiense model, DB820 is the most potent of these three compounds (13).  Both DB75 
and DB820 can also be administered as lipophilic prodrugs, which enables an oral 
formulation for the treatment of trypanosomiasis (24).  This is useful, especially for early 
stage disease, because it eliminates the need for parenteral administration.  The prodrug of 
DB75, DB289, is currently in Phase III clinical trials for sleeping sickness.  DB844, the 
prodrug of DB820, is an excellent drug candidate for the treatment of CNS trypanosomiasis.  
DB844 is able to cure mouse models infected with the chronic GVR35 strain of T. b. brucei 
after an oral dose of 5 × 100 mg/kg, and is being investigated in further animal models.   
In these studies, T. b. brucei accumulates millimolar concentrations of both DB75 and 
DB820 after in both vitro incubation and after in vivo administration to infected mice (Figure 
2.2 and Figure 2.3).  The in vitro concentrations are very similar to concentrations previously 
reported for pentamidine accumulation published by Carter et al. (6).  In vitro, they found 
that pentamidine was accumulated in 108 cells to a concentration of 1 mM, or 6.05 nmol/108 
cells, after a 3-hour in vitro incubation with 1 µM pentamidine.  This concentration of 
pentamidine is approximately 1000 fold the IC50 value.  In the experiments presented here, 
trypanosomes were incubated with 7.5 µM of DB75 or DB820, which was approximately 
1000 times the IC50 value for both compounds, and both accumulated at millimolar levels in 
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vitro over a 24-h period (Figure 2.2).  After 4 hours, DB75 and DB820 are concentrated in 
trypanosomes almost 200 times the initial concentration, whereas in Carter’s experiments, 
pentamidine reaches levels inside trypanosomes that are approximately 1000 times the 
incubation concentration.   
The in vitro accumulation differences of pentamidine and DB75 and DB820 could be 
explained by the differing mechanisms for transport into trypanosomes.  Pentamidine is 
transported into trypanosomes by three transporters, the high and low affinity pentamidine 
transporters (HAPT1 and LAPT1) and the P2 transporter (8).  The P2 transporter has also 
been shown to accumulate DB75 and related diamidines (23), but to our knowledge, there is 
no evidence that HAPT1 or LAPT1 can transport DB75 and DB820 into trypanosomes.  
Therefore, pentamidine could have accumulated to a greater extent in trypanosomes due to 
the multiple routes of drug entry, which may not be available to DB75 and DB820.  A more 
accurate comparison for DB75 and DB820 and related diamidines may be diaminazene, 
which is taken up into trypanosomes almost exclusively through the P2 transporter (9).   
DB75 and DB820 were shown to accumulate in trypanosomes to concentrations of 1-
2 millimolar levels after in vivo treatment (Figure 2.3).  DB820 has a higher peak 
concentration and higher AUC0-24h in trypanosomes than DB75.  The same holds in plasma – 
DB820 had a higher peak concentration and slightly higher AUC0-24h in infected plasma than 
DB75.  For most time points, DB820 concentrations in infected plasma were higher than 
DB75 plasma concentrations.  Plasma concentrations were also variable, which could be a 
result of the infection itself.  At the peak concentration in trypanosomes, the organisms were 
able to accumulate between 6,000 and 17,000 times the plasma concentrations, which is a 
very large concentration factor.   
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Previously published data (6) suggests that the concentration of pentamidine in vivo 
in trypanosomes after a 4 mg/kg dose administered intraperitoneally to rats is approximately 
0.84 mM, lower than what was shown here for DB75 and DB820.  A 4 mg/kg dose of 
pentamidine is equivalent to approximately 6.75 µmol/kg of the isethionate salt, and 
therefore the dose of pentamidine administered by Carter et al. was slightly lower than the 
dose of DB75 and DB820 administered in our studies, 7.5 µmol/kg.  Also the route of 
administration used for pentamidine in those experiments was intraperitoneal injection.  
Thus, pentamidine required additional time to enter circulation and distribute into 
trypanosomes, and the peak concentration may not have occurred at their tested time point of 
4 hours.  DB75 and DB820 were administered by intravenous injection, and do not require 
extra time to distribute into circulation.  Both the lower dosage and the different route of 
administration could explain the lower concentration of pentamidine in trypanosomes at 4 
hours.  It is also our experience that diamidines need to be administered at a much higher 
dose intraperitoneally to achieve comparable cure rates to a dose after intravenous 
administration.  Although the routes of administration are different in the two studies and 
there are other confounding factors, it is clear that trypanosomes are able to accumulate high 
concentrations of diamidines which leads to killing of the organisms.   
Diamidines such as DB75, DB820, and pentamidine are able to bind DNA in AT rich 
regions of the minor groove (5, 28).  In fact, one of the long hypothesized mechanisms of 
action has been binding to DNA and/or interference with DNA associated enzymes such as 
Topoisomerase II (21, 22).  We expected to, and did, see accumulation of DB75 and DB820 
in the nucleus and the kinetoplast of trypanosomes, the two DNA containing organelles.  
Although DB75 and DB820 bind to DNA in both the nucleus and the kinetoplast, it is not 
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known for certain what effects this may have, or whether accumulation in one organelle has a 
greater impact on the death of the trypanosome.  Future studies are planned to investigate 
whether different amounts of compound bind to the DNA in these organelles and how this 
affects the mechanism of action of the compounds.   
Accumulation in other organelles, such as the organelles believed to be 
acidocalcisomes and several unknown perinuclear organelles was unexpected.  Accumulation 
in these organelles begins about 1 hour after treatment is administered.  This organelle 
accumulation could represent some unknown mechanism of action for diamidines, or it could 
be a source of loss for the compounds.  If these organelles are acidocalcisomes, it is possible 
that the diamidines may have some kind of interaction with polyphosphates that are 
sequestered there.  Acidocalcisomes have been postulated to be involved in many processes, 
including pH regulation and osmoregulation within trypanosomes.  Disruption of these 
processes could potentially be a mechanism of action.  Additionally, these diamidines could 
interfere in polyphosphate accumulation and hydrolysis in acidocalcisomes, a mechanism 
that has previously been shown to interfere with trypanosome virulence in animals (16).  
Supporting the idea of accumulation in the acidocalcisomes as a mechanism of action of 
these compounds, is the investigation by Ormerod and Shaw (19).  In this study it was found 
that stilbamidine and hydroxystilbamidine accumulate in “volutin granules” in trypanosomes.  
One of these authors also noted a shift in the fluorescence of hydroxystilbamidine in these 
granules, much as is seen here with DB75 and DB820 (18).  It is important to consider that 
there may be more than one mechanism of action for diamidine compounds as a class.  
Additionally, individual diamidines may display one or more of these mechanisms of action.  
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In future studies we hope to examine the mechanism of action for these and other diamidine 
compounds.   
Another question that arises from the distribution micrographs shown in Figure 3 is 
what could explain the shift in fluorescence seen with DB75 and DB820 in the kinetoplast, 
acidocalcisomes, and other organelles.  DAPI has been postulated to undergo a red shift in its 
fluorescence emission when accumulated in volutin granules of yeast (1).  Volutin granules 
or the acidocalcisomes in trypanosomes concentrate polyphosphates and pyrophosphates at 
high concentrations, and it has been hypothesized that diamidines such as DAPI interact with 
phosphates, leading to a shift in the fluorescence emission (25).  It appears that the same 
phenomenon occurs with DB75 and DB820 in the posterior organelles, but this does not 
explain why there is a shift in the fluorescence emission in the kinetoplast.  Potentially, two 
different mechanisms could cause the shifts in fluorescence in the organelles.  Fluorescence 
scans of DB75 solutions prepared at low pH indicated no shift in the fluorescence spectrum 
to longer wavelengths; therefore the shift that occurs in these organelles probably does not 
occur due to low pH found inside any of the organelles (J. E. Hall, unpublished data).   
The studies described here have opened many opportunities for the further study of 
diamidine compounds.  The use of fluorescence to track the distribution of compounds in 
trypanosomes will enable us to examine uptake and intracellular accumulation as well as 
distribution and mechanism of action.  When combined with HPLC analysis of 
concentrations of drugs in trypanosomes, this is an exciting technique to evaluate drugs and 
their anti-trypanosomal activity.   The studies described here will be extended to other 
compounds in a library of almost 2000 structurally diverse diamidines in order to assess 
distribution and accumulation over time and how that relates to activity.  Furthermore, using 
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techniques to isolate trypanosome organelles, it will be possible to evaluate the accumulation 
of the compounds in each organelle in order to determine how that may relate to mechanism 
of action.   
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Table 2.1.  in vitro and in vivo activity of diamidine compounds 
Compound In vitro IC50 (nM) 
Dose 
(µmol/kg) Cure Rate (%) 
Mean Survival 
Time (days)a 
1 x 10 67 51 
1 x 5 67 50 
1 x 1.25 0 10 
Pentamidine 1.1 
1 x 0.63 0 7 
     
1 x 10 100 60 
1 x 5 67 47 
1 x 1.25 36 37 
DB75 3.4 
1 x 0.63 17 24 
     
1 x 10 100 60 
1 X 7.5 83 58 
1 x 5 75 49 
1 x 1.25 25 35 
DB820 7.3 
1 x 0.63 0 9 
a Mean Survival Time for untreated control animals was 5-6 days. 
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Figure 2.1.  Chemical structures of DB75, also known as furamidine, and DB820, anti-
trypanosomal diamidine derivatives of pentamidine.   
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Figure 2.2.  In vitro accumulation of DB75 (▲) and DB820 (■) over 24 hours (n=3).  
Trypanosomes were incubated with 7.5 µM of either compound.  Concentrations are 
presented ± SE. 
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Figure 2.3.  Concentration of DB75 (A) and DB820 (B) in S427 trypanosomes and plasma 
after intravenous administration of 7.5 µmol/kg of DB75 or DB820.  Experiments were 
performed with 3-6 mice per time point.  Concentrations in trypanosomes were determined 
based on a volume determination of 58µm3, determined by Opperdoes et al (16).  
Concentrations are presented ± SE. 
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 Figure 2.4.  Fluorescence micrographs of DB75 and DB820 in trypanosomes after 7.5 
µmol/kg intravenous dose of either compound.  A-E show selected time points from DB75 
treated mice, while F-J are from DB820 treated mice.  In select micrographs, the nucleus is 
represented by the arrow (→), the kinetoplast is depicted by an asterisk (*), and the 
acidocalcisomes are indicated by an arrowhead (►). 
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CHAPTER 3 
 
 
ACCUMULATION AND DISTRIBUTION OF DB75 IN TRYPANOSOMES 
LACKING THE P2 TRANSPORTER 
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A. Abstract 
DB75, or furamidine, is the active diamidine of DB289, currently in Phase III clinical trials 
in Africa for the treatment of early stage human African trypanosomiasis.  DB75 has been 
shown in the past to accumulate in trypanosomes via the P2 transporter on the trypanosome 
cell surface.  Accumulation and intracellular distribution of DB75 in three lines which lack 
the drug uptake transporter activity was investigated.  These diamidine resistant lines were 
approximately 20 fold resistant to DB75 in vitro.  DB75 accumulated to high concentrations 
in trypanosomes over time both in vitro and in vivo, although to a lesser extent in the 
resistant lines than in the wild type S427 line.  DB75 accumulated in vitro to concentrations 
between 30 – 60 % of concentrations seen in the wild type line in all three resistant lines, 
TbAT1-/-, DB75R-CL1, and B48.  Accumulation in the three resistant lines was greatly 
reduced in vivo in comparison to the wild type line, especially at the low dose of 5 µmol/kg.  
There was a lack of dose proportionality seen with both trypanosome and plasma 
concentrations.  Trypanosome exposure in the resistant lines was only 5-20% of that seen in 
the wild type S427 line at both doses administered.  Additionally, intracellular distribution 
studies showed that the spread of DB75 to organelles in the resistant lines was much slower 
than that seen in the wild type S427 trypanosomes.  In vivo, in the resistant lines, DB75 did 
not localize extensively to the acidocalcisomes, and was primarily found in the kinetoplast 
and nucleus.  Accumulation in the resistant lines, while not as extensive as in the wild type 
line, indicated that there may be alternate routes of drug accumulation in trypanosomes. 
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B. Introduction 
Human African trypanosomiasis, a parasitic infection caused by Trypanosoma brucei 
spp., is found in sub-Saharan Africa.  Trypanosomiasis has the potential to affect millions of 
people in this African region (19).  Treatments available are limited primarily to four drugs 
which were developed, for the most part, many years ago.  The diamidine pentamidine and 
polysulfated naphthalene suramin are used to treat trypanosomiasis infections in the early, or 
hemolymphatic stage, while melarsoprol and eflornithine are treatments used for the late 
stage of infection, or when the parasite has infected the central nervous system (CNS) (15).  
The prodrug pafuramidine, also known as DB289, is currently in phase III clinical trials for 
the treatment of early stage trypanosomiasis.   
Diamidines, as positively charged molecules at physiological pH, should have slow 
rates of passive diffusion across cellular membranes (4).  DB75 has been shown to have 
limited permeability across Caco2 cell monolayers, especially in relation to its prodrug 
DB289 (20).  Several transporters on the surface of trypanosomes have been implicated in 
the uptake of diamidines in trypanosomes.  Activity for a  high affinity and low affinity 
transporter for pentamidine (HAPT1 and LAPT1) has been determined (4), but no 
endogenous substrates for these transporters have been identified (5).  A purine nucleoside 
transporter, the P2 transporter, has also been found to transport pentamidine, melarsoprol, 
diminazene, and DB75 into trypanosomes (1, 4, 5, 7, 14).    
DB75 is the active diamidine formed from DB289, and has been shown to accumulate 
in trypanosomes through the P2 transporter to high concentrations (10, 11).  Short term 
uptake experiments have shown that the P2 transporter is the primary means of DB75 
accumulation in trypanosomes, and when the transporter activity is eliminated, accumulation 
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is minimal (10).  Use of only one uptake transporter could lead to the development of drug 
resistant parasites in the future, which is important to consider during the drug development 
process.  Pentamidine, a widely studied diamidine, has been shown to accumulate in 
trypanosomes by three uptake transporters, P2, HAPT1 and LAPT1, which could explain the 
lack of resistance associated with this compound despite wide use as a prophylactic for many 
years in Africa (15).   
Melarsoprol and diaminazene (Berenil) are used for human and animal 
trypanosomiasis, respectively.  Both compounds have been shown to be transported by the 
P2 transporter, but TbAT1-/- trypanosomes are 20-fold resistant to diaminazene in 
comparison to the wild type strain, while the trypanosomes are only 2-3 fold resistant to 
melarsoprol (14).  Interestingly, several melarsoprol resistant trypanosome field isolates have 
mutated P2 transporters (13), indicating the importance of this transporter for melarsoprol 
uptake.   
Several trypanosome lines have been developed with alterations to various uptake 
transporters.  The TbAT1-/-, or P2KO, is a double knockout of the TbAT1 allele, which 
encodes the gene for the P2 transporter (14).  Additionally, a laboratory line has been 
generated which is resistant to DB75, and is designated DB75R-CL1.  Genetically, this line is 
also missing the DNA encoding the P2 transporter (10).  A third line, B48, has been 
generated from the TbAT1-/-.  To develop this line, TbAT1-/- was made pentamidine 
resistant, and has lost the activity of HAPT1 (3).  All of these lines are resistant to DB75, and 
display reduced uptake of the compound and other diamidines over short periods of time.  
However, the impact of the lack of the P2 transporter over longer periods of time (i.e. hours) 
has not been investigated until now. 
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 These investigations show that even in trypanosomes lacking the P2 transporter, 
accumulation of DB75 still occurs over time, although to a lesser extent than that of the wild 
type S427 line.  The accumulation in the resistant lines lacking the P2 transporter may be 
indicative of other transport mechanisms able to accumulate DB75 in trypanosomes.  
Distribution studies also show that in resistant trypanosomes, intracellular distribution is 
altered.  Decreased accumulation and altered distribution may explain lower in vitro and in 
vivo potency seen in these resistant trypanosome lines.   
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C. Materials and Methods 
Trypanosomes.  The S427 Trypanosoma brucei brucei line was used as a wild type control 
in all experiments.  TbAT1-/- was derived from S427 as previously described (14).  The 
DB75R-CL1 was derived by incubating S427 trypanosomes with increasing DB75 pressure 
as previously described (10).  B48 was the TbAT1-/- line further selected for pentamidine 
resistance (3).  B48, in addition to loss of the P2 transporter, has lost HAPT1 activity.  
TbAT1-/- and DB75R-CL1 were obtained from Dr. Mike Barrett, and B48 was obtained from 
Dr. Harry de Koning.  The resistant lines were originally cultured in HMI-9 media, and were 
adapted to CBMEM media for in vitro culture.  All four lines were then cultured in CBMEM 
media, as previously described (11).   
In vitro Anti-trypanosomal Activity.  To determine IC50 values, T. b. brucei S427 and T. b. 
rhodesiense STIB900 trypanosomes (2 x 104 per ml) were cultured at 37 ºC and 5% CO2 
with serial dilutions of DB75 for 72 h using a method previously described (16).  After 70 h, 
10 % vol/vol Alamar Blue was added to trypanosomes.  Fluorescence intensity (ex: 544 nm, 
em: 588 nm) was measured 2 h later to determine viability of trypanosomes.  Experiments 
were performed in triplicate with each trypanosome line.  IC50 values were determined using 
the Hill Equation in Prism 4.0 (Graphpad, San Diego, CA) and are the average of at least 3 
determinations.  Fold resistance was calculated by dividing IC50 values determined for 
TbAT1-/-, DB75R-CL1, and B48 lines by the IC50 value determined for the wild type S427 
line.   
In vitro Time-Dose Response.  Time – dose experiments were performed using a method 
adapted from Kaminsky and Brun (8).  These experiments were used to investigate how long 
trypanosomes need to be exposed to DB75 in vitro for the compound to kill the cells.  
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Briefly, trypanosomes were incubated with either 500 nM or 7.5 µM for periods of time 
between 1 h and 48 h (1h, 2h, 4h, 8h, 24h, 48h).  At each time point, trypanosomes were 
washed twice in 1 ml of medium and resuspended in drug free medium.  Trypanosomes were 
inspected daily for survival and motility.  When all trypanosomes in a well were dead as 
determined by microscopic inspection, the time of death and corresponding incubation time 
of DB75 were recorded.   
In vitro accumulation of DB75.  The in vitro accumulation of DB75 was determined in all 
four lines over 8 h, as previously described (11).  Briefly, 106 trypanosomes were incubated 
with DB75 for varying periods of time between 1 and 8 h.  At each time point, trypanosomes 
were washed twice in drug free medium (1 ml), and DB75 was extracted from cells with 4 
volumes of methanol: 0.1 N HCl (8:1 vol/vol).  Half of each sample was evaporated in a 
Zymark (Hopkinton, MA) Turbovap-LV under nitrogen gas (7 psi) and reconstituted in High 
Performance Liquid Chromatography (HPLC) solvent A (described in detail in HPLC 
Analysis of DB75).  The remainder of the sample was retained for future analysis if needed.  
DB75 concentrations in trypanosomes were determined as described previously (11).  
Accumulation of DB75 in each line was measured at 3 concentrations:  150 nM, 500 nM and 
7.5 µM.  150 nM was chosen as it is approximately the IC50 value of the resistant lines.  500 
nM and 7.5 µM were 6 fold lower than and 2 fold higher than the km of DB75 for the P2 
transporter, respectively.   
In vivo Accumulation of DB75 in Trypanosomes and Plasma.  Male Swiss Webster mice 
(25-35 g) were infected with each line of trypanosomes (105 trypanosomes) intraperitoneally 
(IP).  All animal experiments adhered to guidelines outlined by the University of North 
Carolina-Chapel Hill Institutional Animal Care and Use Committee (IACUC).  On the third 
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day post infection, parasitemia was determined by microscopic examination of a drop of 
blood from the tail vein.  Infected mice were treated with one of two doses of DB75 
administered IP: 5 µmol/kg or 15 µmol/kg.  At time points after treatment was administered, 
mice were euthanized by CO2 asphyxiation, and blood was collected by cardiac puncture into 
two lithium heparin coated microtainer tubes (BD Biosciences).  As previously described 
(11), one tube was used to isolate trypanosomes from whole blood, while the other was used 
to determine plasma concentrations of DB75.  Briefly, trypanosomes were isolated by mixing 
whole blood with a Percoll solution (100%) containing 0.25 M sucrose and 0.1 M glucose 
(pH 7.4).  This mixture was centrifuged for 35 min at 13200 rpm (16100 g) in an Eppendorf 
5415R microcentrifuge.  Trypanosomes were isolated from suspension above the red blood 
cell layer, and were washed twice in 1 ml of phosphate saline glucose (PSG), counted and 
drug was extracted with four volumes of 8:1 methanol: 0.1N HCl (vol/vol).  Half of each 
sample was evaporated in a Zymark (Hopkinton, MA) Turbovap-LV under nitrogen gas (7 
psi) and reconstituted in (HPLC) solvent A.  The remainder of the sample was retained for 
future analysis if needed.  Diamidine concentrations in trypanosomes were determined as 
described previously (11).  Plasma was isolated by centrifuging blood at 3000 rpm (1500 g) 
for 10 min to pellet red blood cells, and extracted as described above.  
Intracellular Distribution of DB75 in Trypanosomes.  Intracellular distribution of DB75 in 
the wild type S427, TbAT1-/-, DB75R-CL1, and B48 lines was compared over time in vitro 
and in vivo.  For in vitro experiments, approximately 106 trypanosomes were incubated with 
500 nM DB75.  At time points ranging from 15 min to 8 h after the incubation was started, 
trypanosomes were removed, washed twice in drug free medium (1 ml), and then 
resuspended in 20 µl of freshly isolated mouse blood.  A small drop of blood was placed on a 
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microscope slide and thin films were prepared.  Thin films were viewed within 1 day of 
preparation.  For in vivo experiments, thin films were prepared at each time point in above 
mentioned pharmacokinetic studies.   
Fluorescence Microscopy of DB75 in Trypanosomes.  Thin films were mounted with a 
drop of glycerol before observation.  A Nikon Microphot FXA microscope (Garden City, NJ) 
with a 60 DM x 1.4 NA objective lens, a mercury lamp, and QImaging Micropublisher 3.3 
CCD Digital Camera (QImaging Corporation, Surrey, BC, CA) was used for fluorescence 
microscopy.  QCapture version 3.0 imaging software was used to capture images 
(QImaging).  The microscope was equipped with a Nikon UV2A cube that limits excitation 
wavelengths to 330-380 nm and emission wavelengths to ≥ 420 nm.  The UV2A cube allows 
for the visualization of the blue fluorescence seen in the nucleus and kinetoplast, and the 
yellow/orange fluorescence seen in the acidocalcisomes due to interactions of diamidines 
with polyphosphates in these organelles, as seen previously with yeast volutin granules (18).   
HPLC Analysis of DB75 in Trypanosomes.  HPLC analysis of DB75 was 
performed in a manner similar to that previously described (11).  Evaporated samples were 
reconstituted in HPLC Solvent A (15 mM ammonium formate, 35 mM formic acid in 100% 
HPLC grade water).  A gradient elution was used to resolve DB75, with a starting 
concentration of 95% Solvent A, 5% Solvent B (15 mM ammonium formate, 35 mM formic 
acid dissolved in 4:1 ratio of acetonitrile and HPLC grade water).  Over 18 min, % B was 
linearly increased to 100%, followed by a 5 min post time re-equilibration to starting 
conditions.   
An Agilent 1100 series HPLC equipped with a fluorescence detector (Agilent 
Technologies) was used for analytical procedures.  DB75 was resolved on a 3.5 µm Zorbax 
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Bonus – RP 2.1 x 50 mm column (Agilent Technologies, New Castle, DE) with a flow rate of 
0.35 ml/min.  The column was maintained at 25 ºC throughout the analytical method.  
Injection volume for each sample was 5 µl.  The wavelengths used for fluorescence detection 
were λex = 365 nm and λem = 462 nm.  Compounds were quantified by comparing to 
standards injected during each analytical run.  The standard was used to determine the 
concentration of DB75 in plasma and in trypanosomes.  Concentrations for both compounds 
were expressed as µM for plasma and trypanosomes (based on trypanosome volume of 58 
µm3, or 58 fl).  Concentrations are reported as plus or minus the SE. 
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D. Results 
In vitro Anti-trypanosomal Activity of DB75.  The in vitro anti-trypanosomal activity of 
DB75 was determined in four T. b. brucei lines of trypanosomes – the S427 wild type, and 
three resistant clones derived from it, TbAT1-/-, DB75R-CL1, and B48 (derived from TbAT1-
/-).  DB75 was a potent compound against the wild type line S427 (Table 3.1), with an IC50 
value of 7 nM.  DB75 was less potent against the three resistant lines, which had 
approximately 30 fold resistance to DB75 in comparison to the wild type line.  There was no 
significant difference in the IC50 values for the three resistant lines, but the activity of DB75 
against the three resistant lines was significantly different from that seen in the wild type line 
(p value = 0.007, 0.03, and 0.03 for TbAT1-/-, DB75R-CL1, and B48 respectively, as 
determined by Student’s T-test).  Removal of HAPT1 activity, which is known to be one of 
the transporters involved in uptake of pentamidine into trypanosomes (3), did not further 
increase resistance to DB75 in vitro.   
In vitro Time-Dose Response of DB75.  The incubation time with DB75 required to kill 
trypanosomes was determined.  Each line of trypanosomes was incubated with either 500 nM 
or 7.5 µM DB75 for periods of time ranging between 1 h and 48 h.  With the wild type S427, 
DB75 only needed to be exposed to trypanosomes for 1 h in order for death to occur (Table 
3.2).  Although only 1 hour exposure was sufficient to kill trypanosomes at either 
concentration, the actual time required for trypanosomes to die was at least 48 h, as DB75 is 
a slow acting compound.  With the resistant lines, DB75 needed to be incubated with 
trypanosomes for much longer periods of time in order for killing to occur.  Again, cell death 
did not occur for at least 48 h.  At the 500 nM dose, DB75 needed to be incubated with the 
resistant trypanosomes for at least 24 h for death to occur at 48 h or a few hours later, 
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whereas at the higher dose, 7.5 µM, the resistant trypanosomes needed to be incubated with 
DB75 for between 4-24 h, depending on the line (Table 3.2).  When a range of time is given, 
at least one of the three wells had live trypanosomes at the shorter incubation time, but all 
trypanosomes were dead after the longer exposure time.  It is apparent that even when the P2 
transporter is not present in trypanosomes, DB75 still accumulates sufficiently inside the 
cells to cause death, but either accumulation is less than in the wild type S427 or occurs by a 
much slower route, and therefore longer exposure times are needed to kill trypanosomes.   
In vitro Accumulation of DB75 in Trypanosomes.  Accumulation of DB75 in the wild type 
and resistant lines was measured at three incubation concentrations: 150 nM, 500 nM, and 
7.5 µM (Fig 3.1).  The concentrations were chosen for the following reasons:  150nM is the 
approximate IC50 value for DB75 against the resistant lines, and 500 nM and 7.5 µM are 6 
fold lower and 2 fold higher than the Km value of DB75 for the P2 transporter (3.2 µM), as 
determined by Lanteri et al. (10).  We also attempted to investigate the accumulation of 
DB75 after 10 nM incubation, but concentrations in trypanosomes were at or below the limit 
of quantification by LC/MS detection.   
In vitro accumulation after exposure to 150 nM DB75.  In the wild type S427 line, DB75 was 
accumulated to a peak concentration of approximately 300 µM at 8 h (Figure 3.1A), and 
concentrations of DB75 increased over all time points measured.  In comparison, 
accumulation in the three resistant lines was lower and did not increase substantially over 
time.  After 8 h incubation the TbAT1-/- the DB75 concentration was approximately 50 µM, a 
concentration 17% of the DB75 found in the wild type line.  Concentrations of DB75 in the 
DB75R-CL1 and B48 lines at 8 h were 20% and 23% of wild type concentrations, 
respectively.   
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In vitro accumulation after exposure to 500 nM DB75.  The wild type S427 line accumulated 
DB75 to a concentration of 1.0 ± 0.2 mM after 8 h (Figure 3.1B).  Concentrations in the 
TbAT1-/- line were approximately 600 µM at 8 h.  This concentration represents only 54% of 
the wild type accumulation.  The DB75R-CL1 line accumulated less than 400 µM at 8 h, only 
41% of the wild type.  Accumulation of DB75 in the B48 line was approximately 66% of 
wild type accumulation after 8 h.  As seen in Figure 3.1B, there was no substantial increase 
in trypanosome concentrations over time in any of the lines investigated.   
In vitro accumulation after exposure to 7.5 µM DB75.  At the highest concentration 
investigated, all four lines accumulated DB75 concentrations close to 2 mM after 1 h, even 
when trypanosomes lacked P2 transporter activity (Figure 3.1C).  At the later time points 
investigated, a larger difference was seen between the wild type and resistant lines, as 
concentrations in the S427 increased over the 8 h.  Concentrations in the resistant lines did 
not increase much over the 8 h investigated.  Accumulation in the wild type S427 line at 8 h 
was 6.3 ± 0.8 mM, while concentrations in the resistant lines were around 2-3 mM.  TbAT1-/- 
accumulated approximately 55% of the DB75 found in the wild type line.  DB75R-CL1 
accumulated the least amount of DB75 at 8 h, only 37% of the wild type accumulation.  The 
B48 line accumulated approximately 40% of wild type concentrations.   
In vitro Distribution of DB75 in Trypanosomes.  A time course of DB75 distribution in all 
four lines of trypanosomes was determined over 8 h using a concentration of 500 nM.  
Despite large differences in the fluorescence intensity of DB75 in the four lines (as 
determined by exposure time), care was taken to ensure that pictures were taken at an 
exposure that yielded similar intensity in the micrographs in order to make a better 
comparison between the four lines.  The resistant lines needed to be exposed to UV light for 
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a longer period of time to see fluorescence equivalent to that seen in the wild type line at a 
much shorter exposure time.   
 In the wild type S427 line, DB75 rapidly localized to the kinetoplast and nucleus, the 
two DNA containing organelles in trypanosomes, within 15 min (Figure3.2-S427).  By 2 h, 
DB75 appeared faintly in the acidocalcisomes, which were much brighter by 4 h.  By 6 and 8 
h, fluorescence in the kinetoplast and acidocalcisomes was bright enough to overwhelm the 
appearance of nuclear fluorescence.   
 The distribution to organelles in the resistant lines (Figure 3.2 labeled by 
trypanosome line name), though similar, took longer to occur than in the wild type line.  
When 500 nM DB75 was incubated with the TbAT1-/- line, the compound was barely visible 
in the kinetoplast at 15 min (Figure 3.2), but was found only in this organelle until 4 h, when 
the DB75 was also localized in the nucleus.  Acidocalcisomes were faintly visible at 8 h, but 
only a small number of the organelles appeared to fluoresce yellow and contain DB75.  
DB75 was localized to the kinetoplast after 15 min of incubation with the DB75R-CL1 line 
(Figure 3.2), and appeared much brighter in this organelle than in the TbAT1-/- line.  As with 
the TbAT1-/- line, in the DB75R-CL1 line, DB75 was localized to both the nucleus and 
kinetoplast by 4 h, and appeared in the acidocalcisomes by 8 h.  It qualitatively appeared that 
DB75 accumulated more in the acidocalcisomes at this time point than in TbAT1-/-.  With the 
B48 line, again DB75 appeared first in the kinetoplast by 15 min (Figure 3.2), and spread to 
the nucleus as well by 2 h.  A few acidocalcisomes began fluorescing starting at 6 h.  The 
longer amount of time needed for compounds to accumulate in the nucleus and 
acidocalcisomes may be related to results showing that one needs to incubate the resistant 
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lines with DB75 for longer periods of time in order to kill the resistant trypanosomes (Table 
2).   
In vivo Efficacy of DB75 in Trypanosomes.  The in vivo efficacy of DB75 against the wild 
type S427 and three resistant lines was determined at three doses administered 
intraperitoneally (IP) – 5 µmol/kg, 15 µmol/kg, and 45 µmol/kg (Table 3.3).  The 5 µmol/kg 
dose was unable to cure any resistant lines.  Actually, all three resistant lines were unable to 
clear parasitemia after this dose was administered.  DB75 was able to cure 1 of 3 test mice 
infected with the S427 wild type line, however.  One mouse relapsed 26 days post treatment, 
and was sacrificed due to a high parasitemia burden on day 32 (>>100 parasites/40X field), 
while the second mouse relapsed on day 57 post treatment, and died one day later.  Mice that 
appear lethargic and have very high parasitemia, like the mouse described above, are unlikely 
to self-cure the infection and are euthanized to prevent suffering.   
 At the 15 µmol/kg dose level, all of the mice infected with S427 trypanosomes have 
survived, with no relapses for 60 days (Table 3.3).  2 of 3 TbAT1-/- infected mice treated 
with this dose of DB75 survived for 60 days without relapse; the third mouse did not clear 
the initial parasitemia.  Only 1 mouse infected with DB75R-CL1 trypanosomes survived for 
the 60 day test period with no relapses.  The other two mice in this test group were unable to 
clear the initial parasitemia after treatment with 15 µmol/kg DB75.  Mice infected with B48 
trypanosomes, on the other hand, survived for 60 days with no relapse (Table 3.3).   
 When treated with a 45 µmol/kg dose of DB75, 2 of 3 mice infected with S427 wild 
type trypanosomes have survived for greater than 50 days without relapsing.  One mouse 
died almost 40 days into the test period, but died in between parasitemia measurement 
periods.  Therefore it is unable to conclusively state whether this death was due to a relapse 
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of the infection.  However, mice infected with the TbAT1-/- or DB75R-CL1 lines, so far only 
have 2 of 3 surviving mice (Table 3.3).  With both of these lines, one mouse was unable to 
clear the initial parasitemia, but the other mice were able to survive for greater than 47 days.  
Each of the mice infected with B48 trypanosomes were able to clear parasitemia and have 
not relapsed after 60 days (Table 3.3).    
In vivo Accumulation of DB75 in Trypanosomes and Plasma.  DB75 concentrations were 
determined in trypanosomes isolated from infected mice after a dose of either 5 µmol/kg or 
15 µmol/kg IP was administered.  Plasma concentrations of DB75 were also determined at 
each time point.   
Accumulation of DB75 in trypanosomes and plasma after 5 µmol/kg dose IP.  Concentrations 
of DB75 in all four trypanosome lines were determined at the low dose of 5 µmol/kg IP 
(Figure 3.3 - Figure 3.6).  As seen with the efficacy experiments above, this dose is partially 
curative (1/3) for the wild type S427 line, but was unable to cure mice infected with any of 
the three resistant lines, and was actually insufficient to clear initial parasitemia.   
 In mice infected with the wild type S427 line, the peak plasma concentration, seen at 
15 min after DB75 was administered was 1.6 ± 0.4 µM.  The concentration of DB75 in 
plasma at 24 h was 0.028 ± 0.007 µM.  DB75 accumulated to a peak concentration of 800 ± 
600 µM in trypanosomes at 4 h, before declining to a concentration of 16 ± 4.6 µM at 24 h 
(Figure 3.3A).  The peak concentration in trypanosomes is similar to peak concentrations 
seen after 7.5 µmol/kg DB75 is administered IV to infected mice (11).  Area Under the Curve 
over 24 hours (AUC0-24h) for S427 trypanosomes after the 5 µmol/kg dose was over 5000 
µM*h, while the plasma AUC was only 3 µM*h (Table 3.4).  This represents a 1600 fold 
greater accumulation in trypanosomes than plasma over the investigated time period.   
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 The peak plasma concentration of DB75 in TbAT1-/- infected mice was 2.1 ± 0.4 µM 
after 15 min, and at 24 hours, plasma concentrations were 0.022 ± 0.003 µM, again similar to 
concentrations in the wild type line.  Concentrations of DB75 in TbAT1-/- peaked at 114 ± 94 
µM at 8 h after administration (Figure 3.4A).  24 h after DB75 was administered 
trypanosome concentrations were 16 ± 2.6 µM, similar to 24 h concentrations seen with the 
wild type S427 line.  The AUC of DB75 in TbAT1-/- trypanosomes was approximately 830 
µM*h, only 16% of the AUC of DB75 in S427 trypanosomes (Table 3.4).  Plasma AUC of 
DB75 in the TbAT1-/- line was similar to that seen with the S427 infection (Table 3.4).  The 
ratio of trypanosome AUC to plasma AUC was approximately 270.   
 In mice infected with DB75R-CL1, the peak plasma concentration at 15 min was 2.1 ± 
1.1 µM, and the concentration of DB75 in plasma at 24 h was 0.05 ± 0.008 µM.  In the 
DB75R-CL1 line, the peak concentration in trypanosomes was 50 ± 25 µM 1 hour after DB75 
was administered (Figure 3.5A).  By 24 h, trypanosome concentrations had declined to 2 ± 
0.04 µM, 8 fold lower than the 24 h trypanosome concentration in the S427 and TbAT1-/- 
lines.  The AUC of DB75 in the DB75R-CL1 line was 270 µM*h, only 5% of the AUC seen 
in S427 trypanosomes.  Again, the AUC found in plasma was similar to that of the S427 and 
TbAT1-/- trypanosomes.  The AUC ratio for trypanosomes to plasma was about 70 fold for 
the DB75R-CL1 infection. 
 Mice infected with B48 trypanosomes had plasma concentrations that were higher 
than in the other three lines at all time points examined.  After a peak concentration in plasma 
of 2.4 ± 0.6 µM at 15 min, a low concentration of 0.13 ± 0.04 µM was found in plasma at 24 
h.  This plasma concentration is between 2.6 and 6.5 fold higher than the 24 h plasma 
concentration determined in the other three lines.  DB75 also accumulated the least in the 
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B48 line of trypanosomes.  The peak trypanosome concentration was only 17 ± 5 µM, and 
occurred 12 hours after the compound was administered (Figure 3.6A).  Concentrations in 
trypanosomes did not decline much at 24 h, with a concentration of 13 ± 10 µM seen in 
trypanosomes at that time.  The AUC of DB75 in B48 trypanosomes was approximately 320 
µM*h, 6% of the AUC in S427 trypanosomes.  The plasma AUC was determined to be 4.9 
µM*h, which was higher than plasma AUC values determined for the other three lines 
investigated (Table 3.4).  The AUC ratio for B48 trypanosomes to plasma was about 60 fold.   
Accumulation of DB75 in trypanosomes and plasma after 15 µmol/kg dose IP.  The 15 
µmol/kg IP dose is curative for the wild type S427, and the B48 line.  This dose is the 
approximate ED50 dose for TbAT1-/- and DB75R-CL1. 
 The peak plasma concentration was 15 ± 9 µM, 15 min after DB75 was administered 
to mice infected with S427 trypanosomes.  The peak trypanosome concentration in the S427 
line after the 15 µmol/kg dose was 3289 ± 1236 µM at 2 h (Figure 3.3B).  This concentration 
was almost 4 fold higher than the peak concentration seen after the 5 µmol/kg dose was 
administered.  By 24 h, trypanosome concentrations had only declined to about 400 µM.  The 
AUC of DB75 in trypanosomes was approximately 18000 µM*h, which is a little more than 
3 fold higher than the AUC in trypanosomes after the 5 µmol/kg dose.  The plasma AUC was 
22 µM*h (Table 3.4).  There was almost 800 fold AUC trypanosome/plasma ratio with the 
S427 infection.   
 The peak plasma concentration in mice infected with the TbAT1-/- line was similar to 
that found in the S427 line, with a plasma concentration of 17 ± 4 µM after 15 min (Figure 
3.4B).  For the TbAT1-/- line, peak trypanosome concentrations were 380 ± 280 µM 1 h after 
administration, a concentration 3 fold the peak concentration seen with the lower dose.  This 
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peak concentration was also approximately 10 fold lower than the S427 peak concentration.  
Trypanosome concentrations at 24 h were 26 ± 15 µM.  The trypanosome AUC in the 
TbAT1-/- was 3500 µM*h, 20% of the AUC determined for S427 trypanosomes (Table 3.4).  
Plasma AUC was similar to that of the S427 infected mice at the 15 µmol/kg dose.  
Trypanosome to plasma AUC ratio for TbAT1-/- infected mice was about 160 fold.   
 In mice infected with DB75R-CL1 trypanosomes, plasma concentrations peaked at 29 
± 9 µM after 15 min, double the concentration seen in the plasma of S427 and TbAT1-/- 
trypanosomes (Figure 3.5B).  At 24 h, 2 of the 3 mice investigated had plasma concentrations 
of DB75 that were below the limit of quantification by HPLC with fluorescence detection, 
which was surprising given the low trypanosome concentrations at 24 h.  A peak 
trypanosome concentration of 430 ± 350 µM DB75 occurred after 1 hour.  This peak 
concentration is 9 fold higher than the peak trypanosome concentration after the 5 µmol/kg 
dose.  Trypanosome concentrations decline to about 16 ± 15 µM at 24 h (Figure 3.5B).  
DB75R-CL1 AUC was approximately 3000 µM*h, 17% of the AUC seen in S427 
trypanosomes (Table 3.4).  Plasma AUC was 32 µM*h, which was slightly higher than seen 
with either the S427 or TbAT1-/- infected mice.  The ratio of DB75R-CL1 AUC to plasma 
AUC was almost 90 fold.   
 The peak plasma concentration in mice infected with B48 trypanosomes was 31 ± 12 
µM, similar to plasma concentrations from DB75R-CL1 infected mice.  As with the low dose, 
DB75 peaked in B48 trypanosomes at 12 h, with at concentration of 146 ± 75 µM.  The peak 
concentration in trypanosomes after the 15 µmol/kg dose was 9 fold higher than after the 5 
µmol/kg dose.  After the peak, concentrations in trypanosomes declined to 40 ±18 µM at 24 h 
(Figure 3.6B).  The AUC in B48 trypanosomes was determined to be 2000 µM*h, which is 
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11% of the S427 AUC (Table 3.4).  Similar to the DB75R-CL1 infected mice, the plasma 
AUC for the B48 infected mice was approximately 30 µM*h.  The ratio of trypanosome to 
plasma AUC was approximately 65 fold.  As mentioned previously, the concentrations 
achieved in the B48 trypanosomes were sufficient to clear parasitemia and cure the infection 
(Table 3.3). 
Additionally, if the concentration vs. time profile is normalized for the dose 
administered, differences were seen.  For all of the four lines, overall concentrations in 
trypanosomes did not increase linearly with increasing dose.  For the wild type S47 and 
TbAT1-/- lines, the Cmax concentrations normalized for dose did increase linearly, but it 
must be cautioned that the Tmax shifted with increasing dose, especially with the TbAT1-/- 
line (8 h to 1 h).  In terms of AUC in relation to dose, the trypanosome AUC in the S427 wild 
type line and the TbAT1-/- line increased approximately linearly with increasing dose, 
although both lines had a slightly higher AUC at the 15 µmol/kg dose than would be 
predicted based on the 5 µmol/kg dose.  For the DB75R-CL1 and B48 lines, the trypanosome 
AUC increase with increased dose was nonlinear, as the AUC values determined at the 
higher dose were 7-11 times higher than the AUC found at the lower dose (Table 3.4).  
Plasma concentrations also increased nonlinearly with increasing dose, as the peak 
concentrations and AUC were much higher with the 15 µmol/kg dose in comparison to the 5 
µmol/kg dose for all lines investigated.   
In vivo Distribution of DB75 in Trypanosomes.  In vivo distribution of DB75 in all four 
trypanosome lines was similar to that seen in vitro.  Distribution of DB75 in each 
trypanosome line after both 5 µmol/kg and 15 µmol/kg doses is presented.   
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Intracellular distribution after 5 µmol/kg dose.  After a 5 µmol/kg dose administered to mice 
infected with the wild type S427 strain, DB75 appeared in the nucleus and kinetoplast after 
15 min.  By 1 – 2 h, acidocalcisomes were becoming fluorescent as well.  Fluorescence in the 
acidocalcisomes became more intense over the 24 h period investigated.  By 24 h, DB75 
appeared to primarily be localized only in the nucleus and acidocalcisomes (Figure 3.7).   
 In the three resistant lines, DB75 appeared in the kinetoplast after 15 min (Figure 
3.7).  DB75 then localized to the nucleus, as well as the kinetoplast, over time in each of the 
lines.  By 1 h, DB75 appeared in the nucleus of TbAT1-/- trypanosomes, but faded over time.  
By 24 h, DB75 was localized to only the kinetoplast in TbAT1-/- trypanosomes.  For the 
DB75R-CL1 line, DB75 was localized to the nucleus by 2-4 h, and like TbAT1-/- 
trypanosomes, appeared only in the kinetoplast by 24 h.  In the B48 line, DB75 appeared in 
the nucleus by 4 h, but by 8 h was again found only in the kinetoplast (Figure 3.7).   
Intracellular distribution after 15 µmol/kg dose.  In the wild type S427 line, DB75 was 
localized to the kinetoplast and nucleus 15 min after administration of the compound IP 
(Figure 3.8).  By 2 hours, DB75 was localized to the nucleus, kinetoplast and 
acidocalcisomes, a pattern which remained the same over the 24 h investigated.   
 In the resistant lines, DB75 appeared in the kinetoplast by 15 min, and sometimes 
very faintly in the nucleus at this time as well (Figure 3.8).  Between 2 and 4 h, DB75 spread 
to the nucleus as well as the kinetoplast for all three resistant lines.  Distribution in the 
acidocalcisomes was found at varying times in the resistant lines – between 4 and 8 h.  At 
later time points, the three lines differed in their distribution profiles, perhaps related to 
differing concentrations in these lines at the later time points.  DB75 is found in the nucleus, 
kinetoplast and acidocalcisomes at 24 h in the TbAT1-/- line, but was only faintly localized in 
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some of these organelles for the DB75R-CL1 and B48 lines.  DB75 appears very faint in 
these two lines at 24 h (Figure 3.8).  
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E. Discussion 
 Drug resistance is an important consideration for any new potential therapy, but is 
especially important for new drugs for trypanosomiasis.  Only a few treatments are currently 
available for treating trypanosomiasis, with melarsoprol already associated with drug 
resistance and treatment failures.  Diamidine compounds like pentamidine and DB75 are 
accumulated in trypanosomes through uptake transporters on the surface of the cell (4, 5, 10).  
Uptake of a diamidine through more than one transporter has been shown to be beneficial in 
the past.  Pentamidine is accumulated through three transporters and has shown little clinical 
resistance despite extensive use (5).  Melarsoprol and diminazene, on the other hand, are 
thought to be transported into trypanosomes primarily by one transporter, and have been 
associated with drug resistance (6, 12, 13).  Additionally, several clinical isolated strains that 
are drug resistant have been found to have mutated drug uptake transporters (13).   
 Several trypanosome lines have been created which lack uptake transporters or 
transporter activity.  TbAT1-/- and the DB75R-CL1 are both missing DNA containing the 
gene for the P2 transporter (10, 14).  The B48 line, created as a pentamidine resistant line 
from TbAT1-/-, lacks both the P2 transporter and HAPT1 activity (3).  Past studies have 
suggested that the P2 transporter is the primary means for accumulation of DB75 in 
trypanosomes, and that without this transporter, short term uptake of DB75 was almost 
nonexistent (10).  However, investigations here have shown that accumulation of DB75 still 
occurs in trypanosomes lacking the P2 transporter over longer periods of time both in vitro 
and in vivo.   
 In vitro activity of DB75 against wild type S427, TbAT1-/-, and DB75R-CL1 lines 
determined here were lower than previously reported (10), but the fold resistance is similar to 
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the previous work.  B48, which also lacks HAPT1 activity, has a similar resistance profile to 
the other two resistant lines, indicating that HAPT1 does not play a major role in the uptake 
of DB75 into trypanosomes.  However, there were large differences in the time that DB75 
needs to be exposed to the different trypanosome lines in order for killing to occur.  With the 
wild type line, DB75 only needs to accumulate in trypanosomes for an hour (from 
accumulation data, this would be an accumulation of 1-2 mM).  In the resistant lines, DB75 
needs to accumulate in the cells for much longer periods of time in order to cause 
trypanosome death.  This could be due to differences in intracellular distribution, and that the 
resistant lines appear to need much longer times to achieve similar intracellular distribution 
patterns to the wild type line.   
 Surprisingly, accumulation of DB75 in the lines lacking uptake transporters was high 
(µM to mM concentrations), as seen in Figure 3.1.  At the lowest concentration of DB75 
investigated, 150 nM, we saw the largest difference in accumulation between the wild type 
and resistant lines.  In the S427 line, DB75 concentrations increased over the 8 h period 
investigated, while concentrations in the other lines investigated reached a plateau between 
50 and 100 µM, about 20% of wild type S427 concentrations.  At the higher doses, the gap 
between the wild type and resistant line concentrations became smaller, with the resistant 
lines accumulating 40-60% of the DB75 found in the wild type line.  The higher 
concentrations may have been overwhelming to trypanosome transporters, which could have 
reduced the effect of the line differences.  It is possible that at higher concentrations of DB75 
other uptake processes may have taken over in the resistant lines, allowing for increased 
accumulation at the higher dose levels.  Perhaps there is an unknown low affinity, high 
capacity transporter capable of accumulating DB75.   
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 The discrepancies in the in vitro accumulation experiments and previous experiments 
detailing short term uptake rates bear further investigation.  Extrapolating from the rate 
determined by Lanteri et al. for uptake in TbAT1-/- and DB75R-CL1 lines (approximately 
0.01 pmol/107cells/min (10)), concentrations of DB75 in trypanosomes after 8 h would be 8.3 
µM after a 1 µM dose, yet after 500 nM DB75, a concentration of almost 400 µM was seen.  
Therefore, it is unlikely that one can extrapolate from short term experiments to longer ones.  
It would be prudent to investigate uptake and accumulation over short and long periods of 
time.   
The in vitro experiments performed in this study were performed in CBMEM media, 
while short term accumulation experiments were conducted in Carter’s Balanced Salt 
Solution (CBSS) (10).  Additionally, in the short term experiments, trypanosomes are usually 
isolated from rats, and used ex vivo.  There may be some differences between trypanosomes 
in vitro and in vivo.  Although the media contains more protein, it is unclear if there is any 
advantage to DB75 accumulation in trypanosomes in the presence of serum proteins.  Further 
experiments are planned in which accumulation is investigated in several serum free media 
and buffer systems.   
 Additionally, CBMEM media contains high concentrations of adenosine and other 
purines.  The concentration of adenosine in the media is approximately 80 µM.  Adenosine 
has been shown to inhibit DB75 uptake into trypanosomes with an IC50 value of 0.8 µM (9).  
With concentrations in media 100 fold above the concentration necessary to inhibit DB75 
uptake by 50%, it is possible that the P2 transporter is saturated.  Therefore, accumulation of 
DB75 that occurs in this media system may be largely independent of the P2 transporter.  It is 
unknown whether adenosine’s ability to inhibit DB75 accumulation extends over time or if it 
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is a short term phenomenon.  Furthermore, DB75 has a similar affinity for the P2 transporter 
and has been shown to inhibit adenosine uptake into trypanosomes with a similar IC50 value 
(9).  However, this does not explain why accumulation of DB75 is still reduced in the 
absence of the P2 transporter.  This puzzling finding needs further investigation.  One 
research strategy may be to implement a stepwise change in the media/buffer system – from 
the CBMEM media to a buffer system like CBSS, with accumulation of DB75 measured 
with each change.  The first step would be to remove adenosine alone from the media, 
leaving other purines (for example, hypoxanthine) in the media which are not substrates for 
the P2 transporter.  A gradual decrease in the amount of fetal bovine serum (FBS) could be 
the next step, with the final media containing no protein.  Then a change to various buffer 
systems, with and without serum proteins can be used to determine accumulation of DB75.   
 In vitro distribution studies showed DB75 accumulation (at a 500 nM dose) in the 
kinetoplast of TbAT1-/-, DB75R-CL1, and B48 after 15 min.  This concentration is much 
lower than ones previously used before (10, 17).  Although DB75 is found in the kinetoplast 
after 15 min in all three resistant lines, the distribution pattern spreads over a much longer 
time course than in the wild type line.  It is not until 8 h that the resistant lines show the same 
distribution that is found in the wild type line after 1-2 h.  This delayed distribution could 
explain the need for longer incubation times with DB75 to induce killing in the resistant lines 
in vitro.   
 In vivo efficacy of DB75 against the S427 line was similar to previous reports (10), 
where a 4 X 0.5 mg/kg dose cured infected mice.  In the TbAT1-/- and DB75R-CL1, DB75 
was able to cure infections after a dose of 4 X 2.5mg/kg and 4 X 1 mg/kg respectively. The 
cumulative dose administered to wild type trypanosomes in the previous report was 2 mg/kg, 
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equivalent to the 5 µmol/kg dose administered in these experiments, which cured 2 of 3 mice 
infected with S427 trypanosomes in this investigation.  The 15 µmol/kg dose cured all 
animals infected with S427 trypanosomes and B48 trypanosomes, but only partially cured 
TbAT1-/- and DB75R-CL1 lines.  Similar response was seen after a 45 µmol/kg dose was 
administered.  Efficacy of DB75 in all strains needs to be examined in larger test groups in 
order to have sufficient power to determine differences between dose levels administered.   
One discrepancy between our results and previous data is in relation to the in vivo 
virulence and infectivity of B48.  Bridges et al. report that in their hands, B48 was unable to 
produce a virulent infection in ICR mice, with self – cures occurring even when mice were 
immunosuppressed with cyclophosphamide before infection (3).  Berger et al. also developed 
a pentamidine resistant line under laboratory conditions and found that it had reduced 
virulence in Tyler’s original mice.  However, by increasing the concentration of 
trypanosomes injected into mice 250 fold, they were able to see equivalent survival time (2).  
It has been suggested that the acquisition of pentamidine resistance has led to decreased 
virulence of both of these lines, but in our hands, we saw no decreased virulence when Swiss 
Webster mice were infected with the B48 line.  Our experiments did use a higher inoculum 
(105 trypanosomes compared to 104 trypanosomes) than that of Bridges et al. (3).  At this 
infection concentration, we saw similar virulence in terms of parasitemia and mouse death 
due to the infection.  It is unknown at this time whether the ICR mice and Swiss Webster 
mice react differently to this parasite, or if there is some other cause for the differences in 
virulence of the B48 line.   
In vivo accumulation of DB75 in the trypanosome lines investigated yielded 
interesting results.  At the lowest dose investigated, 5 µmol/kg DB75, peak concentrations in 
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the S427 wild type trypanosomes were very similar to concentrations seen previously with a 
7.5 µmol/kg IV dose (11).  However, the resistant lines concentrations were greatly reduced.  
Peak accumulation of DB75 in TbAT1-/- trypanosomes was 14% of S427 accumulation, and 
was only 6% and 2% in DB75R-CL1 and B48, respectively, after the 5 µmol/kg dose.  These 
low concentrations are likely to be why this dose was insufficient to cure mice infected with 
the resistant lines.  This indicates that we may need to be concerned with under dosing of 
DB75 leading to a greater chance of drug resistance in patients.   
What was really interesting though was the lack of dose proportionality in 
trypanosome and plasma concentrations with the two doses.  While the peak concentration of 
DB75 in S427 trypanosomes at the 15 µmol/kg dose was a little more than 3 fold higher than 
after the 5µmol/kg dose, in two of the resistant lines, peak concentrations were 9 fold higher 
at the higher dose (DB75R-CL1 and B48).  Like the S427 line, TbAT1-/- concentrations were 
3 fold higher at the 15 µmol/kg dose compared to the 5 µmol/kg dose.  Peak plasma 
concentrations after the 15 µmol/kg dose were also much higher than that seen after the 5 
µmol/kg dose was administered.  Plasma AUC at the higher dose was 7-8 fold higher than 
seen at the lower dose for mice infected with any of the 4 lines, despite only a 3 fold increase 
in dose.  Additionally much lower concentrations were able to cure the B48 trypanosome 
infection compared to the other resistant lines.   
The studies described here are the first to investigate long term accumulation of 
diamidines like DB75 in trypanosomes which lack the P2 transporter, and are therefore 
resistant to DB75.  Short term accumulation experiments have indicated minimum 
accumulation in the DB75R-CL1 and TbAT1-/-, but nonetheless, the authors of those 
experiments found that DB75 was still able to kill these trypanosomes in vitro, albeit over a 
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longer period of time (10).  Lanteri et al. were unable to grow the DB75R-CL1 line in vitro in 
the presence of DB75 for longer than 4 days, even at concentrations well below that with 
which resistance was selected (10).  The studies here have shown that this is due to 
accumulation in these resistant lines, perhaps by some unknown uptake transporter.  
Although the distribution in all three of these resistant lines spreads slower throughout the 
trypanosome, by 8 h in vitro similar distributions are seen in drug resistant and wild type 
trypanosomes.  In vivo accumulation of DB75 in resistant trypanosomes was much lower, 
but in some lines, concentrations were high enough to cure infection.  In vivo distribution in 
the resistant lines never achieved the distribution seen in the wild type line.  This is likely 
related to the much lower concentration of DB75 found in the three resistant lines.   
Much remains to be studied with drug resistance and DB75, especially since DB289 
will likely be available for clinical use in a few years.  Whether clinical resistance to this 
compound will be a factor in the future still needs to be determined.  Melarsoprol resistant 
lines isolated from patients in the clinic have been shown to have defective P2 transporters 
(with mutated amino acids) (13).  To our knowledge accumulation and distribution of DB75 
over long periods of time has not been investigated in any of these clinical lines.  Since the 
resistant lines created in the laboratory actually have the entire genetic sequence of the P2 
transporter removed, it is unknown how well these lines will actually predict the many forms 
of mutations that may be seen in patients due to drug resistance.  Additionally, it seems 
imperative that the accumulation and distribution of DB75 in these drug resistant 
trypanosomes be determined after the administration of the prodrug DB289.  DB75 
concentrations in plasma after administration of DB289 are not as high as that seen after 
administration of the active drug alone, and this may lead to lower concentrations in drug 
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resistant trypanosomes.  Determining concentrations in trypanosomes during a multiple dose 
administration regimen will also allow us to investigate the impact of drug resistance in these 
resistant lines in a more clinically relevant manner, as DB289 will be administered as on a 5 
day dosing schedule.   
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Table 3.1:  In vitro Antitrypanosomal Activity of DB75 Against Wild Type Line and 
Resistant Lines Lacking Uptake Transporters 
Line IC50 value (nM) Fold Resistance 
S427 (wild type) 6.5 ± 5.7  
TbAT1-/- 179.6 ± 34.7 25 
DB75R-CL1 200 ± 71.3 28 
B48 159.6 ± 30.6 31 
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Table 3.2:  Time of Incubation Necessary for DB75 to Kill Trypanosomes in vitro 
 S427 TbAT1-/- DB75R-CL1 B48 
500 nM 1 h 24 h >48 h 48 h 
7.5 µM 1 h 4-8 h 8-24 h 8-24 h 
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Table 3.3:  In vivo Efficacy of DB75 Against Wild Type Line and Lines Lacking Uptake 
Transporters at Three Doses 
Line Dose Cure Rate MST (days) 
45 µmol/kg IP 2/3 >55 
15 µmol/kg IP 3/3 60 S427 
5 µmol/kg IP 1/3 49 
    
45 µmol/kg IP 2/3* >33 
15 µmol/kg IP 2/3* 41 TbAT1-/- 
5 µmol/kg IP 0/3 4 
    
45 µmol/kg IP 2/3* >33 
15 µmol/kg IP 1/3* 23 DB75R-CL1 
5 µmol/kg IP 0/3 5 
    
45 µmol/kg IP 3/3 >53 
15 µmol/kg IP 3/3 60 B48 
5 µmol/kg IP 0/3 6 
MST = mean survival time in days, cure rate represents animals surviving without 
parasitemia 
*Animal(s) died before clearing initial parasitemia, and the survivors did not relapse over the 
60 day test period. 
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Figure 3.1:  In vitro accumulation of DB75 in wild type and drug resistant trypanosomes over 
time at three concentrations. 
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Figure 3.2:  in vitro distribution of 500 nM DB75 in the wild type S427 and three resistant 
lines (TbAT1-/-, DB75R-CL1, and B48) over time.   
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Figure 3.3:  Accumulation of DB75 in wild type S427 trypanosomes at a dose of 5 µmol/kg 
and 15 µmol/kg administered IP.   
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Figure 3.4:  Accumulation of DB75 in TbAT1-/- trypanosomes after a 5 µmol/kg dose and a 
15 µmol/kg dose administered IP.   
0 4 8 12 16 20 24
0.01
0.1
1
10
100
1000
TbAT1-/-
plasma
tim e (h)
µM
 D
B
75
0 4 8 12 16 20 24
0.1
1
10
100
1000
TbAT1-/-
plasma
time (h)
µM
 D
B
75
A. 5 µmol/kg DB75
B. 15 µmol/kg DB75
 
 
 113
Figure 3.5:  Accumulation of DB75 in DB75R-CL1 trypanosomes after a 5 µmol/kg and a 15 
µmol/kg dose administered IP.   
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Figure 3.6:  Accumulation of DB75 in B48 trypanosomes after a 5 µmol/kg and a 15 µmol/kg 
dose administered IP.   
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Figure 3.7:  in vivo distribution of DB75 in wild type and drug resistant trypanosomes after a 
5 µmol/kg dose of DB75 administered IP.  Distribution in S427, the wild type line is shown 
in the left column, with the distribution in the resistant lines in the three right columns 
(TbAT1-/-, DB75R-CL1, and B48, respectively). 
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Figure 3.8:  in vivo distribution of DB75 in wild type and drug resistant trypanosomes after a 
15 µmol/kg dose of DB75 administered IP.  Distribution in S427, the wild type line is shown 
in the left column, with the distribution in the resistant lines in the three right columns 
(TbAT1-/-, DB75R-CL1, and B48, respectively). 
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A.  Abstract  
Human African trypanosomiasis is a devastating disease with only a few treatment options, 
including pentamidine.  Diamidine compounds such as pentamidine, DB75, and DB820 are 
potent antitrypanosomal compounds.  Previous investigations have shown that diamidines 
accumulate to high concentrations in trypanosomes.  However, the mechanism of action of 
this class of compounds remains unknown.  A long-hypothesized mechanism of action has 
been binding to DNA and interference with DNA-associated enzymes.  The fluorescent 
diamidines, DB75 and DB820, have been shown to localize not only in the DNA containing 
nucleus and kinetoplast of trypanosomes, but also to the acidocalcisomes.  Here we 
investigate two series of analogs of DB75 and DB820 with varying in vitro antitrypanosomal 
activity to determine whether any correlation exists between trypanosome accumulation, 
distribution and in vitro activity.  Despite wide ranges of in vitro antitrypanosomal activity, 
all of the compounds investigated accumulated to millimolar concentrations in trypanosomes 
over 8 hours.  Interestingly, some of the less potent compounds accumulated to 
concentrations much higher than more potent compounds.  All of the compounds were 
localized to one or both of the DNA containing nucleus or kinetoplast, and many were also 
found in the acidocalcisomes.  Accumulation in the nucleus and kinetoplast should be 
important to the mechanism of action of these compounds. The acidocalcisomes also may 
play a role in the mechanism of action of these compounds.  This investigation suggests that 
the extent of accumulation alone is not responsible for killing trypanosomes and that 
organelle specific accumulation may not predict in vitro activity.    
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B.  Introduction 
 Diamidine compounds, such as pentamidine, propamidine and diminazene have been 
used for many years as chemotherapeutic agents for infections caused by a variety of 
microbes, including parasites and fungi.  Pentamidine has been used for almost 60 years as a 
treatment for human African trypanosomiasis, and is also used to treat leishmaniasis and the 
opportunistic infection Pneumocystis pneumonia (32).  Diminazene has been used widely for 
animal trypanosomiasis (9), and has also been used for humans (25).  Recently pafuramidine, 
or DB289, a methamidoxime prodrug of the diamidine DB75 (furamidine), has been 
developed as an oral treatment for early stage sleeping sickness caused by Trypanosoma 
brucei gambiense.  DB289 is currently in Phase III clinical trials in sub-Saharan Africa (6).  
In addition to DB75 and DB289, a library of diamidines and prodrugs has been synthesized, 
with variable activity against many parasites (1-3, 14-18, 32).   
Although diamidines have been used therapeutically for over half a century, their 
mechanism of action is not well understood.  Many mechanisms of action have been 
proposed (32), but one mechanism of action of diamidines that has often been hypothesized 
is binding to DNA in the nucleus or kinetoplast, leading to interference of DNA associated 
enzymes such as Topoisomerase II (27, 34).  Pentamidine has also been shown to linearize 
kinetoplast DNA (kDNA) isolated from trypanosomes (27), which could play an important 
role in the compound’s mechanism of action.  Furthermore, ultrastructural studies of whole 
trypanosomes have demonstrated that diamidines such as pentamidine have an impact on the 
kinetoplast of trypanosomes, perhaps leading to the disintegration of kDNA (33).  However, 
neither quantitative nor qualitative investigations have been performed to determine in which 
compartments pentamidine localizes in trypanosomes.  This is not surprising, as pentamidine 
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is not a fluorescent compound, and therefore its intracellular distribution cannot be tracked 
using microscopy.   
Several innately fluorescent compounds related to pentamidine have been 
investigated qualitatively in cancer cells (19, 20) to determine effects of structural 
modifications on nuclear distribution.  Compounds tested included DB75, and the substituted 
diamidines DB569, DB244 and DB249, and the imidazoline DB60 (Figure 4.1).  Lansiaux et 
al. found that of the three substituted diamidines, only the N-phenyl substituted DB569 had 
an altered distribution in cells.  While the other compounds were localized to the nuclei of 
cancer cells, DB569 was found only in the mitochondria (20). 
More recently, the accumulation and distribution of two fluorescent analogs of 
pentamidine, DB75, and its aza analog, DB820, in trypanosomes were described (24).  Both 
compounds accumulated within trypanosomes to millimolar concentrations both in vitro, and 
in an in vivo mouse model, with concentrations in trypanosomes approximately 1000 fold, or 
greater, the environmental concentrations.  These compounds are distributed not only in the 
nucleus and kinetoplast, the DNA containing organelles of trypanosomes, but were also 
found to be localized to acidocalcisomes.  Although DNA binding has been hypothesized to 
be the mechanism of action for diamidines, accumulation in the acidocalcisomes or other 
organelles may also play an important role in killing these parasites.  
This paper describes the in vitro activity, DNA binding ability, accumulation, and 
distribution for thirteen structurally related compounds.  While some are intensely 
fluorescent and others are not as fluorescent, we have combined qualitative microscopy 
studies to determine intracellular localization of the compounds with quantitative High 
Pressure Liquid Chromatography (HPLC) and Liquid Chromatography/Mass Spectrometry 
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(LC/MS) to determine the concentration of compounds within trypanosomes.  The 
compounds investigated, which have the same core structure, do have several structural 
modifications that could influence activity and DNA binding, as well as accumulation and 
distribution within trypanosomes.  Here we investigate two series of compounds – diphenyl 
furans (including DB75) and aza analogs of diphenyl furans (including DB820) to determine 
whether any correlation exists between trypanosome accumulation and intracellular 
distribution and in vitro activity.   
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C.  Materials and methods 
Antitrypanosomal Diamidines.  Diamidine compounds were synthesized as previously 
described (3, 7, 16, 20).  Stock solutions of the compounds were prepared at a concentration 
of 1 mM in sterile distilled water.   
In vitro Antitrypanosomal Activity.  To determine IC50 values, T. b. brucei S427 and T. b. 
rhodesiense STIB900 trypanosomes (2 x 104 per ml) were cultured at 37 ºC and 5% CO2 
with serial dilutions of the diamidines for 72 h using a method previously described (26).  
The T. b. brucei S427 strain is routinely used at UNC for in vitro activity, compound 
accumulation and intracellular distribution studies.  The T. b. rhodesiense STIB900 strain is 
routinely used at the Swiss Tropical Institute for screening diamidine compounds for both in 
vitro and in vivo activity (15).  Experiments were performed in triplicate with each 
trypanosome strain.  IC50 values were determined using the Hill Equation, and are the 
average of at least 3 determinations.   
DNA binding by thermal melting. Thermal melting experiments were conducted with a 
Cary 300 Bio UV-Visible spectrophotometer (Walnut Creek, CA) as previously described 
(35).  DNA samples for melting studies were added to 1 ml of MES buffer (0.01 M MES, 0.1 
M NaCl, 0.001 M EDTA, pH 6.2) in 1 cm path length reduced volume quartz cells.  
Experiments were generally conducted at a concentration of 5×10-5 M in base pairs for 
polydA·polydT or 1×10-6 M in duplex for the self-complementary oligomer, 
[d(CGCGAATTCGCG)2] (The Midland Certified Reagent Company, Inc., Midland, Texas) 
which has a single AT binding site for the diamidines.  The concentration of DNA was 
determined by measuring the absorbance at 260 nm.  For the diamidine-DNA complexes, a 
ratio of 1:1 compound to DNA oligomer duplex or a ratio of 0.6 compound/DNA base pairs 
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with polydA·polydT was used.  A thermistor fixed into a reference cuvette was used to 
monitor the temperature and the heating rate was 0.5 °C/min.  The data were collected as 
absorbance (A) versus temperature (T) by a computer which also controlled the instrument. 
The melting temperature (Tm) values for DNA alone or for the complex of DNA and 
compound were determined by first derivative analysis (plot ∆A/∆T versus T) where the 
maximum marks Tm at the inflection point in the sigmoidal melting curve (A versus T). 
∆Tm = Tm for complex – Tm for DNA 
 
Fluorescence Spectra of Diamidines in Aqueous Solution.  Fluorescence scans to 
determine excitation and emission maxima were performed using a Perkin Elmer 
Luminescence Spectrophotometer (LS 50B) using FL Winlab Version 4.00.02 software 
(Perkin Elmer, Wellesley, MA).  Compounds were prepared as 500 nM solutions in distilled 
water.  One ml of each solution was transferred to a disposable cuvette (Fisher Scientific) and 
the fluorescence spectrum was determined.  Fluorescence intensity measurements were then 
determined using the λex and λem maxima.   
For some compounds, the fluorescence properties were determined in the presence of 
DNA.  Briefly, fluorescence emission spectra were obtained with a Cary Eclipse 
spectrofluorometer with software provided to control the instrument and collect the 
fluorescence data. Typically, the fluorescence intensity for a compound at a concentration of 
1 µM was measured at 25 °C in MES buffer.  Compounds were excited at their maximum 
excitation wavelength as determined above and fluorescence emission spectra were collected.  
A solution of the compound was titrated with aliquots of a stock solution of Clostridium 
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perfringens genomic DNA (Sigma) that contains 72% AT base pairs and the samples were 
rescanned for the emission spectra.   
In vitro Accumulation of Diamidines in S427 Trypanosomes.  To determine in vitro 
accumulation of diamidines within trypanosomes over time, approximately 106 trypanosomes 
were incubated with 7.5 µM of each diamidine for time periods ranging from 1 to 8 h.  At 
each time point, trypanosomes were washed twice in fresh drug-free media, lysed, and 
extracted in 4 volumes of 8:1 methanol: 0.1 N HCl (vol/vol).  Half of each sample was 
evaporated in a Zymark (Hopkinton, MA) Turbovap-LV under nitrogen gas (7 psi) and 
reconstituted in High Performance Liquid Chromatography (HPLC) solvent A (described in 
detail in HPLC Analysis of Diamidines).  The remainder of the sample was retained for 
future analysis if needed.  Diamidine concentrations in trypanosomes were determined as 
described previously (24).   
In vitro Distribution of Diamidines in S427 Trypanosomes.  S427 trypanosomes were 
cultured in 24 well plates (Corning Costar, Fisher Scientific) at a starting concentration of 
105 trypanosomes/ml.  Diamidines were added to each well to a final concentration of 500 
nM.  Trypanosomes were incubated with the diamidines for 8 h at 37ºC, and then 
trypanosomes were examined under a light microscope for motility and viability.  
Trypanosomes were washed twice in 1 ml fresh medium which contained no diamidine and 
resuspended in 20 µl of freshly isolated mouse blood.  A small drop of blood was placed on a 
microscope slide and thin films were prepared.  Thin films were used to reduce the photo 
bleaching that occurs when viewing live trypanosomes under the UV-fluorescence cube.  No 
differences in intracellular distribution of fluorescence were seen when live trypanosomes 
were viewed under fluorescent light.   
  
  
 127
Fluorescence Microscopy of Diamidines in Trypanosomes.  Thin films were mounted with 
a drop of glycerol before observation.  A Nikon Microphot FXA microscope (Garden City, 
NJ) with a 60 DM x 1.4 NA objective lens, a mercury lamp, and an Optronics DEI 750 CCD 
camera (Goleta, CA), was used for fluorescence microscopy.  The microscope was equipped 
with a Nikon UV2A cube that limits excitation wavelengths to 330-380 nm and emission 
wavelengths to ≥ 420 nm.  The UV2A cube allows for the visualization of the blue 
fluorescence seen in the nucleus and kinetoplast, and the yellow/orange fluorescence seen in 
the acidocalcisomes due to interactions of diamidines with polyphosphates in these 
organelles (31).   
Distribution of DB75 in the Acidocalcisomes.  Trypanosoma brucei brucei S427 
trypanosomes were cultured in CBMEM media as previously described (24).  For various 
time points from 5 min - 1 h, 106 trypanosomes were pretreated with a stock solution of 5 µM 
monensin (Sigma) prepared in ethanol or 20 mM ammonium chloride.  After pretreatment, 
trypanosomes were washed and then DB75 was added to a final concentration of 7.5 µM.  
DB75 was incubated with trypanosomes for 2 h, and then trypanosomes were washed twice 
and resuspended in freshly isolated mouse blood (20 µl).  Thin films were prepared from a 
drop of blood, and viewed with a Nikon Microphot FXA microscope equipped with a 60 DM 
x 1.4 NA objective lens, a mercury lamp, and QImaging Micropublisher 3.3 CCD Digital 
Camera (QImaging Corporation, Surrey, BC, CA) was used for fluorescence microscopy.  
QCapture version 3.0 imaging software was used to capture images (QImaging Corporation).  
The microscope was equipped with a Nikon UV2A cube that limits excitation wavelengths to 
330-380 nm and emission wavelengths to ≥ 420 nm.  Acridine orange (Sigma) was also used 
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as a marker for acidocalcisome accumulation.  Acridine orange has been shown in the past to 
accumulate in acidocalcisomes and be displaced by alkalinizing agents (12).   
HPLC Analysis of Diamidines.  HPLC analytical methods for DB1017, DB244, DB249, 
DB103, DB60, DB935, and DB829 were based on analytical methods previously described 
for DB75 and DB820 (24, 30).  HPLC Solvent A consisted of 15 mM ammonium formate, 
30 mM formic acid in HPLC water, while Solvent B contained the same buffer system 
prepared in 4:1 acetonitrile: HPLC water.  A gradient elution was used to resolve each 
diamidine, with starting conditions of 95% Solvent A: 5% Solvent B, which increased 
linearly over 10-15 min, followed by a 3-5 min re-equilibration to starting conditions.  An 
Agilent Zorbax Bonus RP (New Castle, DE) column (2.1 X 50 mm, 3.5µm) was used for 
compound resolution.  Compounds were detected using their maximum excitation and 
emission wavelengths (Table 4.3).   
Mass Spectrometry Analysis of Diamidines.  DB690, DB867, DB1057, and DB879 
concentrations were determined by Liquid Chromatography/Mass Spectrometry (LC/MS).  
To verify results, analyses of DB103 and DB60 were conducted via HPLC with fluorescence 
detection as well as LC/MS.  Depending on molecular weight of the test diamidine, either 
DB75 or DB103 was used as internal standard.  Automated sample analysis was performed 
using Analyst software (version 1.4.1, Applied Biosystems, Foster City, CA).  The Analyst 
controlled HPLC-MS/MS system consisted of two Shimadzu Scientific (Columbia, MD) 
solvent delivery pumps, a thermostated (6 °C) LEAP HTC autosampler (Carrboro, NC), and 
an Applied Biosystems API4000 triple quadrupole mass spectrometer.  Reversed-phase 
gradient chromatography was used to elute the diamidines from an Aquasil (C18 5µm, 50 × 
2.1 mm) analytical column (Torrance, CA) at a flow rate of 0.75 ml/min, following a 4µL 
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injection.  Starting conditions for each injection were 95:5, water/methanol with 0.1% formic 
acid (vol/vol) in each.  The relative amounts of water/methanol were held constant for 0.5 
min while the column eluted to waste.  After 0.5 min, the eluent was directed to the mass 
spectrometer and the relative amount of methanol increased linearly to 90% at 3 min post-
injection.  This amount of methanol was held for 0.5 min to wash the column.  The column 
was re-equilibrated under the starting conditions for the final 0.5 min.  Total run time was 4 
min.  The mass spectrometer was connected to the HPLC system by a TurboIonSpray 
interface. Nitrogen, from a Peak Scientific (Bedford, MA) nitrogen generator, was used as 
the curtain, nebulizer, and collision gases.  User controlled voltages, gas pressures, and 
source temperature were optimized for the detection of the parent and product ions of the 
diamidines.  All diamidines were analyzed in positive ion mode using multiple reaction 
monitoring.   
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D.  Results 
In vitro Antitrypanosomal Activity of Diamidines.  Two series of diamidines were 
investigated – the diphenyl furan series, which includes DB75, and the aza analogs, which 
includes DB820 (Figures 4.1 and 4.2).  Compounds in the diphenyl furan series had the 
greatest structural diversity, with modifications to the core structure, N-substitutions on the 
diamidines, and cyclic diamidines.  Compounds in the aza series had less structural diversity, 
with modifications to the core structure only.  All compounds were active in vitro, although 
activities against S427 T. b. brucei and STIB900 T. b. rhodesiense varied greatly (Tables 4.1 
and 4.2).   
The majority of the diamidines used in this study have two positive charges at 
physiological pH (pH 7.0), and lower pH values.  pKa values for DB75, for example, have 
been determined to be around pH 11 (Table 4.1).  Calculated LogD and calculated pKa 
values, obtained from ChemAxon MarvinSketch 
(http://www.chemaxon.com/demosite/marvin/index.html), are shown in Tables 4.1 and 4.2 
for both series of compounds.  ChemAxon’s program calculated values consistent with 
measured values.  This program was a better predictor than ACD LogD Suite v 4.5 
(Advanced Chemistry Development, Inc, Toronto, CA).  As seen in Tables 4.1 and 4.2, pKa 
values for all the diamidines are approximately 10 or greater, indicating that the compounds 
will be doubly charged at physiological pH.  Most compounds, with the exception of DB244 
and DB249, are hydrophilic at pH 7.4.  DB244 and DB249 are both slightly lipophilic at this 
pH, likely due to the substitution of bulky cyclic groups off of the diamidines, which could 
mask the positive charges.   
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Diphenyl furans.  Diamidines in the diphenyl furan series had IC50 values ranging between 2 
and 260 nM against the S427 strain, a greater than 100-fold difference in activity (Table 4.1).  
The three compounds with unmodified diamidines (DB690, DB75, and DB1017) were the 
most potent.  Changes in the bond positioning (DB690) or addition of functional groups to 
the core nucleus (DB1017) had only a modest 2-3 fold effect on activity compared to DB75.  
Compounds which had substituted amidines (DB244, DB249) had intermediate potency 
against S427 trypanosomes, with IC50 values between 100 – 150 nM.  The cyclic diamidines, 
the imidazoline DB60 and the tetrahydropyrimidyl DB103, were the least potent compounds 
in this series against S427 trypanosomes.  Against the STIB900 strain, the trend in activity 
for diphenyl furans was similar to that of the S427 strain, with 6 of the 8 compounds having 
the same rank order against both strains (Table 4.1).  The only exception was DB103, which 
had an IC50 value of over 100 nM in the S427 strain, but was much more active against the 
STIB900 strain (IC50 value of 33 nM),   
Aza analogs.  All aza analogs had unmodified amidine moieties.  Five of the six compounds 
were potent, with activities against S427 T. b. brucei varying only 10-fold (Table 4.2).  
DB867 was the most potent compound, with an IC50 value of 3.3 nM.  The positioning of the 
nitrogen in the aromatic rings had only minor effects (DB867, DB820, and DB829).  As with 
the diphenyl furans, there was little impact on activity when functional groups were added to 
the aromatic rings (DB935, DB1057).  Between DB867 and DB1057, there is only a 10-fold 
difference in IC50 values.  DB879, which has a methylene group inserted between the furan 
and phenyl rings, was much less potent than other compounds in this series.  IC50 values for 
the compounds in this series against the STIB900 strain were similar for all compounds, and 
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in the same rank order.  DB879 was about 2 fold more potent against STIB900 trypanosomes 
than against S427 trypanosomes, but overall was still not a very potent compound.   
Thermal Melting Analysis of DNA binding. Increases in Tm values for compound-DNA 
oligomer and compound-polymer complexes are shown in Tables 4.1 and 4.2.  The majority 
of the compounds in these two series were potent DNA binders and bound strongly to both 
polydA·polydT, which has multiple AT binding sites, and to the d(CGCGAATTCGCG) 
oligomer duplex, which has a single AT binding site for diamidines (Tables 4.1 and 4.2).  
Studies with a wide array of diamidines have shown that evaluation of increases in the 
melting temperature of DNA on addition of the compounds provides a rapid method for 
ranking diamidines according to their binding affinity (23).  
All of the diphenyl furans are potent binders with ∆Tm values greater than 15°C for 
polydA·polydT and greater than 8°C for the d(CGCGAATTCGCG) oligomer duplex.  The 
largest increases in the melting temperature were seen with DB244, DB249, DB103, and 
DB75 (Table 4.1), however, there was no correlation between activity of the diphenyl furans 
and DNA binding affinity (r2 = 0.09).  With the aza analogs (Table 4.2), there appeared to be 
a correlation between the activity and the increase in melting temperature with the 
polydA·polydT oligomer and the d(CGCGAATTCGCG) oligomer duplex (r2= 0.9, slope --
0.05 and 0.03 respectively), but this correlation was driven by the low ∆Tm values 
determined with DB879.  When DB879 is removed from the series, no correlation exists (r2 
equal to 0.4 and 0.03 for the two oligomers respectively).  DB879, the least potent compound 
investigated, had little effect on the melting temperature of the DNA complex (Table 4.2).    
Intracellular Accumulation of Diamidines in S427 T. b. brucei.  DB75 and DB820 were 
previously shown to accumulate to approximately 12 mM and 3 mM, respectively, after a 24 
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hour in vitro incubation with 7.5 µM of either compound (24).  Since the compounds chosen 
for investigation have a wide range of in vitro activity, we chose the concentration of 7.5 µM 
to incubate with trypanosomes to compare to previous work.  After investigating the 
accumulation of several of the diamidines, the pattern of intracellular concentration was 
similar to that reported previously (24).  However, the toxicity of some of the compounds 
became an issue with the accumulation experiments (increasing cell death when incubated 
for longer than 8 hours), so investigations were limited to 8 h.   
Due to poor fluorescence intensity, some compounds were analyzed and quantified by 
LC/MS instead of HPLC, which was used for the more fluorescent compounds.  DB75, 
DB1017, DB244, DB249, DB103, DB60, DB935, DB820, and DB829 were analyzed using 
HPLC, while DB690, DB867, DB1057, and DB879 were analyzed by LC/MS.   
Diphenyl furans.  All of the diphenyl furans accumulated to high concentrations, ranging 
from peak concentrations of 1 mM to 30 mM (Figure 4.3) after 8 h incubation with 7.5µM.  
Three of the diphenyl furans (DB690, DB244, DB249) investigated accumulated to higher 
peak concentrations in trypanosomes than seen previously for DB75 (4.5 ± 0.3 mM at 8 h, 
Figure 4.3A).  DB690, the most potent diphenyl furan investigated, as well as DB244 and 
DB249, with intermediate potency, accumulated to peak concentrations of approximately 30 
mM (Figure 4.3A).  The other diphenyl furans accumulated in trypanosomes to peak 
concentrations similar to that of DB75 (Figure 4.3B).  Thus, there appears to be no trend 
linking potency of the diamidines and accumulation of the diphenyl furans in trypanosomes 
over time.   
Aza analogs.  Compounds in the aza analog series accumulated linearly over 8 h in 
trypanosomes for the most part (Figure 4.4), except for DB867, which accumulated in a non 
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linear manner.  DB820 had a peak concentration of 1.0 ± 0.2 mM at 8 h.  DB867, the most 
potent compound in this series (Table 4.2), which has the nitrogen in the pyrimidine ring 
moved meta- to the furan ring, accumulated to a concentration of 9.3 ± 2.0 mM after 8 h, 
which is significantly greater than the accumulation of DB820.  DB935, which has a methyl 
substituent on the phenyl ring, accumulated to concentrations in trypanosomes 4-fold higher 
than DB820, despite being 3 fold less potent.  All compounds in the aza analog series 
accumulated to higher concentrations than DB820, including DB879, the least potent 
diamidine investigated, as seen in Figure 4.4.   
Fluorescence Spectra of Diamidines in Aqueous Solution.  The fluorescence spectra of 
diamidines were determined for developing analysis methods, and for the fluorescence 
microscopy studies.  Fluorescence of the diamidines varied in terms of intensity, and 
excitation (λex) and emission (λem) wavelengths (Table 4.3).   
Diphenyl furans.  In the diphenyl furan series, four compounds had similar fluorescence 
spectra in water.  DB75, DB1017, DB244, and DB249 had excitation maxima around 355 
nm, with maximum emission around 455 nm.  Of these compounds, DB249 had the highest 
emission intensity, and DB75 had the lowest emission intensity.  Other structural 
modifications to DB75 tended to shift either the excitation wavelength by about 20 nm 
(DB690 or DB60), or the emission maximum by 20 nm (DB103) in either direction.  In 
addition to shifting fluorescence spectra, some of the modifications also greatly decreased 
fluorescence intensity, as seen with DB690 (Table 4.3).   
The fluorescence properties of select diphenyl furan diamidines were also 
investigated in the presence of AT rich DNA.  The fluorescence of DB690, which is only 
weakly fluorescent in solution, increased almost 300% in the presence of DNA, while the 
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fluorescence of DB75 decreased 17% in the presence of DNA (Table 4.3).  The fluorescence 
intensity of DB60 also decreased by 23% when bound to DNA. 
Aza analogs.  In the aza series, only DB820 and DB935 had similar excitation and emission 
spectra, with a maximum excitation of about 360 nm and emission around 460 nm.  The 
spectra of other compounds were shifted in either excitation or emission wavelength or both.  
Placing the nitrogen in the pyrimidine ring ortho- to the amidine (DB867) opposed to meta- 
to the amidine (DB820), shifted the excitation maximum by 10 nm, and the emission 
maximum was also shifted by 20 nm.  This modification also decreased the fluorescence 
intensity by approximately 60 fold.  However, having two nitrogens – one in each pyrimidine 
ring (DB867) increased the fluorescence intensity two-fold over that of DB820, while 
shifting the maximum emission wavelength down by 20 nm.  Addition of either an alcohol 
group to the phenyl ring or addition of a methylene linker between the phenyl and furan ring 
decreased the fluorescence intensity dramatically (Table 4.3).   
 The fluorescence of select diamidines was investigated in the presence of AT rich 
DNA.  As with DB690 in the diphenyl furan series, fluorescence of the weakly fluorescent 
DB867 is greatly enhanced (almost 400%) with increasing concentrations of DNA (Table 
4.3).  The very fluorescent DB820 and DB829 exhibit decreased fluorescence when bound to 
DNA (50% and 86%, respectively).   
Intracellular Distribution of Diamidines in S427 T. b. brucei.  The majority of the 
compounds in both series distributed to three organelles in the trypanosomes:  the 
kinetoplast, the nucleus, and the acidocalcisomes (See next section).  A concentration of 500 
nM was chosen for microscopy studies for several reasons, including prevention of 
fluorescence signal saturation of the compounds, and because of the toxicity of some 
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compounds at higher concentrations.  For some compounds that were less fluorescent, 
distribution at 5 µM was also investigated, but no difference in the fluorescence intensity 
within trypanosomes was identified.   
DB75 localization to the acidocalcisome.  After two hour incubation in vitro with S427 
trypanosomes, DB75 accumulated in the nucleus, kinetoplast and acidocalcisomes (Figure 
4.5, first column).  However, when ammonium chloride or monensin were used as a 
pretreatment before DB75 was added, accumulation in the acidocalcisomes was not seen 
(Figure 4.5, columns 2 and 3).  A 60 min pretreatment of ammonium chloride was needed to 
prevent DB75 accumulation in acidocalcisomes, although partial inhibition of 
acidocalcisomes localization was seen after 30 min.  The sodium ionophore monensin, on the 
other hand, only needed to be incubated with trypanosomes for 15 min before DB75 was 
added to abolish acidocalcisome accumulation.  Partial inhibition of accumulation was seen 
after 5 min.  Additionally, monensin prevented acridine orange fluorescence in the 
acidocalcisomes of trypanosomes after only 15 min (data not shown).  We were unable to use 
fixation and colocalization techniques due to issues with redistribution of DB75 or loss of 
fluorescence (30).   
Diphenyl furans.  DB75, accumulated in the nucleus, kinetoplast and acidocalcisomes after 8 
hrs of in vitro incubation (Figure 4.6).  There were four compounds in the diphenyl furan 
series that had similar fluorescence spectra and relatively similar fluorescence intensity – 
DB75,DB1017, DB244, and DB249.  Compounds with similar fluorescence properties can 
be compared directly, but it must be considered that each compound may behave differently 
when accumulated in cells (i.e. fluorescence could be shifted, enhanced or quenched upon 
sequestration in organelles, and this may be different for each compound).  Like DB75, 
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DB1017 appeared to be localized to the kinetoplast, nucleus and acidocalcisomes (based on 
comparison of localization between DB75 and DB1017).  The color shift in the 
acidocalcisomes with this compound is to more of an orange color, compared to the yellow 
color seen in DB75 stained acidocalcisomes.  DB244 and DB249 were both found only in the 
nucleus and kinetoplast (Figure 4.6).   
For the rest of the diphenyl furans, the excitation and/or emission wavelengths were shifted 
slightly, and no direct comparisons can be made as to their relative fluorescence intensities.  
DB690 appeared to accumulate only in the kinetoplast as shown in Figure 4.6.  However, due 
to the weak innate fluorescence of DB690 (Table 4.3), it is possible that there is some low 
level fluorescence in other organelles in the trypanosomes which we were unable to observe.  
Additionally, the peak excitation of DB690 is below the limit of the UV2A cube, and we are 
likely not seeing the compound excited at its maximal excitation wavelength.  The 
imidazoline DB60 was localized to the kinetoplast, nucleus and acidocalcisomes.  DB103 
accumulated only in the nucleus and the kinetoplast (Figure 4.6).   
Aza analogs.  DB820, as shown previously, was localized to the nucleus, kinetoplast, and 
faintly in the acidocalcisomes (Figure 4.7).  DB935, the only compound with similar 
excitation and emission wavelengths to DB820, was localized to the nucleus and kinetoplast.  
The most potent analog, DB867 appeared in the nucleus, kinetoplast and acidocalcisomes 
(Figure 4.7).  Despite being weakly fluorescent in solution, the compound exhibited intense 
fluorescence in trypanosomes, which may be related to an increase in fluorescence when 
bound to DNA (Table 4.3).  DB1057 was found in the nucleus and kinetoplast, while DB829 
was found in the nucleus, kinetoplast and acidocalcisomes.  DB879, the least potent of the 
DB820 analogs was located very faintly in the kinetoplast.  The compound is weakly 
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fluorescent, which may affect the appearance of fluorescence seen in the trypanosome, 
although DB879 concentrates in trypanosomes to levels comparable to that of the other aza 
analogs.   
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E.  Discussion 
Diphenyl furan and aza diphenyl furan diamidines represent two potent classes of 
antitrypanosomal compounds.  The compounds shown here had a greater than 150 fold range 
of in vitro activity, and some had different organelle distribution within the cells.  However, 
despite the wide range of activity and distribution and, for the most part, similar DNA 
binding properties, the compounds accumulated to similar concentrations in the cells, with 
only a few exceptions.   
Eight compounds in the diphenyl furan series were investigated.  The substituted and 
cyclic diamidines were the least potent compounds in this series, and the fact that 
modification to the diamidine affects their potency reinforces the importance of the moiety in 
the potential mechanism of action of these compounds.  Other modifications of DB75 had 
little effect on the IC50 value, only changing potency by approximately 2 fold.   
In the aza analog series, the only modification to have a major effect on potency was 
the methylene linker in DB879, which also decreased DNA binding, likely due to the change 
in curvature of the molecule.  This illustrates the importance of a threshold DNA binding 
activity necessary for antitrypanosomal activity of these compounds.   
DNA binding for the two series of compounds, as determined by measuring the ∆Tm 
in the presence of compound, was similar for most of the compounds.  With the exception of 
DB879, all of the compounds tested increased the melting temperature of a polydA·polydT 
complex by greater than 15ºC.  With DB879, the methylene linker appears to inhibit DNA 
binding.  Surprisingly, differing effects were seen when fluorescence of select diamidines 
was measured when the compounds were bound to DNA.  The least fluorescent analogs, 
DB690 and DB867, exhibited increased fluorescence when bound to AT rich DNA, while 
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more fluorescent analogs had decreased fluorescence when bound to DNA.  The DNA used 
for this experiment was chosen because of its high AT content.  However, conclusions about 
changes in fluorescence in the trypanosome organelles can not be made until measured with 
isolated kinetoplast and nuclear DNA.   
We have previously proposed (34) that interaction with DNA alone was insufficient 
to generate biological activity. In one possible mechanism for biological activity of the 
dications, however, DNA binding would be an initial requirement but specific secondary 
effects, which occur subsequent to binding, would be required for activity. Such effects could 
be topological changes induced in DNA, as a result of binding that cause errors in DNA 
structure with resulting instability and eventual destruction. It is also possible that binding 
could result in direct inhibition of DNA targeted enzymes or control proteins, which could 
also lead to cell death. These secondary effects could vary significantly among compounds 
with similar binding affinities for DNA and could account for the different activities of 
compounds with similar uptake and DNA affinity. The set of compounds in this paper that 
have similar DNA binding and uptake would make an excellent test set for testing the 
possible influence of secondary effects, after DNA binding, on biological activity. 
Changes to the structure of the compounds also resulted in changes in the 
accumulation of the compounds in trypanosomes.  Surprisingly, some of the more potent 
compounds, including DB75 and DB820, accumulated to lesser extent than some less active 
compounds, such as DB244, and DB249.  Additionally, in the aza analog series, all of the 
compounds investigated accumulated to higher concentrations in trypanosomes than the very 
potent compound DB820 (Figure 4.4).   
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There also does not appear to be any correlation between which organelles the 
compounds are distribute to and overall accumulation in trypanosomes.  For example, 
DB820, one of the most potent compounds examined, had the lowest accumulation in 
trypanosomes.  Of the three compounds that accumulate to the highest concentrations in 
trypanosomes, one appears to be localized to the kinetoplast only (DB690), while the other 
two are localized to the nucleus and kinetoplast (DB244 and DB249).  DB690 was the most 
potent of the compounds tested, while DB244 and DB249 had intermediate IC50 values, yet 
all three accumulated to similar concentrations in trypanosomes.  However, as stated 
previously, DB690 is a weakly fluorescent compound with a peak excitation wavelength 
below the limit of the UV2A cube used for fluorescence microscopy.  It is thus possible that 
we are not seeing the true distribution of DB690 in trypanosomes, even accounting for the 
enhancement of DB690 fluorescence when bound to AT rich DNA (Table 4.3).  This 
indicates that neither concentrations nor distribution in trypanosomes can be predicted from 
in vitro activity.  Additionally, the site of localization in trypanosomes cannot be predicted 
from the accumulation in the cells, or vice versa.   
It is likely from these series of diamidines that DNA binding, in either the nucleus or 
kinetoplast, is important, especially considering that for the most part, all of these compounds 
are excellent DNA binders.  Further studies are needed to determine relative amounts of 
diamidines in each organelles, as well as relative affinity for DNA associated proteins found 
in either, or both organelles.  Only then can organelle specific mechanisms of action be 
determined.  Additionally, changes in fluorescence intensity and/or shifts in excitation or 
emission wavelengths may occur when compounds bind DNA, as shown in Table 4.3.  
Although the DNA used for that investigation was AT rich, to be certain of relative 
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fluorescence changes in the nucleus or kinetoplast, DNA from both organelles must be 
isolated and binding and fluorescence changes measured.  With the dramatic changes seen 
here, these measurements should be routinely determined in the future in order to extrapolate 
from DNA binding to distribution studies.   
Tools used for investigating transport and uptake of compounds in trypanosomes 
include rapid transport experiments with various inhibitors that prevent uptake via particular 
transporters.  Transport of diamidines has been attributed to uptake via the P2 transporter (5, 
8, 22, 29), and in the case of pentamidine, the HAPT1 and LAPT1 are also involved in 
uptake and accumulation (4).  Lanteri et al. were able to inhibit uptake of DB75 over 30 sec 
with inhibitors of the P2 transporter such as adenosine, adenine, pentamidine, and 
diminazene (21), indicating that it is likely a substrate of the P2 transporter.  However, 
transport studies with all of the compounds investigated here have not been implemented, 
and further investigation is needed to determine the impact of transporters on long term 
accumulation.  The high levels of DB690, DB244, and DB249 in trypanosomes may indicate 
that others transporters or transport processes are involved in the uptake of this compound. 
The effects of endogenous substrates of the transporters, such as adenosine, can be 
assayed during in vitro antitrypanosomal activity experiments to determine if the presence of 
other substrates affects potency (i.e. increases the IC50 value) of the test compounds (13).  
When an IC50 value was determined for DB75 in the presence of 1 mM adenosine (a 
substrate of the P1 and P2 transporters), we found that the IC50 value increased 10-fold over 
controls without adenosine (data not shown).  However, there was no effect seen in the 
presence of inosine, a substrate for the P1 transporter.  This phenomenon has also been 
shown with the adenosine antimetabolite tubercidin in trypanosomes, where addition of 1 
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mM adenosine or inosine decreased the antitrypanosomal IC50 value of tubercidin 4-5 fold 
(13).  The decrease in potency of DB75 in the presence of excess adenosine is likely due to 
less DB75 getting into trypanosomes, but this should be further evaluated over time to 
determine if there is a significant reduction in the amount of DB75 accumulating in the 
trypanosomes.  
Additionally, the impact of increasing the lipophilicity of compounds on the transport 
properties, as with DB244 and DB249, should be further investigated.  It is possible that 
other transporters or uptake processes involved in the accumulation of the more lipophilic 
compounds.  Is it possible that these compounds are accumulated by both passive diffusion 
and active transport?  Both DB244 and DB249, according to calculations performed using 
ChemAxon MarvinSketch, are lipophilic at physiological pH 7.4, and could potentially 
diffuse across trypanosome membranes.   
We also attempted to investigate the accumulation and distribution of another 
compound in the diphenyl furan series, DB569.  DB569 is an N-phenyl substituted 
diamidine.  In cancer cells, DB569 was found localized to the mitochondria instead of the 
nucleus (20).  However, this compound was rapidly toxic to trypanosomes, inducing cell 
death in 1 h.  At lower concentrations, the substituted diamidine appeared to be widely 
distributed throughout trypanosomes (data not shown).  Increased lipophilicity could be one 
reason that DB569 rapidly kills trypanosomes, due to high levels accumulating in 
trypanosomes.  The pKa of DB569 has been determined to occur at pH 6.9 (average, data not 
shown), indicating that at the pH of the media (pH 7.4), over half of the drug is unionized, 
compared to less than 1% unionized with DB75, which has a pKa around 11.  The LogD of 
DB569 at pH 7.4 has been calculated to be 5.1 using ChemAxon MarvinSketch, indicating 
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that the substituted diamidine is highly lipophilic at this pH and would likely diffuse across 
cell membranes more rapidly than unsubstituted diamidines.  DB569 is an interesting 
diamidine, as it has very different physicochemical properties than other diamidines we have 
examined.  Additionally, due to its rapid killing of trypanosomes, it may have different 
mechanisms of action.  It is clear that more than one approach is needed to fully characterize 
the processes of transport and accumulation of diamidines in trypanosomes.  One interesting 
avenue would be to investigate the long term accumulation of diamidines in trypanosomes 
that lack the P2 transporter.   
All of the compounds investigated in both series of diamidines were found in the 
nucleus or the kinetoplast, or both.  A few of the compounds, of varying potency, also 
accumulated in the acidocalcisomes.  Due to previous evidence to support DNA binding as a 
mechanism of action, primarily studied with pentamidine (27, 28), our original hypothesis 
when we began working with DB75 and DB820, was that their mechanism of action would 
be related to DNA binding as well.  It is still not understood what impact the acidocalcisomes 
could have on the mechanism of action.  It may be that even in this closely related group of 
compounds, there could be potentially two or three mechanisms of action, involving DNA in 
the nucleus and kinetoplast, as well as some mechanism in the acidocalcisomes.  As 
dicationic molecules, the diamidines may accumulate in the low pH acidocalcisomes and 
interfere with homeostasis mechanisms in the trypanosomes.   
Many questions still remain about the mechanisms of action in these compounds.  
The lack of correlation between accumulation and activity of the compounds is intriguing.  
Why are some of the less active compounds accumulating to levels much higher than the 
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more active compounds?  There is also likely to be a time dependency to the amount of drug 
that is necessary to kill trypanosomes.   
Investigations with DB569, DB75 and DB820 indicate that only about 30 minutes to 
1 hour of drug treatment is necessary to cause trypanosome death.  With DB75 and DB820, 
death occurred 24-48 h after washing away drug (data not shown), but with DB569, death 
occurred within 1 hour, which may indicate a different mechanism of action than that of 
DB75 and DB820.  DB569 also has been shown to cause apoptosis in T. cruzi, to a greater 
extent than DB75 (10).  However, no indication of the time in which this process needs to 
take place was indicated.  In vivo, DB569 resulted in increased survival of mice infected with 
T. cruzi, and decreased cardiac parasitism, but was unable to clear parasitemia (11).  Since 
we were unable to investigate the accumulation of DB569 in our trypanosomes, we cannot 
compare it completely to other substituted diamidines such as DB244 and DB249.  However, 
the differences in killing seen between DB569 and other compounds in this series are very 
intriguing and require further investigation, especially since it would appear to be not very 
potent on a typical in vitro screen for antitrypanosomal activity, and in light of its different 
physicochemical properties.   
In summary, the accumulation and distribution of a diphenyl furan or an aza analog in 
trypanosomes is not indicative of its antitrypanosomal activity.  In actuality, there may be a 
minimum in vitro accumulation of a diamidine in trypanosomes necessary for killing.  From 
this study, it seems that a minimum accumulation concentration of 1 mM in trypanosomes is 
necessary for this type of compound – DB820, the compound that accumulated the least in 
trypanosomes, was also one of the most potent compounds.  Whether this ‘minimum 
accumulation level’ would hold true for other series of diamidines remains to be investigated. 
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The overall accumulation depends on a variety of factors, including which transporters play a 
role in accumulation and the relative affinity for the transporters as well.  The factors that 
affect transport, accumulation, and ultimately mechanism of action will be further 
investigated using this series of diamidines, as well as other, more structurally diverse 
diamidines.   
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Table 4.3:  Fluorescence properties of aqueous solutions (500 nM) of diphenyl furan and 
aza analogs and Change in fluorescence of select analogs when bound to DNA 
Compound λex max λem max Intensity at 
Max 
% Change in Fluorescence when 
Bound to DNA1 
DB690 323 452 51 ↑ 270% 
DB75 356 458 464 ↓ 17% 
DB1017 354 455 840 ND2 
DB244 356 450 625 ND 
DB249 356 453 920 ND 
DB60 373 458 630 ↓ 23% 
DB103 352 437 860 ND 
     
DB867 370 481 51 ↑ 360% 
DB820 359 455 318 ↓ 50% 
DB935 358 461 330 ND 
DB829 359 433 701 ↓ 86% 
DB1057 352 470 16 ND 
DB879 337 435 17 ND 
1Change in fluorescence of compounds determined at a concentration of 1 µM  
2ND: Not Determined 
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Figure 4.1.  Structures of diphenyl furan diamidines, presented in order of IC50 values 
against T. b. brucei S427 trypanosomes.  DB75, which is bolded, represents the 
prototypical diamidine in this series.  All other compounds are modifications of DB75.   
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Figure 4.2.  Structures of the aza analog diamidines, presented in order of IC50 values 
against T. b. brucei S427 trypanosomes.  DB820, which is in bold type, represents the 
prototypical diamidine in this series.  All other compounds are modifications of DB820. 
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Figure 4.3.   In vitro accumulation of diphenyl furans (7.5 µM) over 8h.  Shown in Figure 
4.3A is the accumulation of diphenyl furans to concentrations much higher than DB75.  
Figure 4.3B depicts accumulation at lower millimolar levels over 8h.  Accumulation is 
presented as concentration ± SE. 
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Figure 4.4.  In vitro accumulation of Aza analogues (7.5µM) over 8 h.  Data is presented 
as concentration ± SE.   
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Figure 4.5:  In  vitro distribution of DB75 (7.5 µM) after pretreatment with either 
ammonium chloride (20 mM) and monensin (5 µM).   
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Figure 4.6.  Fluorescence microscopy of the diphenyl furans (listed in order of IC50 
values) at 8 hours following incubation with 500 nM of each compound.  Images on the 
left depict phase contrast images of trypanosomes, while on right are fluorescence images 
of the same trypanosome. 
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Figure 4.7.  Fluorescence microscopy of the aza analogues (listed in order of IC50 values) 
at 8 hours following incubation with 500 nM of each compound.  Images on the left 
depict phase contrast images of trypanosomes, while on right are fluorescence images of 
the same trypanosome. 
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A. Abstract 
 Only four treatments exist for human African trypanosomiasis, and there is a great 
need for new therapies.  All of the currently used drugs are associated with problems 
including toxicity, cost, the need for parenteral administration, and increasing reports of 
treatment failure and drug resistance.  Pafuramidine, or DB289, the methoxime prodrug of 
furamidine (DB75), is the only new drug developed for the treatment of trypanosomiasis in 
recent years.  Pafuramidine is currently in Phase III clinical trials in Africa.  However, 
pafuramidine is ineffective against late stage trypanosomiasis, so drug development efforts 
continue.  A library of more than 2000 diamidine analogs has been synthesized with varying 
anti-trypanosomal activity in vitro and in vivo.  It has long been thought that DNA binding 
plays an important role in the mechanism of action of diamidines.  Here in vitro activity and 
distribution for two series of diamidines is presented.  Both series of compounds have a wide 
range of in vitro activity.  The benzimidazoles show the typical distribution pattern shown to 
be associated with related diamidines, localizing to the nucleus and kinetoplast.  Compounds 
in the benzofuran series do not appear to extensively localize to the DNA containing 
organelles, but instead are found in cytoplasmic organelles believed to be the 
acidocalcisomes.  One benzofuran, 150OXD049, was further investigated in vitro.  Despite 
only a 200 fold concentration in trypanosomes over plasma, 150OXD049 was able to cure 
trypanosome infection in mice.  The benzofuran series of diamidines are a new class of 
compounds with potentially different mechanisms of action than previously studied 
diamidines.   
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B. Introduction 
 There is a great need for new treatments of parasitic diseases such as human African 
trypanosomiasis.  Currently only four drugs are available for treatment of trypanosomiasis – 
pentamidine, suramin, melarsoprol, and eflornithine (11).  Pentamidine and suramin are 
hydrophilic compounds which can only be used to treat the first stage of the disease, when 
trypanosomes are confined to the bloodstream.  For treatment of the late stage of 
trypanosomiasis, melarsoprol and eflornithine are used (6, 7, 11).  In addition to being stage 
specific, treatment is also parasite specific.  There are two forms of trypanosomiasis caused 
by morphologically identical parasites – Trypanosoma brucei rhodesiense and T. brucei 
gambiense.  The Gambian form of the infection is chronic, while the Rhodesian form is more 
acute and virulent (1).  Pentamidine is used for T. b. gambiense infections, while suramin is 
used to treat early stage T. b. rhodesiense infections.  While melarsoprol can be used to treat 
the late stage of infection caused by either parasite, eflornithine is only effective against the 
Gambian form of the infection (7).   
 In addition to the limited treatment options, all currently used therapies are associated 
with problems including toxicity, treatment failures and drug resistance, cost of production, 
and the need for parenteral administration (6, 7).  The prodrug pafuramidine, or DB289, is 
the only compound to be developed for trypanosomiasis in recent years.  DB289 is the 
prodrug of the active diamidine, DB75, which has been shown to have excellent 
antitrypanosomal activity in vitro and in vivo (9).  However, DB289 is not effective against 
late stage trypanosomiasis, and therefore it is necessary to continue investigating diamidines 
to find compounds that will be effective against the late stage of the infection.  A library of 
diamidines and prodrugs has been synthesized, which consists of many structurally diverse 
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diamidines, including diphenyl furans, benzofurans, benzimidazoles, and terphenyl 
diamidines with varying activity against trypanosomes (3-5).  
The mechanism of action of diamidines is poorly understood.  Evidence exists for the 
mechanism of diamidine action being DNA binding and topoisomerase inhibition, inhibition 
of protease inhibitors, or inhibition of polyamine metabolism (13-15).  Although much work 
on mechanism of action has been done with pentamidine, it is unknown if the non fluorescent 
compound actually is located at the hypothesized sites of action.  Fluorescent analogues of 
pentamidine have already been useful for investigating distribution inside trypanosomes with 
the hope of discovering mechanism of action.  With a large number of compounds available 
it is possible to investigate the distribution of many compounds to determine whether 
different mechanisms occur with different classes of diamidines.   
We have previously provided evidence for the in vitro activity, and accumulation and 
intracellular distribution of a series of fluorescent diaryl furan diamidines in trypanosomes 
(9), presented in Chapter 2 and 4.  Here we have expanded those investigations to other series 
of compounds in the available diamidine library.  Approximately 100 compounds from 
different classes were screened (Table 5.1).  Two series of compounds are presented here.  
Compounds were investigated for fluorescence properties, in vitro activity, and intracellular 
distribution in trypanosomes.  In these two series, a wide distribution of in vitro activity and 
intracellular distribution was found.  One compound which showed a unique distribution in 
trypanosomes, 150OXD049, was further investigated in vivo to determine accumulation, 
distribution and activity in an infected mouse model of trypanosomiasis.   
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C. Methods and Materials 
Materials.  All materials and reagents were obtained from Fisher Scientific or Sigma unless 
otherwise stated.   
Trypanosome Culture.  S427 T. b. brucei trypanosomes were grown in vitro in CBMEM 
media as previously described (9).  Trypanosomes were grown in 24 well plates (Corning 
Costar), and serially passaged twice a week.   
Diamidines.  Diamidine compounds were obtained from the Tidwell Laboratory at the 
University of North Carolina (benzofurans) and the Boykin Laboratory at Georgia State 
University (benzimidazoles).  Benzimidazoles were synthesized as previously described (5, 
8, 10).  Benzofuran synthesis was as described (Bakanov, S, in preparation).  These 
compounds are covered under the US patent application 20050197378.   
Fluorescence Spectra of Diamidines in Aqueous Solution.  Fluorescence scans to 
determine excitation and emission maxima were performed using a Perkin Elmer 
Luminescence Spectrophotometer (LS 50B) using FL Winlab Version 4.00.02 software 
(Perkin Elmer, Wellesley, MA).  Compounds were prepared as 500 nM solutions in distilled 
water.  One ml of each solution was transferred to a disposable cuvette (Fisher Scientific) and 
the fluorescence spectrum was determined.  Fluorescence intensity measurements were then 
determined using the λex and λem maxima. 
In vitro Antitrypanosomal Activity.  To determine IC50 values, T. b. brucei S427 
trypanosomes (2 x 104 trypanosomes/ml) were cultured at 37 ºC and 5% CO2 with serial 
dilutions of the diamidines for 72 h using a method previously described (12).  Alamar Blue 
(10% vol/vol) was added after 70 h incubation with diamidines.  At 72h, fluorescence was 
determined at λex: 544 nM, and λem: 588 nm, using a PolarStar fluorescence plate reader 
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(BMG, Durham, NC).  The fluorescence emission derived from each drug concentration was 
normalized to fluorescence of the untreated control trypanosomes.  The background 
fluorescence (determined in wells in which 10% Alamar Blue was added to CBMEM media) 
was subtracted from total fluorescence values.  IC50 values were determined using the Hill 
Equation (Graphpad Prism, San Diego, CA), and are the average of at least 3 determinations.   
In vitro Distribution of Diamidines in S427 Trypanosomes.  S427 trypanosomes were 
cultured in 24 well plates (Corning Costar, Fisher Scientific) at a starting concentration of 
106 trypanosomes/ml.  Diamidines were added to each well to a final concentration of 500 
nM.  Trypanosomes were incubated with the diamidines for 8 h at 37ºC, and then 
trypanosomes were examined under a light microscope for motility and viability.  
Trypanosomes were washed twice in fresh medium (1 ml) which contained no diamidine and 
resuspended in 20 µL of freshly isolated mouse blood.  A small drop of blood was placed on 
a microscope slide and thin films were prepared.  Thin films were used to reduce the photo 
bleaching that occurs when viewing live trypanosomes under the UV-fluorescence cube.  No 
differences in intracellular distribution of fluorescence were seen when live trypanosomes 
were viewed under fluorescent light.  Thin films were examined using Nikon Microphot 
FXA (Garden City, NJ) with a 60 DM x 1.4 NA objective lens, a mercury lamp, and a 
QImaging Micropublisher 3.3 CCD Digital Camera (QImaging Corporation, Surrey, BC, 
CA).  QCapture version 3.0 imaging software was used to capture images (QImaging).  The 
microscope was equipped with a Nikon UV2A cube that limits excitation wavelengths to 
330-380 nm and emission wavelengths to ≥ 420 nm.  Before viewing, thin films were 
mounted with a drop of glycerol.   
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In vivo Accumulation of 150OXD049 in Plasma and Trypanosomes.  Male Swiss 
Webster mice (25-35 g) were infected with S427 trypanosomes (105 trypanosomes IP).  All 
animal experiments adhered to guidelines outlined by the University of North Carolina-
Chapel Hill Institutional Animal Care and Use Committee (IACUC).  On the third day post 
infection, parasitemia was determined with a drop of blood from the tail vein.  Infected mice 
were treated with 15 µmol/kg 150OXD049 administered intraperitoneally (IP). At selected 
times after treatment, mice were euthanized by CO2 asphyxiation, and blood was collected by 
cardiac puncture into two lithium heparin coated microtainer tubes (BD Biosciences).  As 
previously described (9), one tube was used to isolate trypanosomes from whole blood, while 
the other was used to determine plasma concentrations of DB75.  Briefly, trypanosomes were 
isolated by mixing whole blood with a Percoll solution (100%) containing 0.25 M sucrose 
and 0.1 M glucose (pH 7.4).  This mixture was centrifuged for 35 min at 13200 rpm (16100 
g) in an Eppendorf 5415R microcentrifuge.  Trypanosomes were isolated from suspension 
above the red blood cell layer, and were washed twice in 1 ml of phosphate saline glucose 
buffer, pH 7.4, counted and 150OXD049 was extracted with four volumes of 8:1 methanol: 
1.0 N HCl (vol/vol).  Half of each sample was evaporated in a Zymark Turbovap-LV 
(Hopkinton, MA) under nitrogen gas (7 psi) and reconstituted in HPLC solvent A.  The 
remainder of the sample was retained for future analysis if needed.  Plasma was isolated by 
centrifuging blood at 3000 rpm for 10 min to pellet red blood cells, and extracted as 
described above.   
In vivo Distribution of 150OXD049 in Trypanosomes.  Thin films were prepared from a 
drop of blood at each time point where trypanosome and plasma concentrations were 
determined.  Thin films were mounted with a drop of glycerol, and examined using a Nikon 
 168
Microphot FXA microscope (Garden City, NJ) as before, but with an Optronics DEI 750 
CCD camera (Goleta, CA).  The UV2A cube was used to visualize 150OXD049 in 
trypanosomes.   
HPLC Analysis of 150OXD049.  Analytical methods for 150OXD049 were similar to those 
used for DB75 (Chapters 2-4).  The solvent system consisted of HPLC solvent A (30 mM 
ammonium formate, 60 mM formic acid at pH 3.0) in 100% HPLC grade water, and HPLC 
solvent B (80% acetonitrile, 20% ammonium formate/formic acid buffer).  A gradient was 
used to elute 150OXD049, with starting conditions of 95% solvent A/5% solvent B.  Over 10 
min, the % solvent B was increased linearly, followed by a 6 min re-equilibration to starting 
conditions.   
An Agilent 1100 series HPLC equipped with a fluorescence detector (Agilent 
Technologies) was used for analytical procedures.  DB75 and DB820 were eluted on a 3.5 
µm Bonus – RP (Agilent Technologies) 2.1 x 50 mm column with a flow rate of 0.35 ml/min.  
The column was maintained at 25 ºC throughout the analytical method.  Injection volume for 
each sample was 5 µl.  The wavelengths used for fluorescence detection of 150OXD049 were 
λex = 321 nm and λem = 425 nm.  Compounds were quantified by comparing to standards 
injected during each analytical run.  The standards were used to determine the concentration 
of 150OXD049 in plasma and in trypanosomes.  Standards were linear between 5 nM and 1 
µM.  Concentrations were expressed as µM ± SE for plasma and trypanosomes.  
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D. Results 
In vitro Antitrypanosomal Activity.  A wide range of IC50 values was seen in the 
benzofuran series (Table 5.2).  The compounds ranged from the very potent 150OXD049, an 
unsubstituted diamidine with an IC50 value of 11 nM, to the isopropyl substituted 7SAB006, 
which has an IC50 value greater than 3 µM.  150OXD049 was almost 300 fold more potent 
than 7SAB006.  Similar to the effects seen in Chapter 4, substituting benzofurans also had a 
profound effect on the IC50 values.  Surprisingly, differing effects were seen for the 
imidazoline benzofurans.  6SAB042 is almost 40 times more potent than 7SAB085; the only 
difference between the compounds was the –OCH3 substituent on the benzofuran ring (Table 
5.2).   
 The range of IC50 values in the benzimidazole series was similar (approximately 250 
fold).  The most potent benzimidazole, DB818, had an IC50 value of 0.9 nM, as seen in Table 
5.3.  The imidazoline version of this compound, DB819, was only 4 fold less potent, with an 
IC50 value of 3.6 nM.  With an IC50 value of less than 5 nM, DB819 is still a very potent 
diamidine.  This contrasts with the diphenyl furan series in Chapter 4, where the imidazoline 
substituted compound was 30 fold less potent than the unsubstituted diamidine.  The two 
least potent compounds in this series were compounds that had pyrimidine rings incorporated 
into their structure: DB915 and DB920.  DB915 was still potent with an IC50 value of 37 nM, 
while positioning the pyrimidine ring next to the benzimidazole group decreased potency 
more than 6 fold (DB920 had an IC50 value of 232 nM).  The least potent benzimidazole 
investigated, DB920, was still over 10 fold more potent than the least potent compound in the 
benzofuran series.   
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Fluorescence Properties of Diamidines.  The fluorescence spectrum of each diamidine was 
measured in aqueous solution at a concentration of 500 nM.  Fluorescence properties of the 
diamidines were measured to determine whether the compounds could be investigated with 
fluorescence microscopy.  The UV2A cube set has an excitation bandpass between 330 and 
380 nm, and has a long emission bandpass filter, allowing the visualization of emission 
wavelengths greater than 420 nm.  Compound fluorescence in solution is used as an indicator 
of fluorescence in the trypanosomes.  Compounds may have excitation and emission peaks 
that do not fall in the range of the UV2A cube, and the possibility does exist that the 
distribution seen in trypanosomes is not the true distribution.   
 In the benzofuran series, all of the diamidines investigated had similar excitation 
wavelengths, with most of the compounds having a maximum excitation around 320 nm 
(Table 5.4).  Emission wavelengths varied between 400 and 440 nm, although 4 of the 6 
benzofurans investigated had a maximum emission wavelength of approximately 420 nm.  
The isopropyl substituted 7SAB006 was the most fluorescent analog in this series, and the 
other isopropyl benzofuran, 1SAB035, had the next highest fluorescence intensity.  The two 
imidazoline derivatives were only weakly fluorescent (Table 5.4). 
Compounds in the benzimidazole series had wide ranging fluorescence properties.  
Five benzimidazoles had maximum excitation wavelengths of approximately 360 nm, but of 
those five, only two had similar excitation and emission wavelengths (DB915 and DB928, as 
seen in Table 5.4).  Both of these compounds also had furan linker groups.  DB818 and 
DB819 had similar excitation wavelengths, but the imidazoline group in DB819 shifted the 
emission wavelength by 20 nm to a higher wavelength.  DB843 was an interesting compound 
as it had an excitation wavelength of 360 nm and an emission wavelength of 410 nm (Table 
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5.4).  DB920, the benzimidazole with a pyrimidine linker group had a lower excitation and 
emission wavelength than the other compounds (λex: 320 nm, λem: 390 nm), although there 
was a small excitation and emission peak at 360 nm and 410 nm respectively.  The 
imidazoline DB819 was the most fluorescent benzimidazole in aqueous solution (Table 5.3). 
In vitro Intracellular Distribution in Trypanosomes.  The two series of compounds 
investigated showed different distributions inside trypanosomes.  However, the distribution 
within each series was similar.  Of the 6 benzofurans investigated, 5 appeared to be visibly 
fluorescent inside trypanosomes.  Three of the 5 fluorescent benzofurans showed identical 
distribution patterns, and appeared to localize in a punctate pattern throughout the cell 
(Figure 5.1).  These compounds included the highly potent 150OXD049 and the much less 
potent 7SAB085 and 7SAB006.  7SAB081 had a similar distribution in the anterior portion 
of the cells, but also appeared to be localized to the kinetoplast as well.  Based on the 
distribution of the organelles in trypanosomes, it is believed that the organelles are 
acidocalcisomes, although this has not been confirmed.  1SAB035 appeared to be localized 
only in the kinetoplast.  6SAB042 was not fluorescent in trypanosomes at the concentration 
investigated.  Additionally, the compound was only weakly fluorescent in an aqueous 
solution at the same concentration.  As most of these compounds have excitation 
wavelengths that peak around 320 nm, the true distribution of the benzofurans in the 
trypanosomes may not be seen with the UV2A.  In other series of diamidines investigated, 
fluorescence emission of the compounds in the acidocalcisomes is shifted to a higher 
wavelength, which could also occur with these compounds, and may explain why these 
organelles are the only ones visible here.   
 172
 For the most part, the benzimidazoles were found localized to the nucleus and 
kinetoplast in trypanosomes (Figure 5.2).  Two of the 8 compounds, DB846 and DB920, 
were not fluorescent in trypanosomes at all.  DB846 and DB920 were also 2 of the 3 
pyrimidine containing benzimidazoles (Table 5.2).  The emission wavelength of DB920 and 
DB846 was well below the limit of the UV2A cube used for these microscopy experiments 
(Table 5.3).  DB818, DB921, DB819, and DB915 all appeared to be localized to the nucleus 
and kinetoplast at 8 h.  DB843 had the same distribution pattern, but the compound 
fluoresced yellow inside trypanosomes when viewed under the UV2A cube.  Yellow 
fluorescence with these compounds in the past has been associated primarily with the 
acidocalcisomes (Chapters 2-4).  However, this may be due to the low emission wavelength 
of this compound, as seen in aqueous solution (Table 5.3).  DB928 appeared to be localized 
to the kinetoplast only (Figure 5.2).   
In vivo Accumulation and Distribution of 150OXD049 in Plasma and Trypanosomes. 
 The accumulation and distribution of 150OXD049 was further investigated in vivo 
due to its unique intracellular distribution and in vitro antitrypanosomal activity.  The 
compound was curative when administered at a dose of 15 µmol/kg IP (data not shown).  
When the benzofuran 150OXD049 was administered to infected mice, the compound 
achieved a peak plasma concentration of 9 ± 5 µM 15 min after administration (Figure 5.3).  
By 1 h, plasma concentrations had sharply declined to 0.5 ± 0.05 µM.  This was followed by 
a slow decline in concentrations through 24 h, when a concentration of 0.2 ± 0.02 µM 
150OXD049 was measured in plasma.  Trypanosome concentrations peaked in trypanosomes 
1 h after 150OXD049 was administered with a concentration of 111 ± 13 µM inside the cells.  
The concentration of 150OXD049 in trypanosomes at 24 h was approximately 40 µM 
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(Figure 5.3).  Although lower than previously seen for diamidines such as DB75 and DB820, 
these concentrations in trypanosomes were sufficient to clear initial parasitemia and cure 
infected animals over a 60 day period.  The AUC0-24h of 150OXD049 in trypanosomes was 
1772 µM*h, while in plasma the AUC was 8.7 µM*h.  This represents a 200 fold greater 
exposure of 150OXD049 in trypanosomes compared to plasma.   
In vivo Distribution of 150OXD049 in Trypanosomes. Only 15 minutes after 
administration of 150OXD049, the compound was found to accumulate within the 
kinetoplast of trypanosomes (Figure 5.4).  By 1 h, the compound has spread to small 
organelles throughout the cytoplasm, similar in size and location to the acidocalcisomes.  
After 8 h, it appears that kinetoplast fluorescence has disappeared, although the other 
organelles were fluorescing brightly.  At 24 h, fluorescence was concentrated in the anterior 
portion of the cell, with numerous organelles showing fluorescence (Figure 5.4).  As 
mentioned previously, it is believed that these organelles are the acidocalcisomes. 
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E. Discussion 
 Two series of diamidines, benzofurans and benzimidazoles, were investigated in vitro 
to determine activity and intracellular localization.  This was part of a project aimed at 
correlating organelle distribution with in vitro activity, and ultimately, evaluating potential 
mechanisms of action of diamidines against trypanosomes.  DNA binding has long been 
considered a mechanism of action for most diamidines, but the presence of diamidines in 
other organelles argues that there may different or multiple mechanisms of action.  The two 
series here have strikingly different intracellular distribution, but both series have compounds 
that are quite potent against trypanosomes.   
 Although for the most part the benzofurans do not appear to accumulate in the DNA 
containing organelles of the trypanosome, the nucleus and kinetoplast, they are able to kill 
trypanosomes in vitro.  Previously, one of the primary mechanisms of action of aromatic 
diamidines has been based on their DNA binding affinity.  It appears from the localization of 
the fluorescent organelles in the cell that the benzofurans accumulate primarily in the 
acidocalcisomes at 8 h.  However, this must be further investigated with probe molecules and 
antibodies to determine the organelle identity.  Additionally, this investigation should be 
repeated with a fluorescence cube that allows for the visualization of lower excitation and 
emission wavelengths.  Other possible organelles which may accumulate these compounds 
include the endosomes and glycosomes.  Regardless of which organelle is accumulating the 
benzofurans, this class of compounds is likely to have alternate mechanisms of action that 
need to be further investigated.   
However, due to the fluorescence properties of the benzofuran diamidines (Table 
5.4), it is possible that we are unable to see the full distribution of the compounds in 
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trypanosomes, and this should be considered in future investigations.  The maximum 
fluorescence excitation of most of the benzofurans is lower than the UV2A excitation range, 
and the emission is at the limit of the fluorescence emission for the UV2A cube set.  The 
impact of DNA binding on fluorescence has been shown to not only enhance or decrease 
fluorescence, but also to shift fluorescence excitation or emission peaks (data not shown).  It 
is unknown if similar effects occur upon organelle binding, and this should be investigated 
further.   
 In the benzimidazole series, all compounds accumulated exclusively in the nucleus 
and kinetoplast, highlighting the importance of DNA binding to the mechanism of action of 
these compounds.  The least potent compound in the benzimidazole series had an IC50 value 
of approximately 230 nM, compared to the benzofuran series in which the least potent 
compound had an IC50 value greater than 2 µM.  Remarkably, unlike the diphenyl furan and 
aza analogue series (Chapter 4), none of the compounds accumulated in other organelles like 
the acidocalcisomes.  This could potentially highlight a difference in the mechanisms of 
action between these series of compounds, as the diphenyl furans may have some action in 
the acidocalcisomes.  However, like the benzofurans, it must be cautioned that due to the 
fluorescence properties of these compounds in solution, the true distribution of these 
compounds may not be seen in trypanosomes.   
It is possible due to the fluorescence properties of both series of compounds that the 
intracellular distribution seen in trypanosomes is not the true distribution.  However, the 
UV2A cube used for fluorescence microscopy is to our knowledge, the only Nikon cube set 
available with an excitation band pass filter that extends this low (330 nm).  It may be 
possible in the future to design a fluorescence cube set that allows the visualization of lower 
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fluorescence excitation and emission wavelengths.  Alternatively, another microscope and 
fluorescence cube set may be utilized.  Although comparing the compounds with the UV2A 
cube set may not allow the visualization of the full distribution of the compounds in 
trypanosomes, it may still give valid information about the distribution of the compounds in 
the cells.   
 In vivo, 150OXD049 was able to cure an acute infection with S427 trypanosomes 
with trypanosomes concentrations much lower than that previously seen with DB75 and 
DB820 (Chapter 2).  Additionally, when DB820 was administered IP at the same 15 µmol/kg 
dose, concentrations in trypanosomes were similar to that of the 7.5 µmol/kg IV dose 
administered in Chapter 2 (data not shown).  Although the concentrations of 150OXD049 in 
trypanosomes were much lower than seen with other compounds, they were sufficient to 
clear the initial parasitemia, and none of the animals tested relapsed over the 60 day test 
period used to determine diamidine efficacy.  This combined with the unique distribution of 
150OXD049 in trypanosomes, is very promising for investigations of the mechanism of 
action of these compounds. 
 It has been assumed that selective accumulation of diamidines in trypanosomes has a 
lot to do with their mechanism of action.  If a compound can selectively accumulate within 
the target cell over other (host) cells, it has a better chance to act on the target cell.  With both 
DB75 and DB820, we have previously seen millimolar concentrations in trypanosomes and 
10000 – 20000 fold concentration factors of the diamidines in trypanosomes over plasma.  
With the benzofuran 150OXD049, this huge concentration in trypanosomes is not necessary 
for killing trypanosomes, perhaps indicating that different transport mechanisms are used to 
accumulate the compound in the cells.  This needs to be further investigated in the resistant 
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isolates of the S427 strain which lack the P2 transporter.  It is possible that the high 
concentrations of DB75 and related compounds in trypanosomes is due to multiple targets 
compounds interact with in the cell, where with 150OXD049, there is only one target within 
trypanosomes.  This unique distribution in trypanosomes has only been seen with the 
benzofuran diamidines (out of more than 100 diamidines from 8 structural classes 
investigated).  150OXD049 did appear to initially distribute to the kinetoplast (Figure 5.3), 
but for the most part was found in the cytoplasmic organelles that we believe are 
acidocalcisomes.   
 This diamidine may have a different mechanism of action against trypanosomes than 
DB75, which opens many new avenues for potential study of new diamidines.  With this 
series, the benzimidazoles, and the diphenyl furans, three series of compounds exist that may 
have different mechanisms of action.  While the benzimidazoles appear to  be found only in 
the DNA containing organelles, select compounds in the diphenyl furan series, like DB75, 
also accumulate in the acidocalcisomes.  Finally, the benzofurans appear to accumulate 
almost exclusively in the organelles believed to be acidocalcisomes.  These compounds 
especially will be useful for studies investigating what diamidines do in the acidocalcisomes.  
While in the diphenyl furan series, it can be argued that there is little reason other than 
physicochemical properties for diamidine accumulation in acidocalcisomes (i.e. their high 
pKa values leading to sequestration in organelles with low pH); compounds in the 
benzofurans must be exerting some mechanism of action in this organelle in order to kill 
trypanosomes.  Acidocalcisomes have been proposed to be involved in calcium and pH 
homeostasis in trypanosomes (2), and benzofurans may interfere with those processes.  There 
 178
are also enzymes found in the acidocalcisomes that could be inhibited by benzofuran 
diamidines.   
 It would also be interesting to investigate the possibility of synergism between 
compounds in the benzofuran and benzimidazole series, since these compounds likely have 
different mechanisms of action.  In the future, there may be a need for co-administration of 
two diamidines with differing mechanisms of action in an attempt to circumvent drug 
resistance.   
 The two series of compounds investigated were selected from many other series 
investigated based on their differing distribution properties.  While the benzimidazoles 
represent the typical distribution pattern expected of diamidines that potently bind DNA, the 
benzofurans seem to have a unique and different distribution pattern for the most part.  The 
benzofurans will be exciting compounds for future study.  Not only is there the potential for 
different accumulation mechanisms to bring the compounds inside trypanosomes, they also 
likely have a novel mechanism of action.  The compounds will be useful for mechanism of 
action studies, but also could represent a new approach for the future development of 
antitrypanosomal diamidines, targeting other organelles besides the DNA containing nucleus 
and kinetoplast.  
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Table 5.1:  Summary of diamidine compounds investigated 
 Total 
Number 
Fluorescent 
Compounds2 
Non -
Fluorescent 
Compounds2 
IC50 < 10 
nM 
10 nM<IC50 
< 100 nM 
Diphenyl 
furans 
24 18 5* 6 9 
Benzofurans 9 5 4 2 4 
Benzimidazoles 15 14 1 8 4 
Bis-
benzimidazoles 
5 5 0 1 3 
Fused Rings 
 
9 5 4 3 2 
Terphenyls 11 4 6 2 9 
Alkyl linkers# 11 1 10 4 2 
Isoxazoles1 7 0 7 2 3 
Total 91 52 37 28 36 
*One compound too toxic for testing, #Differ in structure, but all generally have alkyl linkers, 
1also oxadiazoles and related compounds, 2indicates fluorescence of the compounds seen 
using UV2A Microphot microscope.  All of the compounds were fluorescent to some extent. 
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Table 5.2:  Structure and In Vitro Antitrypanosomal Activity 
of Benzofuran Diamidines 
Compound Structure IC50 (nM) 
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Table 5.3:  Structure and In vitro Antitrypanosomal 
Activity of Benzimidazole Compounds 
Compound Structure IC50 (nM) 
DB818  0.9 
DB921  1.2 
DB843  1.9 
DB819 
 
 3.6 
DB846  6.7 
DB915  37 
DB928  90 
DB920  232 
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Table 5.4:  Fluorescence Properties of a 500 nM aqueous solution of Benzofuran and 
Benzimidazole Diamidines  
Compound Maximum Excitation 
Wavelength (nm) 
Maximum Emission 
Wavelength (nm) 
Fluorescence 
Intensity  
150OXD049 325 426 444 
7SAB081 320 420 5.1 
6SAB042 310 420 3.3 
1SAB035 320 420 514.7 
7SAB085 323 440 17.2 
7SAB006 326 400 936.5 
    
DB818 360 430 24.4 
DB921 320 434 52.8 
DB843 359 410 2.5 
DB819 360 450 487 
DB846 322 390 21.7 
DB915 358 470 215.7 
DB928 360 467 145.6 
DB920 320 390 240 
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Figure 5.1:  In vitro distribution of benzofuran diamidines in trypanosomes.  On left is phase 
contrast image, on right is fluorescence image.    
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Figure 5.2:  In vitro distribution of benzimidazole diamidines in trypanosomes.  On left is 
phase contrast image of trypanosomes, and on the right is the corresponding fluorescence 
image. 
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Figure 5.3.  In vivo Accumulation of 150OXD049 in Trypanosomes and Plasma.  
Concentrations are presented as µM ± SE (n=3-5 mice).   
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Figure 5.4.  In vivo Distribution of 150OXD049 in trypanosomes. 
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A. Conclusions 
 Aromatic diamidines have long been used for the treatment of parasitic diseases such 
as human African trypanosomiasis.  The investigations described here have focused primarily 
on diphenyl furan and aza analogues related to DB75 and DB820 (Chapters 2-4).  Chapter 5 
introduced two additional series of compounds which may be useful for future investigations 
of mechanism of action or drug development.  Before these studies began, little was known 
about the trypanosomal distribution and accumulation of diamidines.  Metabolism, transport 
and pharmacokinetics of the prodrug DB289, or pafuramidine, had been investigated for 
several years in several models (22, 27, 29, 32, 33).  The investigations presented here have 
added essential information about the disposition of diamidines in their target organism. 
 The diphenyl furan diamidine DB75, and its aza analog DB820, are both very potent 
diamidines against trypanosomes.  Both compounds have IC50 values of less than 10 nM, and 
have potent in vivo efficacy against several mouse models of trypanosomiasis (Chapter 2).  
Investigations showed that both DB75 and DB820 accumulated to high concentrations in 
trypanosomes, 10000-20000 times plasma concentrations.  This is indicative of selective 
transport into trypanosomes, likely through uptake transporters such as the P2 transporter.  
As hypothesized, the strong DNA binding DB75 and DB820 were found to accumulate in the 
two DNA containing organelles of trypanosomes, the nucleus and kinetoplast, and likely lead 
to killing of trypanosomes by accumulating there.  However, acidocalcisomes were also 
found to accumulate DB75 and DB820.  This could be due to the high pKa values of these 
diamidines (pKa’s are approximately 12) causing sequestration in these acidic organelles by 
the pH-partitioning theory, or the diamidines may exert some mechanism of action in these 
organelles.   
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 That diamidines accumulated to high concentrations in trypanosomes was not 
unexpected.  Previously, pentamidine was found to accumulate to concentrations of 
approximately 0.8 mM in trypanosomes isolated from infected rats 4 h after administration 
(4).  However the distribution of pentamidine cannot be easily investigated in trypanosomes 
as the compound is not fluorescent.  Investigations of the intracellular distribution of DB75 
and DB820 are the first to give confirmation that the compounds actually accumulate at the 
hypothesized targets.   
 Transport experiments for DB75 have indicated that the compound accumulated 
rapidly in trypanosomes primarily by only one transporter, the P2 transporter (13).  
Transporter based drug resistance has been shown to be a problem for compounds such as 
melarsoprol in clinical settings (17), and this problem must be considered for DB75 as well.  
Three trypanosome strains have been created in a laboratory setting which lack uptake 
transporter activity.  TbAT1-/- is a trypanosome line in which the alleles for the P2 
transporter (TbAT1 gene) have been removed (18).  DB75R-CL1 is a clone made resistant to 
DB75 in vitro (13), while B48 is the TbAT1-/- made resistant to pentamidine (3).  B48 has 
also lost functional activity of the HAPT1 transporter.  These three trypanosome lines 
allowed us to determine long term accumulation of DB75 in trypanosomes for the first time 
in the absence of the primary uptake transporter.  Surprisingly, DB75 still accumulated to 
high concentrations in vitro, albeit to lower concentrations than seen in the wild type S427 
line despite all these strains being resistant to DB75 in vitro.  The high concentrations found 
in the resistant strains in vitro has raised several questions about the environment (i.e. the 
media) that experiments are conducted in.  CBMEM is a highly supplemented medium, 
which in addition to many amino acids, also includes high concentrations of adenosine, 
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hypoxanthine, and inosine.  High concentrations of these purines may have some effect on 
the presence, activity, and regulation of transporters expressed on the surface of 
trypanosomes.   
 The concentration of adenosine in CBMEM media is approximately 80 µM.  
Adenosine competitively inhibits uptake of DB75 in trypanosomes with an IC50 value of 
0.8µM, after 5 min incubation with 1 µM radiolabeled DB75 and various concentrations of 
adenosine (12).  The 100 fold excess of adenosine in the medium may have saturated the P2 
transporter for DB75 transport.  It is possible that the accumulation seen in trypanosomes, 
both drug sensitive and resistant, is due to another transporter that is active when the P2 
transporter is saturated.  Concentrations of adenosine in human blood have been reported to 
be in the range of 0.1- 1 µM.  The half life of adenosine in the blood is very short (<1 s) (20), 
which keeps concentrations low.   
 In vivo, however, accumulation in the resistant strains was greatly reduced in 
comparison to the wild type line, especially when administered at a low dose (5 µmol/kg).  
Concentrations in the resistant trypanosomes were less than 20% of concentrations in the 
wild type S427 trypanosomes.  This dose was not able to cure any of the resistant lines 
tested, likely due to the low concentrations that accumulate in these trypanosomes.  Even at 
the higher dose investigated the resistant strains accumulated much less DB75 than the wild 
type line.   
 In vitro and in vivo distribution of DB75 in the resistant lines was similar.  Consistent 
with the reduced accumulation, distribution of DB75 in trypanosomes progressed slower than 
that seen in the wild type line.  DB75 first appeared in the kinetoplast, then nucleus, and 
much later, in the acidocalcisomes.  This delayed distribution was also seen when DB75 is 
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incubated with wild type S427 trypanosomes at 4 ºC (preliminary studies described in 
Appendix II).  It is possible that the same mechanism leads to accumulation of DB75 in 
trypanosomes at 4 ºC and in the absence of the P2 transporter, though this needs further 
investigation.   
 Investigation of diphenyl furans related to DB75 and analogues of DB820 yielding 
interesting results.  It was hypothesized that accumulation in trypanosomes would be related 
to in vitro activity, and possibly even in vitro distribution.  In other words, it was expected 
that more potent diamidines would accumulate in trypanosomes to higher concentrations than 
less potent diamidines.  However, this was not the case in the diphenyl furan series, as two 
compounds of intermediate potency accumulated to higher concentrations than the very 
potent DB75.  DB690, a 2,4 diphenyl furan analogue, which was more than 3 fold more 
potent than DB75, did accumulate to peak concentrations 6 fold higher than that of DB75.  
All of the compounds in the diphenyl furan series were potent DNA binders, regardless of 
substitutions on the diamidine compounds.  Additionally, all of the diphenyl furans were 
found to be localized to the nucleus and/or kinetoplast of trypanosomes, supporting DNA 
binding as a major mechanism of action of the compounds.   
 Compounds in the DB820 series yielded similar results.  Again there was no 
correlation between accumulation in trypanosomes over time and activity.  The most potent 
compound in the series did accumulate to the highest concentration in trypanosomes, but 
every compound tested accumulated to higher concentrations than DB820, the second most 
potent compound in the series.  There may be a minimum accumulation necessary for 
activity of the diphenyl furans and aza analogues against trypanosomes – approximately 1 
mM.   
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 In an effort to expand investigation of diamidines to other series of compounds, more 
than 100 compounds from 8 different classes were examined.  In vitro activity and 
distribution experiments with benzofuran diamidines and benzimidazole diamidines showed 
different distribution between the two series.  While the benzimidazoles distributed to the 
nucleus and kinetoplast, several compounds in the benzofuran class were localized to 
organelles in the trypanosomes believed to be the acidocalcisomes based on their localization 
in trypanosomes.  Of the compounds investigated, only 2 appear to be localized to the 
kinetoplast, 1SAB035, and 7SAB081, which is also located in the cytoplasmic organelles.  
Accumulation in these organelles may represent a novel mechanism of action for the 
benzofurans, which must be further investigated.  
 One of the benzofurans, 150OXD049, was investigated in vivo to determine 
accumulation in trypanosomes and plasma.  Unlike DB75 and DB820, this benzofuran was 
not highly concentrated in trypanosomes over plasma; there was only a 200 fold 
concentration in the parasite over plasma.  Despite this, the compound was curative in 
infected animals.  The compound may accumulate in trypanosomes by different mechanisms 
than DB75 and DB820, leading to less compound overall in trypanosomes.  The related 
compound, DAPI, has affinity for all three uptake transporters found on trypanosomes, but 
transport is not mediated by the P2 transporter primarily (3).  In the B48 line, 1 mM 
pentamidine has been shown to prevent the fluorescence of DAPI in trypanosomes over 60 
min.  With the structural similarities between DAPI and the benzofurans, it is possible that 
the compounds have similar uptake properties.  To my knowledge, long term accumulation 
of DAPI in trypanosomes has not been investigated.  Additionally, the lower accumulation in 
trypanosomes may be related to the mechanism of action of 150OXD049.  Since there is 
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predominantly only one target in the cells that these compounds accumulate in, it may not be 
necessary to accumulate millimolar concentrations of 150OXD049 in trypanosomes.  DB75 
and DB820 potentially have at least three targets in trypanosomes – the nucleus, kinetoplast 
and acidocalcisomes.   
 The results with 150OXD049 indicate that the hypothesis of DNA binding being 
essential to the mechanism of action of diamidines may not be true for all diamidine 
compounds.  It is likely that such a generalization can not be made about all diamidine 
compounds.  Investigation of only 100 diamidines has potentially turned up two different 
mechanisms of action.  Future experiments should be planned to identify the mechanism of 
action of the benzofurans.  Also it may be prudent to include other targets for future 
diamidine compounds to be developed.   
 These investigations have yielded promising results, and raised questions for future 
studies.  Diamidines accumulate to high concentrations in trypanosomes, and localize to 
several intracellular targets.  The most intriguing results were found with the trypanosome 
lines lacking uptake transporters.  DB75 concentrations in these lines, although reduced, 
were still high.  These results require further study to determine whether drug resistance to 
DB75 will be a problem with clinical use.  Additionally, investigations on the mechanism of 
action of diamidines can be started with information already available about the distribution 
and accumulation of diamidines in trypanosomes.   
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B. Future Directions 
 Much remains to be investigated with aromatic diamidines.  Pafuramidine, the 
prodrug of DB75, may be on the market in a few years as a treatment for trypanosomiasis, 
and the mechanism of action of this compound is still unknown.  Knowing the accumulation 
and distribution of these compounds is the first step to determining mechanism of action of 
these diamidines.  Additionally, the complete mechanisms for accumulation of diamidines 
like DB75 need to be determined.   
 Fluorescent compounds like the diamidines investigated here will useful for further 
investigation of mechanism of action.  Qualitatively, the distribution of the compounds is 
known using fluorescence microscopy.  Isolation of organelles will allow the study of 
accumulation in the various target organelles, and will allow the investigation of potential 
targets in the isolated organelles.  Separation of the two DNA targets will enable the study of 
affinity for both the kDNA, which is more AT rich, and the nuclear DNA as well inhibition 
of the various DNA associated enzymes like topoisomerase in the both organelles.  It is 
possible that a diamidine could have greater affinity to inhibit the action of topoisomerase in 
the kinetoplast than the nucleus, or vice versa.  A preliminary investigation on the isolation 
of organelles is presented in Appendix III.  With the isolation studies, at least one organelle 
has bee isolated definitively, although purity is unknown.   
 The use of inhibitors which block accumulation in certain organelles is another way 
to investigate mechanism of action.  Altering the acidity of acidocalcisomes with the sodium 
ionophore monensin has already been used to prevent accumulation of DB75 in 
acidocalcisomes (Appendix I).  These studies should be expanded to other inhibitors to verify 
whether DB75 and other compounds exert any action in the acidocalcisomes.  The ability of 
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diamidines to inhibit phosphatases and other enzymes found in the acidocalcisomes should 
be investigated as well.  Several acidocalcisome deficient trypanosome lines have also been 
developed.  These lines have been created though genetic modification of genes found 
expressed in the trypanosome acidocalcisomes (14, 15).  These trypanosomes could be used 
to investigate mechanisms of action of diamidines in the acidocalcisomes.   
 Another way to study mechanism of action would be to use electron microscopy.  In 
the past, transmission electron microscopy has been used to examine effects of 
antitrypanosomal compounds on trypanosome ultrastructure.  For example, pentamidine has 
been shown to have an effect on kinetoplast structure using this technique (31).  TEM 
investigations will be useful to investigate whether any differences exist between the wild 
type and drug resistant strains of trypanosomes (i.e. are the compounds not only 
accumulating in the trypanosomes to a lesser extent, but also accumulating less in the targets 
of interest?).   
 The question of trypanosome drug resistance in the field is a major one that needs to 
be investigated, not only for aromatic diamidines, but also for all compounds currently used.  
For the diamidines, it is vital that the mechanisms of accumulation by all potential transporter 
or transport processes are determined.  For administration of DB75 itself in vivo, it appears 
from the experiments already conducted that the P2 transporter has an effect on accumulation 
of DB75 over time.  However, the accumulation of high micromolar concentrations when the 
primary transporter to accumulate the drug is missing is intriguing.  Based on this work, it is 
clear that DB75 accumulates in trypanosomes via some other means, and this mechanism 
remains to be elucidated.  Previous work has determined that two P1 – type transporters are 
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upregulated in TbAT1-/- trypanosomes, but to date, these transporters have not been shown to 
be involved in drug uptake (10).   
 In vitro experiments investigating accumulation of DB75 in these resistant lines need 
to be expanded to other compounds in the available library, including DB820 and DB829, 
two lead diamidines for treatment of late stage trypanosomiasis.  Furthermore, the 
experiments should be expanded to investigate the accumulation in protein free buffer 
systems, as well as adenosine free media.  The growth media used for the experiments 
described in this dissertation was also used for accumulation experiments.  This media 
contains relatively high concentrations of adenosine and other purines.  Although these 
concentrations should not saturate the P2 transporter, it should be investigated by eliminating 
first the adenosine in the media, and then other media components.  The data presented here 
indicated that over time a higher concentration of DB75 accumulated in drug resistant 
trypanosomes than would be expected based on short term experiments conducted on 
trypanosomes ex vivo in a simple buffer system (13).  It is also unknown whether absence of 
the P2 transporter and HAPT1 activity has led to the upregulation of another transport 
mechanism in the drug resistant trypanosomes.   
 Experiments must also be conducted to compare accumulation of pentamidine, 
propamidine, and berenil in wild type and drug resistant trypanosomes.  Pentamidine and 
propamidine are both substrates for the HAPT1 transporter, while berenil, like DB75, is only 
thought to be a substrate for the P2 transporter.  These three compounds have been widely 
studied, and much is known about their uptake properties.  Differences in the uptake of these 
compounds will be investigated by comparing their long term accumulation to that of DB75.  
Additionally, accumulation of phenyl arsine oxide, a lipophilic derivative of melarsoprol 
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should be investigated.  Studies have shown that the in vitro activity of this compound is 
unchanged in the resistant lines investigated here.  As the compound is lipophilic, it should 
passively diffuse across trypanosome membranes and can be used as a control for 
accumulation in various media and buffer systems. 
 The discrepancy in accumulation of DB75 in the drug resistant strains at the lowest 
dose administered (5 µmol/kg IP) led to the idea that accumulation of DB75 in trypanosomes 
should be determined after curative doses of DB289 are administrated.  After administration 
of DB75, concentrations of the compound in plasma are initially high, but decline rapidly 
over time.  After administration of DB289, concentrations of DB75 in plasma will rise 
slower, and may be elevated longer.  Regardless, accumulation of DB75 in trypanosomes 
after administration of DB289 is more clinically relevant than administration of DB75 alone.  
The possibility that higher doses or longer dosing administrations can overcome the potential 
for drug resistance in these strains may also be investigated.   
 The resistant lines studied so far were all developed in the laboratory.  Clinical 
isolates resistant to melarsoprol have been found to have mutations in the P2 transporter (17), 
but the lines used in this study had the transporter completely removed.  It is possible that 
even with several mutations to the transporter as seen in the clinical strains, some level of 
accumulation in trypanosomes may still occur using this transporter.  It may be prudent to 
investigate accumulation of DB75 and related compounds in these clinical strains to 
determine whether the laboratory created strains are a relevant model.   
 Investigations of other aromatic diamidines should continue for development of 
compounds not only for trypanosomiasis but for other parasitic diseases as well.  Already 
compounds with different distribution and likely different mechanisms of action in 
 200
trypanosomes have been identified, after investigating only 100 diamidines.  Although it is 
unlikely that any more classes of compounds with different distributions will be discovered, 
these investigations have set the groundwork for the further study of diamidines in 
trypanosomes.   
 These proposed future studies will add extensively to our knowledge of diamidine 
accumulation, distribution, and mechanism of action in trypanosomes.  Much remains to be 
learned about DB75 and other diamidines.  Studies proposed here will not only add to the 
knowledge of diamidines, but may also aid in future drug development efforts not only for 
trypanosomes, but also for other parasitic diseases.   
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Introduction 
Exact mechanisms of action of diamidines such as DB75, despite intensive study, are 
still poorly understood.  DB75 and related diamidines are known to bind DNA tightly in AT 
rich regions (2).  There are many hypotheses for the mechanism of action of diamidines in 
addition to DNA binding, including interference with DNA associated enzymes such as 
topoisomerases, interference with polyamine activity, and protease inhibition (30).  
Pentamidine, an early analog of DB75, has been shown to linearize kinetoplast DNA and 
interfere with topoisomerase activity in the kinetoplast (25, 26).  While distribution of 
nonfluorescent pentamidine cannot be followed in trypanosomes, fluorescent DB75 has been 
shown to accumulate in the kinetoplast and nucleus where it binds to DNA.  Further 
experiments are needed to determine whether DB75 affects topoisomerases found in both 
organelles or linearizes kinetoplast DNA.  However, DB75 is also thought to be localized to 
the acidocalcisomes, recently discovered organelles in parasites such as trypanosomes.   
The acidocalcisomes, as their name suggests, are acidic organelles that sequester 
calcium ions, as well as other ions, and polyphosphates (7).  The organelles represent up to 
2% of the total trypanosome volume, and their size is inversely proportional to their number.  
In other words, the more acidocalcisomes present in the cell, the smaller the organelle 
volume.  Several transporters are known to be localized to the surface of acidocalcisomes, 
including a Ca2+-ATPase that is sensitive to vanadate, and a vacuolar H+-ATPase (7).  Also 
found on the membrane of acidocalcisomes are various ion exchangers, such as Na+/H+ and 
Ca+/H+ exchangers, responsible for maintaining the ionic balance in the organelle and 
trypanosomes (7).  Alkalinizing agents such as the ionophores monensin and nigericin, and 
ammonium chloride (NH4Cl), have also been shown to release Ca2+ and acridine orange from 
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acidocalcisomes (7, 8).  Acidocalcisomes are thought to be involved in many intracellular 
processes such as osmoregulation, pH regulation and the storage of ions (7, 8).  However, 
any role that DB75 may play in these organelles is unknown.  This study was initiated to 
investigate whether accumulation in the acidocalcisomes is essential to the accumulation of 
DB75 in trypanosomes.   
Methods 
Trypanosoma brucei brucei S427 trypanosomes were cultured in CBMEM media as 
previously described (16).  For various time points from 5 min - 1 h, 106 trypanosomes were 
pretreated with 5 µM monensin (stock solution prepared in ethanol) or 20 mM ammonium 
chloride.  After pretreatment, trypanosomes were washed and then DB75 was added to a final 
concentration of 7.5 µM.  DB75 was incubated with trypanosomes for 2 h, and then 
trypanosomes were washed twice and resuspended in freshly isolated mouse blood.  Thin 
films were prepared from a drop of blood, and viewed with a Nikon Microphot FXA 
microscope equipped with a 60 DM x 1.4 NA objective lens, a mercury lamp, and QImaging 
Micropublisher 3.3 CCD Digital Camera (QImaging Corporation, Surrey, BC, CA) was used 
for fluorescence microscopy.  QCapture version 3.0 imaging software was used to capture 
images (QImaging).  The microscope was equipped with a Nikon UV2A cube that limits 
excitation wavelengths to 330-370 nm and emission wavelengths to ≥ 420 nm.  Additionally, 
DB75 and monensin or NH4Cl were co-incubated with trypanosomes for the 2-4 h time 
period as well.  Acridine orange (Sigma) was used as a marker for acidocalcisome 
accumulation.  Acridine orange has been shown in the past to accumulate in acidocalcisomes 
and be displaced by alkalinizing agents (8).  Concentrations of DB75 in trypanosomes with 
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and without a monensin pretreatment were determined by High Performance Liquid 
Chromatography (HPLC) as previously described (16).   
Results 
 After two hour incubation in vitro with trypanosomes, DB75 accumulated in the 
nucleus, kinetoplast and acidocalcisomes (Figure 1, first column).  However, when 
ammonium chloride or monensin were used as a pretreatment before DB75 was added, 
accumulation in the acidocalcisomes was not seen (Figure 1, columns 2 and 3).  A 60 min 
pretreatment of ammonium chloride was needed to prevent DB75 accumulation in 
acidocalcisomes, although partial inhibition of acidocalcisomes localization was seen after 30 
min.  The sodium ionophore monensin, on the other hand, only needed to be incubated with 
trypanosomes for 15 min before DB75 was added to abolish acidocalcisome accumulation.  
Partial inhibition of accumulation was seen after 5 min.  Monensin completely abolished 
acridine orange fluorescence in the acidocalcisomes of trypanosomes after only 15 min (data 
not shown).   
 Interestingly, when accumulation of DB75 was determined by HPLC analysis, there 
was no significant difference in trypanosome concentrations with or without the monensin 
pretreatment (Figure 2) after either 1 or 2 h.  This indicates that when DB75 is unable to 
accumulate in acidocalcisomes, it must redistribute to other organelles, and also that 
monensin pretreatment does not inhibit overall accumulation of DB75 in trypanosomes. 
Conclusions 
 Monensin and ammonium chloride inhibited the accumulation of DB75 in 
acidocalcisomes, similar to effects seen previously with monensin and acridine orange (8).  
Treatment with both monensin and ammonium chloride serve to increase alkalinity in acidic 
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organelles like acidocalcisomes.  Therefore, inhibition of acidocalcisome accumulation could 
be related to increased pH in the acidocalcisomes caused by either treatment.  Additionally, 
monensin has been shown to cause the release of calcium ions from acidocalcisomes into the 
cytoplasm of trypanosomes (28).  It is unknown by what mechanism DB75 accumulates in 
the acidocalcisomes (i.e. by what transporter if any), but this should be further investigated 
with inhibitors of the various uptake transporters on the surface of trypanosomes (for review 
see (7)).   
 Despite the lack of accumulation of DB75 in acidocalcisomes after pretreatment of 
monensin (30 min), overall concentrations in the cells were unaffected.  This could be due to 
redistribution of available DB75 to other organelles, such as the nucleus and kinetoplast 
(Figure 1).  The next logical step would be to determine whether monensin affects the IC50 
value of DB75.  In preliminary studies, we have found that monensin is toxic to the cells over 
long periods of time (72 hours for the in vitro activity experiment).  It is not known how long 
the effects of monensin last in the cells.  We plan to further investigate other potential 
inhibiting agents to determine their effects on DB75 accumulation, distribution and activity.  
Then the role that the acidocalcisomes play in the mechanism of action of DB75 can be fully 
assessed.   
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Figure 1:  Distribution of DB75 (7.5 µM) in trypanosomes alone (first column A and B), and 
after either a 60 min pretreatment of ammonium chloride (NH4Cl) or a 15 min 
pretreatment of monensin.   
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Figure 2:  Accumulation of DB75 in trypanosomes alone and after a pretreatment of 
monensin (5 µM).  Student t-tests showed no difference in accumulation of DB75 in 
trypanosomes with or without monensin pretreatment.   
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APPENDIX II 
  
 
TEMPERATURE EFFECTS ON ACCUMULATION AND DISTRIBUTION OF DB75 
AND DB249 IN AFRICAN TRYPANOSOMES 
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Introduction 
 DB75 and DB249 have been shown to accumulate to high concentrations in 
trypanosomes in vitro (CHAPTER 4).  Accumulation of diamidines in trypanosomes is 
thought to occur mainly through uptake transporters on the surface of the cell.  These 
transporters include the P2 adenosine transporter, and the HAPT1 and LAPT1, which are 
known to accumulate pentamidine specifically in trypanosome (5, 6).  Previous work has 
shown that transport of DB75 is reduced when the P2 transporter is missing (CHAPTER 3), 
but accumulation still occurs in trypanosomes.   
 Following work done in CHAPTER 4, showing very high accumulation of several 
diamidines over an 8 h period, additional experiments were planned to investigate 
mechanisms of long term accumulation of diamidines in trypanosomes.  Here data is 
presented showing accumulation of two diamidines, DB75 and the cyclohexyl derivative 
DB249, at 4 ºC.  Short term accumulation experiments have shown minimal accumulation of 
DB75 in trypanosomes at low temperatures (13). 
Methods 
 Trypanosomes were cultured as previously described (16).  DB75 and DB249 (7.5 
µM) were incubated with approximately 106 trypanosomes/ml for time periods between 1 
and 4 h at either 4 ºC or 37 ºC.  At time points after administration of compound, cells were 
washed twice with drug free media and resuspended in fresh media.  The compounds were 
extracted and analyzed as described in Chapter 4.  Additionally, DB75 and DB249 were 
incubated with 7.5 µM to determine intracellular distribution in trypanosomes at both 
temperatures by microscopy.  After 1 h, cells were washed twice and resuspended in freshly 
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isolated mouse blood.  Thin smears were prepared and viewed using a Nikon Microphot 
FXA microscope equipped with a UV-2A cube.   
Results  
 Accumulation of DB75 and DB249 (a cyclohexyl substituted derivative of DB75) 
was reduced at 4 ºC.  The accumulation of DB75 at 4 ºC was only about 40% of the 
accumulation seen at 37 ºC.  DB249 accumulation at 4 ºC, on the other hand was 75-90% of 
accumulation at 37 ºC.  This decrease in accumulation at 4 ºC was not significant (p = 0.3, 
0.4 for 1 h and 4 accumulation of DB249).  P values associated with the decrease in DB75 
accumulation with decreasing temperature were 0.1 and 0.03 for 1 h and 4 h accumulation 
experiments respectively).   
 Distribution studies showed that both DB75 and DB249 accumulate within the 
trypanosomes at 4 ºC, although distribution is not as extensive as it is at the higher 
temperature (Figure 2).  After 1 hour at 4 ºC, DB75 is localized to the nucleus and kinetoplast 
of trypanosomes, while DB249 is found only in the kinetoplast.  After a 37 ºC incubation for 
1 h, DB75 is localized to the kinetoplast and nucleus, and the kinetoplast fluoresces white, 
typically associated with high concentrations of DB75 in the organelle.  At 37 ºC, DB249 is 
found in the nucleus and kinetoplast and appears to be much brighter in these organelles than 
at 4 ºC.  
Conclusions 
 The results shown here indicate that both DB75 and the more lipophilic DB249 
accumulate in trypanosomes when cells are maintained at 4 ºC.  For the 4 ºC experiments, 
cells were chilled before the experiments began to ensure that trypanosomes had reached that 
temperature before the experiments began.  It has been postulated that perhaps the positively 
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charged compounds were only associated with the surface of trypanosomes at low 
temperatures and were not accumulating in the cells, but here we show that both compounds 
are actually localizing in the cells to the theoretical target organelles.  However, the 
mechanism for this accumulation is still unknown.  Using low temperatures, we were 
attempting to stop any active transport processes from occurring, but trypanosomes can retain 
motility and viability at 4 ºC for long periods of time, assuming they are provided with basic 
nutrients like glucose (data not shown).  Since motility of trypanosomes requires energy, it is 
likely that we have not slowed or stopped energy dependent processes over the period of time 
studied.  Therefore, the mechanism of this uptake at 4 ºC can not exclude the possibility of a 
transporter such as P2 operating at this temperature.  However, other investigators have used 
transport at 4 ºC to indicate passive diffusion, albeit over shorter periods of time (1).  
Interestingly, the pattern of accumulation in the organelles of trypanosomes is similar to that 
seen with the P2 transporter knockout trypanosomes, with accumulation first occurring in the 
kinetoplast, then nucleus (seen clearly with DB249).  The possibility exists that whatever 
mechanism leads to the accumulation of DB75 in TbAT1-/-, DB75R-CL1, and B48 lines, is 
responsible for the accumulation of these compounds at 4 ºC.   
 Additional experiments were employed using adenosine (1 mM, in addition to the 
adenosine found in media) to block accumulation of DB75, but concentrations of DB75 were 
not substantially reduced.  It remains to be investigated whether accumulation of DB75 in 
adenosine free media is lower or higher than in the current growth media.  Perhaps the 
adenosine in the media currently used has saturated the P2 transporter, so that any 
accumulation of DB75 seen is through an alternative route.  There is still much to be 
investigated in terms of diamidine accumulation in trypanosomes.   
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Figure 1:  Relative Accumulation of DB249 and DB75 at 37 ºC and 4 ºC.  Accumulation at 
37 ºC at 1 hand 4 h for both compounds is indicated by closed bars, while 
accumulation at 4 ºC at 1 h and 4 h for both compounds is indicated by open 
crosshatched bars.    
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Figure 2:  Distribution of DB75 and DB249 in trypanosomes at 4 ºC and 37 ºC.  Phase 
contrast images are included to visualize trypanosome orientation.  Two images at each 
temperature are provided.   
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APPENDIX III 
 
 
ISOLATION OF TRYPANOSOME ORGANELLES:  PRELIMINARY STUDIES 
FOR INVESTIGATING MECHANISM OF ACTION 
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Introduction 
There are several methods in which mechanism of action of diamidines can be 
determined.  An organelle isolation method was chosen.  This method has been utilized in 
drug sensitive and drug resistant cancer cells to determine that localization of doxorubicin or 
daunorubicin was altered in drug resistant cells (9);(Mathis, unpublished results).  An attempt 
to isolate organelles from trypanosomes in which diamidines like DB75 accumulate was 
made.  DB75 has been shown to accumulate in the kinetoplast of the mitochondrion, the 
nucleus and acidocalcisomes.  After isolating organelles, the amount of compound in each 
organelle could be determined by HPLC or LC/MS analysis.  A mass balance approach could 
be used to determine the relative contribution that each organelle makes to overall 
trypanosome concentrations.   
 Since qualitatively, the distribution of DB75 in trypanosomes was known, isolation 
procedures for several organelles, including the nucleus, kinetoplast and mitochondria, 
acidocalcisomes, lysosomes, and glycosomes were investigated.  This was the first step to 
future investigation of DB75 accumulation in organelles.  Preliminary data here shows the 
isolation of acidocalcisome fractions.   
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Methods and Materials 
Trypanosome Isolation.  Trypanosomes were isolated from rats infected with 106 
trypanosomes 4-5 days post infection.  All animal experiments adhered to guidelines outlined 
by the University of North Carolina-Chapel Hill Institutional Animal Care and Use 
Committee (IACUC).  Approximately 109-1010 trypanosomes were isolated from infected 
rats.  Trypanosomes were isolated from blood by centrifugation to separate plasma and red 
blood cells.  Trypanosomes were found in the buffy coat, which was removed and combined 
with an equal volume of phosphate saline glucose (PSG) pH 7.4.  This solution was passed 
through a DEAE column to separate white blood cells and any contaminating red blood cells 
from trypanosomes.  Due to charge differences, trypanosomes passed through the column 
while blood components were retained on the column.  Isolated trypanosomes were washed 
twice in PSG buffer.   
Trypanosome Lysis.  Trypanosomes were resuspended in lysis buffer with Complete 
proteinase inhibitors (Roche) and lysed in a nitrogen cavitation bomb.  A solution of 
trypanosomes was held under 1000 psi nitrogen for 30 min to lyse cells.  Lysis was 
visualized by viewing an aliquot of the cell suspension with a light microscope.  
 Lysis by nitrogen cavititation was the best lysis method, but other lysis methods were 
attempted before nitrogen cavitation.  These methods included lysis by manual 
homogenization, sonication, and vortexing.  Isolation procedures developed for 
acidocalcisomes (23) called for the use of silicon carbide and a mortar and pestle.  Briefly the 
trypanosome pellet was mixed with silicon carbide, and trypanosomes were ground on ice 
using a mortar and pestle.  After lysis, silicon carbide was removed from the lysed cellular 
components by a low speed centrifugation.   
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 Another method used for lysis was manual homogenization.  Trypanosomes were 
resuspended in lysis buffer and lysed with a Dounce homogenizer.  Alternatively, a 
Tissuemiser or probe sonicator (Fisher Scientific) was used to lyse trypanosomes.  The final 
method used was to mix trypanosomes with glass beads and vortex for several minutes.   
Acidocalcisome Isolation.  Acidocalcisomes were isolated using a lysis buffer containing 
0.125 M sucrose, 50 mM KCl, 4 mM MgCl2, 0.5 mM EDTA, 5 mM DTT, and 20 mM 
HEPES, pH 7.4 (23).  Trypanosomes were lysed in nitrogen cavitation bomb as described 
above.  Lysed trypanosomes were centrifuged at 900 rpm for 10 min to pellet cell debris.  
The supernatant was decanted and centrifuged at 1500 rpm for 10 min.  The supernatant was 
decanted and saved, and the pellet resuspended in fresh lysis buffer (10 ml) and centrifuged 
at 1500 rpm for 10 min.  The two supernatants were combined and centrifuged at 10000 g for 
30 min in a Beckman Ultracentrifuge.  The pellet was resuspended in 2 ml of lysis buffer by 
passage through a 22 gauge needle, and loaded on top of an Optiprep gradient 
(24/28/34/37/40% Optiprep in lysis buffer).  The gradient was centrifuged at 50000 g for 1 h 
in a Beckman Ultracentrifuge.  Acidocalcisomes were pelleted to the bottom.  Fractions were 
collected from the top into 2 ml centrifuge tubes.  The bottom 2 fractions and resuspended 
pellet were analyzed for the presence of acidocalcisomes.   
Isolation of Other Organelles.  The isolation of mitochondria and kinetoplast, nucleus, 
glycosomes and lysosomes were attempted.   
Kinetoplast/Mitochondria Isolation.  This isolation procedure was modified from previously 
published reports (19).  Trypanosomes were suspended in a lysis buffer containing 50 mM 
HEPES-NaOH buffer (pH 7.2) containing 0.27 M sucrose, 1.0 mM EDTA, 1.0 mM MgCl2, 
and a Complete protease inhibitor tablet (Roche).  Trypanosomes were lysed as described 
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previously, and mitochondria were isolated.  Residual cell debris was removed by a 900 g 
centrifugation at 4 ºC.  The supernatant was centrifuged for 10 min at 12000 g to pellet crude 
mitochondria.  The pellet was resuspended in 10 mM potassium phosphate buffer (pH 7.5) 
containing 0.25 M sucrose and 1.0 mM EDTA, and was centrifuged again at 12000 g for 10 
min.  Isolated mitochondria were resuspended in a small amount of buffer.   
Lysosome and Glycosome Isolation.  Trypanosomes were resuspended in SHK buffer (250 
mM sucrose, 50 mM HEPES, 25 mM KCl, pH 7.4), containing protease inhibitors.  
Trypanosomes were lysed in a nitrogen cavitation bomb as described above.  After lysis, 1 
mM EDTA was added to the buffer containing trypanosomes.  Cell debris was pelleted at 
700 g for 10 min to yield crude nuclear pellet.  The supernatant was clarified by centrifuging 
at 2800 g for 10 min to produce a large granule fraction (LG).  The supernatant was then 
centrifuged at 15000 g for 10 min to yield a small granule fraction (SG).  Optionally, the post 
SG supernatant could be centrifuged at 123000 g for 90 min in a 50.2 Ti rotor.  This 
centrifugation produced a microsomal pellet fraction and soluble supernatant.  Otherwise, the 
LG and SG fractions were further fractionated by isopycnic centrifugation in Percoll.  LG 
and SG fractions were made 57.6% with respect to Percoll in SHKE and layered underneath 
a discontinuous gradient (43.2/28.8/20.3%) and centrifuged for 30-35 minutes at 25000 rpm 
in SW41 or SW28 rotor (depending on volume of supernatant).  Fractions banding between 
the 28.8/43.2% and 43.2/57.6% interfaces were made 57.6% with respect to Percoll again 
and centrifuged again through the same gradient.  Fractions on top of and in the 20.3% 
Percoll layer (crude flagella) were adjusted to 28.8 % Percoll and layered under a 
discontinuous gradient containing 20.3/17.3/14.4% Percoll in SHKE buffer.  This was 
centrifuged again as above to obtain the lighter membrane fractions.  The lysosomes are at 
 219
the 28.8/43.2% interface and the glycosomes are at the 43.2/57.6% interface after the second 
centrifugation.  This isolation procedure was modified from a method published by Grab et al 
(11).   
Nuclei Isolation.  Trypanosomes were lysed as described above.  Lysed cells were underlaid 
with 10 ml of 0.3 M sucrose in 8% poly vinyl pyrolidine (PVP) plus Complete protease 
inhibitors, 5 µL of 1 M DTT, and centrifuged at 11000 g, at 4°C for 20 min as described 
previously (21).  The crude nuclear pellet was immediately resuspended with 1 min bursts of 
the Tissuemiser in a total volume (per 2 X 1010 cells) of 8 ml of 2.1 M sucrose in 8% PVP, 
50 µL of 1 M DTT, protease inhibitors, and 0.05% Tween 20.  Approximately 12 ml of this 
solution was loaded per SW28 tube containing a discontinuous step gradient (from the 
bottom, 8 ml of 2.3 M sucrose/PVP, 8 ml of 2.1 M sucrose/PVP, 8 ml of 2.01 M 
sucrose/PVP, all containing protease inhibitors).  For the preparation to be successful, it is 
essential that no more than 2.5 X 1010 cell equivalents be loaded into each SW28 tube.  The 
gradient was centrifuged at 100000 g, in a SW28 rotor for 3 hours at 4°C and immediately 
unloaded from the top.  Fractions were examined by phase contrast microscopy.  Nuclei were 
recovered at the 2.1/2.3 interface.  Quantification of nuclei was performed by optical density 
at 260 nm; for T. brucei. OD260nm corresponds to ~ 108 nuclei and has an OD260 nm/OD280 nm 
ratio of ~1.3.   
Alternatively, instead of PVP, sucrose solutions were used in buffer.  Briefly, to the 
final homogenate, 10 ml of 2.3 M sucrose in Tris buffer (containing 0.75% Triton X-100) 
was added.  This was placed on top of 2.3 M sucrose in Tris buffer in a 25 X 89 mm 
centrifuge tube and centrifuge at 40500 g in a SW28 rotor for 70 m at 4°C to pellet nuclei.  
This method was adapted from a cancer cell nuclei isolation procedure (9).   
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TEM Analysis of fractions.  Samples were analyzed using a LEO EM 910 Transmission 
Electron Microscope (TEM).  Acidocalcisomes samples were mounted on formvar coated 
grids and allowed to dry.  This was done to retain electron density of the organelles (7).  
Samples were viewed using 8000 – 100000 magnification.  Other organelle fractions 
investigated were fixed in 2.5% gluteraldehyde in 0.1 M sodium cacodylate buffer (Fisher 
Scientific), and were embedded and sectioned by personnel at the Microscopy Services Lab 
at UNC.   
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Results and Conclusions 
 The acidocalcisomes and mitochondria were isolated using protocols adapted from 
previous work (23).  Of all the lysis methods attempted, the use of a nitrogen cavitation bomb 
to disrupt the cellular membranes worked the best.  Other methods, including sonication and 
the use of various homogenizers, did not completely lyse cells.  For many of the methods 
attempted, many trypanosomes survived lysis attempts with motility intact.   
 Acidocalcisomes were analyzed using TEM to visualize electron density of the 
organelles (Figure 1).  Low and high resolution micrographs show electron dense particles, 
which are relatively pure (no contaminating organelles or debris).  The organelles were 
approximately 50 nm in size, consistent with previous data (7).  The fraction also reacted 
with an antibody raised against yeast vacuolar H+ ATPase 69 kDa subunit (data not shown).   
 Isolation procedures for the acidocalcisomes were successful.  However, due to a lack 
of availability of antibodies raised against Trypanosoma brucei organelles, the purity of the 
isolated fraction was not determined.  The isolated fraction did not cross react with an 
antibody raised against lysosome proteins (anti-p67), and was therefore free of lysosomal 
contamination (data not shown).   
 Although it was proven in Appendix I that DB75 accumulated in the acidocalcisomes, 
before quantification of the relative amount of the compound in the organelle can be 
performed, purity of the fraction must be determined.  Additionally, other organelles in the 
trypanosomes must be isolated in order to determine mass balance of diamidines in 
trypanosomes.  Isolation of the nucleus has been a particular problem, with contamination 
from unbroken cells, flagella and membranes being an issue.  Additionally, using optical 
density methods, no purification of nuclei was seen (data not shown).  Another technique to 
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determine DNA associated concentrations could be to isolate total cellular DNA and separate 
it into kinetoplast and nuclear fractions.  For the lysosomes and glycosomes, preliminary 
evidence suggests that the organelle fractions do contain lysosomes, but cross-reactivity with 
antibodies from other organelles has not been attempted yet.  It may be necessary to use 
enzyme assays to determine relative purity of each organelle fraction.  Enzyme assays for 
many organelles have been published (24).   
 Although only one organelle has been successfully isolated, this is an excellent first 
step towards isolating all organelles in trypanosomes that accumulate DB75 and related 
compounds.  It is estimated that with modifications to the other procedures, isolation of the 
other organelles will be successful.  Then quantification of compound accumulation and 
further studies investigating mechanism of action can be undertaken.   
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Figure 1:  Low and high magnification micrographs of isolated acidocalcisomes.  Low 
magnification (8,000X), high magnification (25,000X). 
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